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Abstract
Tuberculosis (TB) conjures up the image of a contagious, chronic, severe 
disease of the lungs that is often fatal without treatment. TB is caused by 
Mycobacterium tuberculosis, a slow-growing, acid-fast obligate aerobe that invades 
host macrophages and is transmitted mainly by inhalation.
TB can take two forms: primary TB, usually a mild disease; and secondary 
TB, a disease caused by reactivation of dormant organisms. TB is currently treated 
with a combination of antibiotics for at least six months to prevent the emergence of 
multidrug-resistance tuberculosis.
Dihydrofolate reductase (DHFR) is an enzyme that present in all cells and is 
required for normal folate metabolism in prokaryotes and eukaryotes. DHFR is a key 
enzyme in the biosynthesis of RNA, DNA and proteins. The three dimensional 
structure of Mtb-DHFR revealed the presence of a glycerol pocket in the active site 
which was absent in the human DHFR. We have studied the glycerol pocket as a new 
avenue for designing novel selective inhibitors to Mtb-DHFR.
Four groups of inhibitors were designed having 2,4-diaminopyrimidine 
nucleus with four different new functional groups at 6 -position. We describe the 
synthetic pathway of the designed compounds which started by the condensation of 
phenylacetonitrile derivatives with esters or lactones to form the corresponding p- 
ketonitriles which, in turn, were O-methylated with diazomethane to form the 
corresponding enol ethers. Enol ethers were cyclised with guanidine to form the 
target 2,4-diaminopyrimidine derivatives.
Evaluation of the synthesised DHFR inhibitors was performed by initial 
screening in two types of genetically engineered strains of the budding yeast that are 
dependent on the Mtb-DHFR and human DHFR respectively for their growth. As 
expected the new functional group at 6 -position provided selectivity as well as 
potency to the synthesised compounds as three novel inhibitors was more potent and 
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1. INTRODUCTION
1.1 The Genus Mycobacterium
The generic name Afycobacterium was introduced by Lehmann and Neumann 
in the first edition of their "Atlas of Bacteriology" published in 1896.1 
Etymologically,"Mycobacterium" is derived from the Greek for fungus (myces) and 
small rod (bacterion). The fungus component of the name derives from the tendency 
of these microorganisms to spread diffusely over the surface of liquid medium in a 
mould-like growth pattern. 2 The minimal standards for identifying bacilli as 
members of the genus Mycobacterium are as follows:
1. Resistance to weak acid decolourisation following staining by carbolfuchsin (basic 
dye) and similar dyes.
2. The unique structure of the cell wall envelope due to the presence of mycolic acids 
containing 60-90 carbons, which can be cleaved to 22-26 carbon fatty acid methyl 
esters by pyrolysis.
3. A guanine and cytosine DNA content of 61-71 mol% . 3
1.1.1 The Species of Mycobacteria
Historically, the most widely used system for classification of mycobacterium 
was that devised by Adanson, in which a large number of cultural and biochemical 
properties were used to group strains into clusters according to their similarity. This 
technique was applied successfully to mycobacteria by The International Working 
Group on Mycobacterial Taxonomy. 1 Mycobacteria are divisible into the rapid 
growers, the slow growers and those not yet cultivated in vitro. The clinical 
microbiologist finds it useful to divide them into the major pathogens of human and 
animals, those species that frequently cause opportunist infections, and those that 
rarely or never do so, table ( l ) . 1 *3 A general, but not exclusive, trend regarding 
mycobacterial species is that the more "slow-growing" species contain most of the 
highly pathogenic organisms, including M. tuberculosis, M. bovis and M  leprae. In 
contrast the "rapid growers," with the exception of a few opportunistic species such 
as M. chelonae and M  fortuitum, tend to be nonpathogenic. Still, as Shinnick and
1
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Good have pointed out, there may be no such thing as a nonpathogenic 







M  avium 
M. intracellulare
Disseminated infection in AIDS patients
M. kansasii Lung infections
M. marinum Skin infections and deeper infections (e.g. arthritis) 








Cervical adenitis in children 
Lung, bone and kidney infections 
Lung, skin and bone infection 
Skin infections 
Lung infections
Associated with Crohn's disease
Rapid growers
M  fortuitum 
M. chelonea
Opportunist infections with introduction of organisms into 




Slow growers require more than 7 days for visible growth from a dilute inoculum; 
rapid growers require less than 7 days for visible growth from dilute inoculum
Table (1) M ajor species of Mycobacterium associated with human disease
At the present time, the emphasis is on the direct study of the genome, for 
example, by the sequence analysis of the DNA coding for the 16S ribosomal RNA. 
This has minor variations in its base sequence that appear to correspond closely with
2
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the established mycobacterial species. Thus determination of the sequence of the 
bases in this RNA may be used to classify mycobacteria and to identify clinical 
isolates. 4
1.1.2 The Structure of the Mycobacterial Cell
The mycobacterial cell consists of cytoplasm bounded by a plasma membrane 
and enclosed by a complex lipid-rich cell wall. The single chromosome is tightly 
wrapped into a nuclear body but is not bounded by a nuclear membrane. Thus, like 
other bacteria, the mycobacteria are prokaryotes (higher unicellular and multicellular 
forms of life have nuclear membranes and are termed eukaryotes). Some 
mycobacteria contain additional small circles of DNA, termed plasmids. The cell 
membrane consists of a bilayer of polar phospholipids with their hydrophobic ends 
facing inwards and their hydrophilic ends facing outwards. The membrane is closely 
associated with the enzymes and cofactors involved in energy production5
1.1.3 Morphology and Staining
Mycobacteria are complex unicellular organisms. They are thin, slightly 
curved to straight, non-spore-forming, non-motile bacilli, measuring 0 . 2  to 6 . 0  pm x 
1.0 to 10 pm. The genus consists of more than 50 species. 6  They are gram-positive 
but many species stain poorly with this stain even after prolonged staining, because 
of the large content of lipid within the cell wall. A distinguishing characteristic of 
mycobacteria species relates to their ability to retain a primary carbofuchsin stain 
after treatment of organisms with an acid alcohol wash. This characteristic is referred 
to as acid fastness. 7
1.1.4 Sensitivity to Physical and Chemical Agents
Although mycobacteria can survive for several weeks in the dark, especially 
under moist conditions, and for many days in dried sputum on clothing and in dust, 
they are rapidly killed by ultraviolet light even through glass, and by heat (60° C for 
15-20 min, or by autoclaving). They are susceptible to phenol and phenolic 
derivatives and to glutaraldehyde, provided that the contact time is adequate. Phenols
3
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such as Hycolin are useful at 5% final concentration in discard flasks for supernatant 
fluids. The most useful disinfectant is 70% alcohol. This is efficient and clean and 
leaves the surface free of any deposit. 8 ,9
1.1.5 Drug Sensitivity
With the exception of the rapid growers, most mycobacteria are fairly 
resistant to conventional antimicrobials. Accordingly, specific antimicrobial drugs 
and treatment regimens have been developed. Until 50 years ago, there were no 
drugs to cure TB. 10
1.2 Mycobacterium Tuberculosis
M. tuberculosis is the causative organism of tuberculosis (TB) in humans. 
The tubercle bacillus, because of its unusual wax envelope, grows slowly and is 
highly successful parasite; it does not affect the life of its victim for many years. 
When it causes extensive damage to the lungs, it ensures its spread from the body 
into the environment and increases its chances of infecting other people.
Mycobacteria grow very slowly; the generation time of tubercle bacilli is 
about 13 hours on the best laboratory media such as Lowenstein-Jensen (L-J) 
medium which is composed of whole eggs, glycerol, other nutrients and trace 
elements. It is possible that slow growth results from inability to transport nutrients 
rapidly across the wax layer. Slow growth causes delay in the diagnosis by culture; 
laboratory cultures of clinical material must be incubated for up to 8  weeks. It also 
greatly delays testing the drug sensitivity of clinical isolates; this delay has tragic 
consequences for AIDS patients infected with drug-resistant tubercle bacilli. The 
patient may die without receiving the most effective drugs. 11
M. tuberculosis is divisible into two major types: the classical type and the 
South Indian or Asian type. The latter type was originally isolated in the Chennai 
area of the South India and differs from the classical type in being attenuated in 
guinea-pig and being susceptible to killing by hydrogen peroxide in vitro. This 
variant was subsequently found to be susceptible to the isoniazid analogue
4
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thiophene-2-carboxylic acid hydrazide (TCH). About 60% of tubercle bacilli isolated 
in the Chennai region are of this type and it is also found in Asian communities who 
have settled in other parts o f the world. Despite its low virulence to guinea pig, it 
appears fully virulent for humans and it causes disease similar to the classical 
strains. 12
1.2.1 Tuberculosis Overview: The Current Situation
TB is a major killer disease and responsible for a higher number of deaths 
than any other single infectious disease. 11 In 1993, the World Health Organization 
(WHO) declared TB a "global health emergency", drawing attention to a problem 
that had been largely ignored over the previous few decades. Rates of TB continue to 
rise in developing and industrialised nations alike, leading to an estimated eight 
million new cases every year and a death toll of three million. Several factors have 
contributed to this increase, such as movement of people around the world, 
homelessness in major cities and, perhaps of greatest significance, the HTV 
pandemic. 13 TB is primarily a disease of the lung but may spread to other sites or 
proceed to a generalised infection . 1 4
HTV and TB form a lethal combination, each speeding the other's progress. 
TB is a leading cause of death among people who are HIV-positive. It accounts for 
about 13% of AIDS deaths worldwide. In Africa, HTV is the single most important 
factor determining the increased incidence of TB in the past 10 years. 15
1.2.2 The Present Global Burden of Tuberculosis
Nearly one third of the global population (that is, 2 billion people) is infected 
with TB or is at risk of developing the disease 9  WHO estimated that there were 8 . 8  
million new cases of TB in 2002, of which 3.9 million developed active TB and 2 
million died. The global incidence rate of TB is growing at approximately 1.1% per 
year and the number of new cases at 2.4% per year. 1 0 ,1 6  TB accounts for 2.5% of the 
global burden of disease and for 26% of preventable deaths and is the commonest 
cause of death in young women. Some 95% of global TB cases and 98% of deaths 
occur in the developing world, where 75% of cases are in the economically most
5
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productive age group (15-54 years). There, on average, three to four months of work 
time are lost if an adult has TB. This results in the loss o f 20-30% of annual 
household income and an average of 15 years' income if the patient dies.13,15
In addition to the devastating economic cost, TB imposes indirect negative 
consequences. In India alone every year, more than 300,000 children leave school 
because of their parents' TB and more than 100,000 women are abandoned by their 
families because of their TB. TB impoverishes and poverty attracts TB. 
Furthermore, co-infection with HIV significantly increases the risk of developing 
TB. Today, worldwide, 11 million people are co-infected with TB and HIV. The 
TB/HIV co-epidemic is increasing and will continue to fuel the TB epidemic. Of the
3.6 million cases of TB cases reported to the WHO, South-East Asia and the Western 
pacific regions accounted for almost 60% of the global caseload, with India and 
China alone reporting more than 40% of all notified cases (fig. I).15
□  < 1000
■  100010 9 999
■  10 000 to 99 999
Q  100 000 to 999 999
1 000 000 of more 
° l— | No Estimate
Fig. (1) Global distribution of tuberculosis, World Health Organization
(2002)
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Although Africa contains only 10% of the 5.9 billion global populations, the 
region reported 18% of the total TB cases where HIV has led to rapid increases in the 
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Fig. (2) Tuberculosis case notification proportion by WHO regions
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Fig. (3) The global rate of incidence of TB, WHO (2002)
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1.2.3 The Terminology and Classification of Tuberculosis
TB is divided into two main types: primary and post-primary (secondary). In 
the past, it was widely assumed that post-primary disease was always due to 
endogenous reactivation of an earlier primary infection, usually after a period of 
latency. It is now realised that this type of TB may be also the result of exogenous 
reinfection. TB is also divided according to whether or not the lung is involved. The 
terms non-pulmonary and extrapulmonary are often used synonymously but it is 
recommended that the former should be used to refer to disease in which the initial 
infection was not in the lung and the latter to lesions due to spread from an initial 
pulmonary focus. The clinical manifestations of TB are so variable in type, extent 
and site that any classification, other than by the simple categorisation above, is of 
little value . 18
1.2.4 Aetiology and Transmission
The causative agent of TB is almost always M. tuberculosis with rare 
instances of three other species of the Mtb complex namely, M  bovis, M. africanum 
and M. microti}4 Infection is acquired by inhalation of M. tuberculosis in aerosols 
and dust. 10 TB is almost universally transmitted through the air by infectious 
particles called droplet nuclei. 1 4 ,1 9 When a person with active pulmonary or laryngeal 
TB coughs (0 to 3,500 particles), sneezes (4,500 to 1,000,000 particles) or even 
speaks ( 0  to 2 1 0  particles), these particles are emitted in droplets that can remain 
suspended in air for several hours. 18
Transmission may occur if  another person inhales the droplet nuclei, as the 
bacilli will be deposited in the lungs of contacts resulting in local infection, then 
dissemination. 1 4 ,1 9  Less frequently, bacilli may be ingested and lodge in the tonsil or 
in the wall of the intestine. Such infection is particularly associated with the 
consumption of contaminated milk or milk products. A third, but rare, mode of 
infection is direct implantation of bacilli into the skin through cuts and abrasions. 
This is a health hazard faced by those working with infected material or cultures of 
tubercle bacilli. 18
8
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Three factors determine the probability that TB will be transmitted; the 
infectiousness of the person with TB, the environment in which the exposure 
occurred and the duration of the exposure. 1 4 ,1 8  Airborne transmission of TB is 
efficient because infected people cough up enormous numbers of mycobacteria ( 1 - 1 0  
million bacilli per milliliter of sputum), projecting them into the environment, where 
their waxy outer coat allows them to withstand drying and thus to survive for long 
periods of time in air and house dust. 14
1.2.5 Pathogenesis
Tubercle bacilli do not produce exotoxins or endotoxin. The severe 
manifestations of TB are largely mediated by the defensive responses that the host's 
immune systems mount against the bacilli. 18 The upper respiratory tract is the body's 
first line of defence against the transmission of TB. Particles smaller than five 
microns in diameter may reach the alveoli and infection may begin.
The pathogenicity of the tubercle bacillus arises from strategies it has 
developed to survive in host cells, including the ability to colonise inside the 
macrophages, and to remain quiescent and then become active decades later. The 
presence of storage proteins in the bacillus points to its ability to stockpile essential 
growth factors, allowing it to persist in the nutrient-limited environment. In this 
regard, the ferritin-like proteins may be important in intracellular survival, as the 
capacity to acquire enough iron in the vacuole is very limited. 2 0 ,2 1
1.2.6 Primary Tuberculosis
This is the disease of persons who are infected for the first time. The 
organisms are phagocytosed by the alveolar macrophages where they can both 
survive and multiply. Bacilli multiply in this intracellular environment until the 
macrophages burst and release them . 2 0 Later, non-resident macrophages are attracted 
to the site and these also ingest the mycobacteria and carry them via the lymphatic 
system to the local (hilar) lymph nodes, where an immune response develops, 
dominated by T-helper cells. Inflammation will now be present in several places: at 
the original site of infection, along lymphatic channels, and in the regional lymph
9
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nodes. The development of inflammation takes (4-10) weeks. The immune defences 
curb the proliferation of the organisms and retard their local spread through 
phagocytosis, although some may survive phagocytosis, grow intracellulary, 
rupturing the macrophages and give rise to haematogenous spread to distant organs.14 
The process of phagocytosis is shown in (fig. 4).22
B
Fig. (4) Phagocytosis, A: Bacilli are engulfed by the cell membrane, B: The 
bacilli lie in a membrane vesicle (the phagosome) which fuses with 
lysosomes containing bactericidal substances, C: These substances destroy 
the bacilli. Mycobacterium avoids such destruction by -  D: inhibiting 
phagosome/lysosome fusion; E: a thick capsule-like outer protective layer; 
and escape from the phagosome and lie freely within the cytoplasm.
The phagocytosis occurs once an engulfed bacterium by a macrophage lies 
within a vesicle formed by invagination of the surface membrane. This vesicle, the 
phagosome, then fuses with the lysosomes which contain bactericidal agents. There 
are three main strategies by which mycobacteria survive within the phagosome. 
Firstly, phagosome/lysosome fusion may be inhibited. Secondly, the pathogen may
10
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cover itself with a protective layer that absorbs or neutralises the bactericidal agents 
or, thirdly, it may escape from the vesicle and he freely in the cytoplasm of the 
cell. 2 0 ,2 2
The extent to which mycobacteria use these strategies is controversial. 
Mycobacterium tuberculosis, in common with the protozoal parasite Toxoplasma 
gondii, inhibits phagosome-lysosome fusion but neither the mechanism nor the 
significance of this activity to intracelluluar survival is clearly understood. 
Mycobacterial pathogens also appear to survive the effects of exposure to reactive 
oxygen intermediates (ROI) on account of the thick outer layer of mycosides which, 
on electron microscopy, appears as an electron transparent zone surrounding the 
bacilli. Lipoarabinomannan (LAM), which is present in all mycobacteria, also 
protects against ROI. In addition, mycobacteria secrete the enzyme superoxide 
dismutase (SOD) which also protects against ROI.
Mycobacteria are able to escape from the phagosome and replicate in the 
cytoplasm. This appears to occur when the cell becomes immunologically effete and 
unable to control intracellular growth or when mycobacteria enter cells other than 
macrophages. 2 2  Sensitised T-cells release lymphokines that activate macrophages 
and increase their ability to destroy the mycobacteria. The body reacts to contain the 
organisms within tubercles, small granulomas consisting of epithelioid cells, giant 
cells and lymphocytes. The lung lesion plus the enlarged lymph nodes is often called 
the Ghon (or primary) complex. 20
Within time, the centres of the tubercles become necrotic and advance to 
form cellular masses of cheesy debris, called caseous material or caseation. Primary 
TB may take two courses: In people who are otherwise healthy, the lesions heal 
spontaneously and become fibrotic or calcified. These lesions usually persist as such 
for a life-time. In contrast to healthy individuals, in an immunocompromised person, 
the mycobacteria are not contained within the tubercles but invade the blood stream 
and cause disseminated disease. The involvement of macrophages has its price. Two 
cytokines produced by these cells, interleukin- 1 which acts as mediator of the fever 
experienced by tuberculosis patients, and tumour necrosis factor, which interferes 
with lipid metabolism and leads to severe weight loss. 1 4 ,2 0
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1.2.7 Secondary (post-primary) Tuberculosis
Secondary TB usually becomes noticeable one or two years or even decades 
after primary disease. 14 Secondary TB is due to reactivation o f  dormant 
mycobacteria, usually as a consequence of impaired immune function resulting from 
some other cause such as malnutrition, infection (e.g. AIDS), cancer chemotherapy 
or corticosteroids for treatment of inflammatory diseases. Reinfection with external 
Mtb could lead to the same manifestation.
Reactivation occurs most commonly in the apex of the lungs. This site is 
more highly oxygenated and has impaired lymphatic drainage which allows the 
mycobacteria to multiply more rapidly to produce caseous necrotic lesions, which, in 
time, liquefy and discharge their contents into bronchi. 2 0 ,2 3  The softened contents are 
coughed out, leaving a well-oxygenated cavity in which the organisms actively 
proliferate. Thus the cavity wall contains millions of freely replicating bacilli, which 
are behaving more like saprophytes than primary pathogens. In addition, large 
numbers of bacilli enter the sputum, rendering the patient open or infectious. 2 2  The 
discharge of caseous material also distributes the organisms to other sites in the lung, 
which can lead to rabidly progressive tuberculosis pneumonia. Coughing and spitting 
transmit the organisms to other people. 2 4  Inflammation of the surface of the bronchi 
causes increased mucus secretion, stimulation of the cough reflex; patients cough up 
sputum and destruction of tissues results in bloody sputum. 1 0 ’14
1.2.8 Clinical Features and Diagnosis of TB
TB is a chronic bacterial infection of the lungs. The onset of TB is insidious, 
the infection proceeding for some time before the patient becomes sufficiently ill to 
seek medical attention. Primary TB is usually mild and asymptomatic and in 90% of 
cases does not proceed further. However, clinical disease develops in the remaining 
10% . 1 0 ,2 0  Secondary infections may occur in any organ as the mycobacteria have the 
ability to colonise almost any site in the body. The clinical manifestations are 
variable; fatigue, weight loss, night sweats, chills, anorexia, weakness and fever are 
all associated with TB. Infection in the lungs characteristically causes chest pain, a 
chronic productive cough, and the sputum may be blood-stained as a result of tissue
12
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destruction. Necrosis may erode blood vessels, which can rupture and cause death 
through haemorrhage. Approximately 15% of TB cases are extrapulmonaiy and the 
specific symptoms depend on the site of involvement. The most prevalent local 
symptom is pain at the affected site and the systemic symptoms are fever, malaise, 
anorexia, loss of weight and sweating. The local symptoms include cough, sputum 
and dyspnea. 10 ’14
Generally, TB lymphadenitis is the most prevalent form of extrapulmonary 
TB, due to infection of the lymph nodes, seen in Great Britain and is common in 
patients of Asian ethnic origin. It is also, for unknown reasons, reported to be more 
prevalent in females in all ethnic groups. The affected nodes are initially discrete, 
rubber-like in texture and usually painless. Less than one half of the patients have 
constitutional symptoms.
Miliary TB , which is a type of disseminated TB, is more prevalent in males. 
It usually occurs as a manifestation of primary TB and is characterised by multiple 
discrete granulomas macroscopically resembling millet seeds. These occur 
throughout the body and, on chest X-ray, may produce a characteristic "snow storm" 
appearance. Occasionally they are seen on the retina by ophthalmoscope. Lesions 
also occur in the kidney and tubercle bacilli are found in the urine of about 25% of 
the patients with miliary disease. 2 5 *2 6
For a person who is suspected of having TB, a medical evaluation should 
include a medical history, a physical examination, a chest radiograph, appropriate 
bacteriological or histological examination and a tuberculin test. A positive 
tuberculine reaction usually manifests as an area of induration which reaches a 
maximum after 48 or 72 hours of intradermal injection of tuberculoprotein. 22
When extrapulmonary TB is suspected, a variety of clinical specimens other 
than sputum (e.g. urine, cerebrospinal fluid, pleural fluid, and pus or biopsy 
specimens) may be needed for examination. 1 0 ’14 These materials are cultured to 
obtain confirmation that the acid-fast organisms are indeed M. tuberculosis and to 
obtain information on the sensitivity of the organism to different anti-tuberculous 
drugs. This process takes two to three months to provide results. A number of
13
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factors, in particular HIV infection, multi-drug resistance (MDR) and rapid air 
transport of people around the world, causes difficulties with diagnostic approach 
which rendering it too slow and unreliable.
These concerns have lead to an urgent search for new techniques to assist in 
making the diagnosis of TB. The M. tuberculosis genome contains distinctive 
sequences which can be utilized to identify the organism. Many studies have taken 
advantage of this opportunity. 2 2 ,2 6  Thus, following culture, it is possible to extract 
DNA, digest it with enzymes and use specific probes for different mycobacteria to 
confirm which cultures are indeed M. tuberculosis, as opposed to other 
mycobacteria. There are now commercial kits, such as the Accuprobe system, which 
can identify a culture as belonging to M. tuberculosis complex in under two hours. 
This approach is widely used combined with the BACTEC system of rapid 
identification by liquid culture to provide results within two weeks. 27
1.1.9 Treatment of TB
Most patients with TB can be cured with adherence to chemotherapeutic 
regimens. The goal of drug therapy of active TB is two fold; to cure the sick and to 
impede the transmission of tubercle bacilli in the community. On the basis of 
controlled clinical trials, three basic principles for the treatment of TB have evolved: 
(a) regimens for treatments of disease must contain multiple drugs to which the 
organisms are susceptible, (b) the drugs must be taken regularly, and (c) drug therapy 
must continue for sufficient period of time.
The aim of therapy is to provide the most efficacious regimen with the least 
toxicity possible for the shortest period of time. 2 8  Three subpopulations of tubercle 
bacilli can potentially coexist during an infection. Antituberculous agents are 
targeted toward various sites of mycobacterial growth in the body. As the first phase, 
tubercle bacilli in the lesions of patients with pulmonary TB lie tightly packed in 
very large number in a narrow zone close to the air-caseum interface. Since caseum 
is composed of dead cells, the bacilli are usually some distance from living 
macrophages and are extracellular. 2 9 The most numerous population consists of the 
extracellular bacteria; these organisms are killed most readily by isoniazid (INH) and
14
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streptomycin (STM) and to a lesser extent by rifampin (RMP). The second 
population is composed of organisms that seek out the acidic environment of 
caseating granulomas. RMP exhibits the greatest activity in killing these organisms. 
The final population of organisms exists within the activated macrophages 
(intracellular). Pyrazinamide (PAZ) possesses the greatest activity against this 
population. 2 8 ,3 0
1.2.10 Current TB Drugs and Their Targets
Current TB drugs can be divided into first-line drugs; INH, RMP, PAZ, STM, 
ethambutol (EMB), and second-line drugs; ^-aminosalicylic acid (PAS), cycloserine 
(CS), kanamycin, capreomycin, thiacetazone, fluoroquinolones. TB drugs can also be 
classified according to their specificity into TB-specific drugs (INH, PZA, EMB, 
PAS, CS, EMB, thiacetazone) and broad-spectrum drugs (RMP, STM, kanamycin, 
amikacin, capreomycin, fluoroquinolones) . 3 0  The first-line drugs, also known as 
primary or standard drugs, are those recommended for the treatment o f newly 
diagnosed TB. The other antituberculosis medications are considered second line, 
secondary, or reserve drugs, as they are used in case of resistance or intolerance to 
the otherwise preferred first-line drugs. 28
1.2.11 The Mechanism of Action of the First-Line Antituberculosis Drugs 
I) Isoniazid (INH)
Since its introduction in 1952, INH has been the most widely used 
antituberculous agent. The drug exhibits many qualities of an ideal agent: it is 
bactericidal, relatively nontoxic, inexpensive and well-absorbed orally or 
parenterally. 14 INH is a prodrug that requires activation by the bacterial catalase- 
peroxidase (Kat G) to generate a range of reactive oxygen species and reactive 
organic derivatives, isonicotinic acid being the major product (scheme 1 ), which then 
attack multiple targets in the tubercle bacillus. 3 0 ,3 1
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Isoniazid (INH) Isonicotinic acid
Scheme (1) Isoniazid (INH) and its active metabolite isonicotinic acid
The most well-known target is the cell wall mycolic acid synthesis pathway 
where at least two enzymes, Inh A (enoyl ACP(acyl carrier protein) reductase) and 
Kas A (p-ketoacyl ACP synthase), have been identified as targets of INH inhibition. 
INH activation generates various reactive organic and reactive oxygen radicals that 
could cause damage to a wide variety of cellular targets including DNA, 
carbohydrates and lipids. The cidal activity of INH is very likely to be due to its 






PZA, a synthetic pyrazine analogue of nicotinamide, exhibits bactericidal 
activity against mycobacteria in an acidic environment. 2 8  PZA is also a prodrug that 
requires activation or conversion to its active form, pyrazonic acid (POA), by 
pyrazinamidase/nicotinamidase enzyme. 3 3  PZA is a unique and paradoxical TB drug: 
it has remarkable in vivo activity and is involved in shortening the TB therapy, yet it 
has no activity against the TB bacteria at normal culture conditions except at acidic
16
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pH . 3 0  The role of acidic pH is to facilitate the formation of uncharged protonated 
POA that can permeate the membrane easily; the acid-facilitated POA influx 
overwhelms the weak POA efflux mechanism and causes accumulation of POA in 
M. tuberculosis 3 4
The protonated POA brings protons into the cell and can eventually causes 
cytoplasmic acidification, which can inhibit vital enzymes. Protonated POA could 
also potentially de-energise the membrane by collapsing the proton motive force and 
affecting membrane transport. While the acid-facilitated uptake of the weak acid 
POA is a non-specific process, the specificity and unique susceptibility of M  
tuberculosis to PZA is most likely to be due to a combination of deficient POA 
efflux mechanism and poor ability to maintain its membrane potential (as in starved 
and nongrowing bacterial populations).
This view is consistent with the observation that PZA/POA is more active 
against semi-dormant organism or old bacilli in stationary phase cultures where 
energy reserve and membrane potential is less well maintained than actively growing 
bacilli in the log phase. Thus the target of PZA/POA appears to be the membrane as 
they cause disruption of the membrane function and energy metabolism. A recent 
study using a related mycobacterium and a related compound, 5-chloro-PZA, 
suggested fatty acid synthase-1 as target for PZA, and this finding remains to be 
confirmed for M. tuberculosis
m ) Rifampin (RMP)
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RMP is a semisynthetic derivative of rifamycin B, which is an antibiotic 
produced by Streptomyces mediterranei. RMP is an important agent in the treatment 
of TB, leprosy and diseases caused by the nontuberculous mycobacteria. 2 9 RMP 
interferes with RNA synthesis by binding to the bacterial DNA-dependent RNA 
polymerase P-subunit. 3 0 ,3 5  RMP is considered to be bactericidal and is active against 
both intracellular and extracellular M. tuberculosis. Its use in combination with INH 
in treatment regimens for TB allowed the duration of therapy to be decreased from 
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Ethambutol (EMB)
Ethambutol hydrochloride is a synthetic agent that was developed from N,1NF- 
diisopropylethylenediamine, which was found to be active against M. tuberculosis in 
a screening program. The J-enantiomer of EMB is approximately 200 times more 
active than the /-enantiomer. 3 6 ,3 7
EMB acts on the biosynthesis of arabinogalactan, a major polysaccharide of 
the mycobacterial cell wall. EMB inhibits the polymerisation of cell wall arabinan of 
arabinogalactan and of lipoarabinomannan and induces accumulation of p-D- 
arabinofuranosyl-^-decaprenol, an intermediate in arabinan bisynthesis. 3 4 ,3 8
18









STM, an aminoglycoside antibiotic, was the first clinically effective drug to 
become available for the treatment of TB. STM is bactericidal in alkaline 
environments and acts by inhibiting protein synthesis. 3 0
Because aminoglycosides are poorly absorbed from the gastrointestinal tract, 
STM must be administered parenterally. The drug is highly effective within the 
extracellular environment; however, it diffuses poorly into granulomas and 
macrophages and lacks activity in the intracellular environment.
1.2.12 Current TB Therapy
Current antituberculous regimens use combinations to kill the slowly dividing 
organisms within granulomas and macrophages and minimise drug resistance. 15 Early 
in the chemotherapy era, it become apparent that the emergence of resistance during 
monotherapy could be circumvented with combination therapy. 14 ’2 8
Current TB therapy consists of an initial phase of treatment with four drugs, 
INH, RMP, PZA and EMB for 2 months daily, followed by a continuation phase of 
treatment with INH and RMP for another 4 months, three times a week. This therapy,
19
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also called DOTS (directly observed treatment, short-course), is the best TB therapy 
and is recommended by WHO for treating every TB patient. DOTS has a cure rate of 
up to 95%, given patient compliance. 3 8
Despite the importance of DOTS in the control of TB, there are indications 
that in areas where there is high incidence of multidrug-resistant tuberculosis (MDR- 
TB), (which is the case of TB that exhibits resistance to the two most powerful 
antituberculous medications, INH and RMP) such as in Russian prisons and some 
African countries, DOTS is failing to control the disease. 3 9 ’4 0  In view of this, DOTS- 
Plus (DOTS plus second-line TB drugs) is now recommended for treating MDR-TB 
and TB in areas with high incidence of MDR-TB. 3 8  However, DOTS-Plus is 
expensive, takes longer to administer and has significant side-effects. 3 0
1.2.13 Problems of the Current TB Therapy
Although DOTS is the best treatment for TB, the therapy takes at least six 
months. The length of the therapy makes patient compliance difficult; this is a 
frequent source of drug-resistant strains. The need for the lengthy treatment is a 
consequence of the presence of a population of persistent bacilli that are not 
effectively eliminated by the current TB drugs.
In fact, TB patients are rendered non-infectous after the first two weeks of 
chemotherapy; the remainder of the six-month therapy is to- kill a population of 
slowly-metabolising persistent bacilli and to allow the host to develop protective 
immunity to control the residual number of bacilli not killed by the drugs. Current 
TB drugs are mainly active against growing bacilli, except RMP and PZA. RMP is 
active against both actively growing and slowly-metabolising non-growing bacilli, 
whereas PZA is active against semi-dormant non-growing bacilli in an acidic 
environment, such as in active inflammation sites in the lesions. These two agents are 
important sterilising drugs that significantly reduce the number of bacilli in infected 
tissues and shorten the therapy from 12-18 months to 6  months30
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1.2.14 Multidrug-Resistant Tuberculosis (MDR-TB)
M. tuberculosis is naturally resistant to many antibiotics, making treatment 
difficult. This resistance is due mainly to the highly hydrophobic cell envelope acting 
as a permeability barrier but many potential resistance determinants are also encoded 
in the genome. These determinants include hydrolytic or drug-modifying enzymes 
such as (3-lactamases and aminoglycoside acetyl transferases, and many potential 
drug-efflux systems. Knowledge of these putative resistance mechanisms will 
promote better use of existing drugs and facilitate the conception of new therapies. 21
Drug-resistant TB is a growing problem throughout the world. MDR-TB is 
defined as a case of TB caused by a strain of M. tuberculosis that exhibits resistance 
to the two most powerful antituberculous medications, INH and RMP. Mortality 
among these patients is extraordinarily high, ranging from 43% to 89%. In addition, 
the median interval from diagnosis to death was very short; only four to sixteen 
weeks. 10 ,15 The occurrence of MDR-TB is favoured by inappropriate management of 
TB. In the presence of TB which is already resistant to a single drug, therapy with 
that drug is ineffective. If one other drug is included in the regimen, or added to the 
regimen, this is equivalent to monotherapy with the potentially effective second drug. 
Emergence of resistance to this second drag is to be anticipated, superimposed upon 
the previously existing resistance to the first drug, thus multiple drag resistance 
emerges. 14 ,28
MDR-TB is more difficult to treat than its fully susceptible counterpart, often 
requiring 18-24 months of therapy with four to eight different medications, including 
daily injection for at least six months. Food security in general is an essential 
consideration in the treatment of MDR-TB patients. Not only is treatment less likely 
to succeed if patients are malnourished, medication side-effects become much more 
pronounced and difficult to manage. 26
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1.2.15 Prevention
The history of TB strongly suggests that it can be effectively controlled by 
sanitary measures and improved standards of living. 1 5 Immunisation with a live 
attenuated vaccine has been used effectively in situations where TB is prevalent. The 
vaccinating agent known as Bacilli Calmette-Guerin (BCG) is derived from M. bovis. 
BCG vaccination is about 80% effective (the incidence of TB being one-fifth that 
occurring in unvaccinated persons) and last at least (10-15) years. 41  
Chemoprophylaxis with INH for one year is recommended for people who have had 
close contact with a case of TB. 10 In the recent past, the availability of modem 
antituberculosis drugs appeared to promise elimination of TB. Now the impaired 
immunity caused by HTV infection, combined with the increasing incidence of drug 
resistance, is making treatment of TB more difficult to achieve 4 2
1.3 Dihydrofolate Reductase (DHFR)
DHFR enzyme (EC 1.5.1.3), also known as 5,6,7,8-tetrahydrofolate:NADP+ 
oxidoreductase, is present in all cells and is required for normal folate metabolism in 

















Fig. (5) Structure of folic acid (pteroylglutamic acid)
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Inside a cell, folate is converted to the active forms by two successive 




















Scheme (2) The catalytic function of DHFR
Both reactions are catalyzed by DHFR using dihydronicotinamide adenine




Fig. (6 ) Structure of NADPH
23
i. im tR p w c rro N
The first reduction yields 7,8-dihydrofolate (DHF) and the second reduction 
yields 5,6,7,8-tetrahydrofolate (FH4). Dihydrofolate is the preferred substrate and 
hence its name is given to the enzyme.34 The FH4 is then converted to one-carbon 
adducts (fig. 7). FH4 and its derivatives are necessary for the biosynthesis of 
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Fig. (7) Structures of the one-carbon adducts derived from FH4.
FFI4 binds single-carbon units at the methyl, methylene, and formyl oxidation 
levels, equivalent in oxidation level to methanol, formaldehyde and formic acid 
respectively (fig. 7). Single-carbon groups on FH4 can be carried on N-5 or N-10, or 
bridged between N-5 and N-10.
Formation of a cyclic bridged adduct involves dehydration, so methylene 
group (-CH2-) is formally equivalent to a hydroxymethyl group (-CH2OH) in an 
unbridged compound, and a formyl group (-CHO) cyclises to become a methenyl 
group (-CH=). In addition, there is a single-carbon adduct of FKU in which the single­
carbon unit contains a nitrogen atom as well. In this formimino group (-C=NH), the 
carbon atom is at the same oxidation level as a formyl group. The structure of such 
adducts are shown in (fig. 7).45
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The coenzymatic function of FH4  is the mobilisation and utilisation of single­
carbon function groups. These reactions are involved in the metabolism of serine, 
glycine, methionine and histidine, and in the biosynthesis of purine nucleotides and 
methyl group of thymine (scheme 3).
The one-carbon units carried by FH4  are interconvertible. 5,10-Methylene- 
FH4  can be reduced to 5 -methyl-FH4  or oxidized to 5 , 1 0 -methenyl-FH4 . These FH4 
derivatives serve as donors of one-carbon units in a variety of biosynthesis. 
Methionine is regenerated from homocysteine by transfer of the methyl group of 5- 
methyl-FH4 . 4 6  Glycine yields 5 , 1 0 -methylene-FH4  through action of the glycine 
cleavage system, a multienzyme complex located in mitochondria. This reaction 
represents the chief catabolic route for glycine in most organisms. 4 5
25




















Scheme (3) Metabolic reactions involving synthesis, interconversion, and 
utilisation of single-carbon adducts of FH4. The enzymes involved are (1) cyclodeaminase, 
(2) methenylFRt synthase, (3) methenylFTL,cyclohydrolase, (4) formylFFL* synthetase, (5) formylFHj 
hydrolase, (6) formylFR* dehydrogenase (7) methyleneFH4 dehydrogenase, (8) methyleneFH4 
reductase, (9) homocysteine methyltransferase, (10) serine hydroxymethyltransferase, (11) glycine 
cleavage system, (12) thymidylate synthase, and (13) DHFR
26
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The reaction of most interest in chemotherapy is the synthesis of 
deoxythymidylate monophosphate (dTMP) from deoxyuridine monophosphate 
(dUMP); this process is vitally dependent on the supply of 5 , 1 0 -methylene-FH4 . This 
reaction, catalysed by thymidylate synthase, is the only de novo source of 
thymidylate, which is an essential constituent of the DNA. Therefore, inhibition of 
thymidylate synthesis in cells inhibits DNA biosynthesis and produces what is 
known as thymineless death of the cell.4 6
Thus, one-carbon units at each of the oxidation levels are utilised in the 
biosynthesis. Furthermore, FH4  serves as an acceptor of one-carbon units in 
degradation reactions. The major source of one carbon-units is the facile conversion 
of serine into glycine, which yields 5 , 1 0 -methylene-FH4 .
FH4 is regenerated from the DHF that is produced in the synthesis of 
thymidylate. 4 5 ’4 6  This regeneration is accomplished by DHFR with the use of 
NADPH as the reductant4 8  A hydride equivalent is directly transferred from the 
nicotinamide ring of NADPH to the C6 of the pteridine ring of the protonated DHF 
with concurrent protonation at the N5 position (scheme 4 ) 4 3 ,4 5
Scheme (4) The hydride transfer reaction from the NADPH cofactor to the
protonated DHF substrate.
1.4 Dihydrofolate Reductase as a Target for Drug Design
There is a considerable pharmacological interest in DHFR because inhibition 
of the enzyme results in depletion of intracellular reduced folates necessary for one- 
carbon transfer reactions which, in turn, are important for the biosynthesis of
DHFR
DHF(H+) NADPH FH4 NADP+
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thymidylate, purine nucleotides, methionine and many other compounds necessary 





















Scheme (5) Biosynthesis of FH 4  and its role in cell metabolism
The major effects, however, are on the biosynthesis of purines and 
pyrimidines, which involve one-carbon transfer reactions at several stages. The 
synthesis of thymine is particularly sensitive to inhibitors of DHFR because of the 
requirement for FH4 in the transformation of dUMP to dTMP as the supply of 
thymine is rate-limiting in DNA biosynthesis. 5 2
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Microorganisms can synthesise essential FH4 cofactors de novo with the help 
of dihydropteroate synthetase while mammals obtain folates from their diets or from 
microorganisms in their intestinal tract. 4 6 ,5 3  Reduction of DHF to FH4 is, however a 
universal requirement and its inhibition leads to decrease cell growth and cell 
death.4 3 ,5 4  When cultures of bacteria are grown in media containing amino acids and 
inosine, antagonism of folic acid synthesis cause the phenomenon known as 
thymineless death, which can be prevented by the addition of excess thymine or 
thymidine.
When the structure of folic acid became known, a search was made for 
antagonists among structural analogues of folic acid itself. These were found, but not 
surprisingly they were highly toxic to human cells. The toxicity of some of these 
compounds towards human cells is actually much greater than towards bacteria since 
bacterial membranes are almost completely impermeable to them . 5 5
1.5 Inhibitors of Dihydrofolate Reductase
DHFR is the major target of drug development against several diseases such 
as cancer and bacterial and parasitic infections. Enzyme inhibition is effective 
because binding affinities of substrate analogues are so great that they are not readily 
displaced by the natural substrates. 4 8  It is also one of the best studied enzymes and 
the wealth of acquired knowledge is useful for selectively targeting this enzyme to 
design inhibitors without disrupting the function of host DHFR. 5 6 ,5 7
Classical DHFR inhibitors have only a small change in structure compared to 
the natural substrate, so that the structure of dihydrofolic acid (fig. 8 ) has been 
utilised as a model for the design of DHFR inhibitors. 5 8 ,5 9  Dihydrofolic acid has been 
divided into four regions which have been varied in structure in many attempts to 
develop better inhibitors of DHFR . 56
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Fig. (8) Structure of dihydrofolic acid
The only change needed to convert dihydrofolic acid to a strong inhibitor is 
the replacement of 4-OH group by 4 -NH2 group, as well as N-methylation, as in 
methotrexate (fig. 9).60,61 Methotrexate is a non-selective inhibitor employed in 
cancer chemotherapy. The cytotoxic action of the antifolate compound methotrexate, 
(fig. 9) has found a practical application in the treatment of certain malignancies, 






Fig. (9) Structure of methotrexate
Methotrexate contains a polar L-glutamic acid moiety in the side chain and 
therefore requires carrier-mediated transport into cells.64 The toxicity and narrow 
spectrum of activity for methotrexate, as well as the development of drug resistance, 
have made DHFR a target for novel antitumour and antimicrobial drug design 65-69
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In non-classical agents, the polar side chain is replaced with a lipophilic side 
chain to increase cell permeability. Lipophilic DHFR inhibitors, exemplified by the 
first-generation antifolates metoprine (DDMP) and etoprine (fig. 10) lack a polar 
glutamate side chain and differ from methotrexate in not requiring a carrier-mediated 
active transport mechanism to gain ingress to cell, entering by passive or facilitated 
diffusion. 6 9  As a consequence, these agents exhibit activity against methotrexate- 
resistant tumours and also against central nervous system (CNS) malignancies 
inaccessible to the more hydrophilic methotrexate. The lipophilic antifolates 
piritrexim (PTX) and trimetrexate (TMQ) (fig. 10) were developed to overcome 
toxicity problems encountered with DDMP, attributed to the prolonged biological 
half-life and inhibition of histamine metabolism observed for this highly lipid soluble 
compound. 6 9 ,7 0
Interestingly, PTX and TMQ, but not the antimalarial antifolate 
pyrimethamine, are substrates for the membrane-bound P-glycoprotein (GP-170) 
which effluxes a diverse range of unrelated antitumour agents from cells and is 
responsible for the Multidrug-resistant (MDR) phenotype. Lipophilic DHFR 
inhibitors, including PTX and TMQ, have also enjoyed a more recent resurgence in 
interest as agents for the treatment of infection by opportunistic pathogens, including 
Candida albicans, Toxoplasma gondii, and Pneumocystis carinii, in
*71 7 iimmunocompomised patients. ’ Indeed, TMQ has recently gained clinical approval 
for the treatment of P. carinii infections in patients with acquired immune deficiency 
syndrome -(AIDS). Unfortunately, unlike pyrimethamine or the antibacterial DHFR 
inhibitor trimethoprim, these antifolates exhibit no selectivity for pathogen DHFR 
and are more potent inhibitors for the mammalian enzyme. As a consequence, the 
concomitant administration of leucovorin is necessary in order to ameliorate host 
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Methylbenzoprim (MBP) 2,4-Diamino-5,6-dihydrotriazine derivative
Fig. (10) Structures of a list of non-classical DHFR inhibitors
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Non-classical DHFR inhibitors have large but appropriate structural changes 
compared to dihydrofolic acid. This class of inhibitors includes quinazolines, 
pyrimidines and triazines. 4 6
1.5.1 Quinazolines
2.4-Diamino-5-methyl-6-substituted quinazolines (fig. 10) were found to be 
moderately to strongly effective inhibitors of mycobacterial DHFR. They also have 
significant anti-leukaemic activity. 4 4 ’7 5  The pyrroloquinazoline GW 345 (fig. 10) is a 
member of series of high-affinity inhibitors of the fungus C. albicans DHFR. 
However, this series of compounds inhibits human DHFR more strongly than it 
inhibits fungal DHFR . 7 5  Compound BW 301U (fig. 10), with a 1,8-naphthyridine 
nucleus, shows considerable promise as an antitumour agent. 7 6
1.5.2 Pyrimidines
2.4-Diaminopyrimidine derivatives (fig. 10) have been tested against various 
forms of DHFR. 6 2  Although most living cells contain DHFR, the enzyme evidently 
differs in structure details amongst major groups of organisms, and a useful degree of 
species specificity in the action of inhibitors is possible. For example, pyrimethamine 
(fig. 1 0 ) is poorly active against the mammalian and bacterial enzymes but has an 
exceptionally strong affinity for the enzyme from the Plasmodium falciparum , which 
account for its specific antimalarials action.7 7  The pyrimidine derivative 
trimethoprim is also a highly selective compound against the bacterial DHFR, (fig. 
10) as reduction of the activity of bacterial DHFR by 50% requires 0.01 pM, whereas 
the same inhibition of the human enzyme requires 300 pM . 5 5 ,6 3
These are considered the largest class of antifolate studied, 7 8 -8 0  probably 
because trimethoprim (fig. 10) is the most potent inhibitor of bacterial DHFR to date. 
It has been in the public domain since 1959 and is far the most widely used 
antibacterial antifolate.
The non-classical antifolate methylbenzoprim (fig. 10) is a potent DHFR 
inhibitor with spectacular antitumour activity against the methotrexate-resistant
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mouse M5076 reticulum cell sarcoma. 5 5 ,8 1  Kinetic studies with rat liver DHFR show 
that MBP is an inhibitor that competes with NADPH as well as DHF. 82
1.5.3 Triazines
2,4-Diamino-5,6-dihydrotriazine derivatives (fig. 10) were found to interfere 
with folic acid metabolism . 8 3  Although these substances are not very active against 
bacterial DHFR, they have shown definite promise in cancer chemotherapy. 5 2 ,8 3
Although the direct analogues of folic acid were of no value as antibacterial 
agents, other compounds more distantly related to folic acid have considerable 
importance. The potential of this type of compound was first realized in two drugs 
developed as antimalarials, pyrimethamine and proguanil. The latter compound is a 
prodrug that is metabolised in the liver to the active agent, cycloguanil (5,6- 
dihydrotriazine derivative), (scheme 6 ) . 56
Cl ( f  )> NH \ M etabolism
cycloguanil
HN — NH in body
HN
Proguanil
Scheme (6) Proguanil and its active metabolite cycloguanil
Although DHFR does not represent a new target for drug design, there is still 
enthusiasm for the development of improved derivatives of this class of
A A AA QA
inhibitors, particularly with regards to mycobacteria. " A unique feature of 
DHFR is the selectivity that is possible in the design of inhibitors; this makes it an 
ideal old target for rational and effective drug design for antimycobacterial
______ 52,65agents.
As DHFR has been studied extensively, especially in the last few years, more 
detailed insight into the structure and mode of action of the enzyme has been gained
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through the X-ray determination of enzyme isolated from different species. The 
three-dimensional structures of the enzyme became available at the same time as 
molecular graphics emerged as a new tool in drug design. Together, they allowed a 
new approach to the design of novel inhibitors of DHFR. 50
1.6 DHFR Structure and Ligands Binding Site
In the past 20 years, considerable advances have been made in the 
understanding DHFR catalysis and inhibitor binding and the most useful information 
has come from correlating physical and kinetic properties with amino-acid sequences 
and protein conformations. The amino-acid sequences of DHFR from numerous 
bacterial and vertebrate sources are known. 5 4 ,9 3 ’9 4
In general, there is much greater homology (76%) among the DHFRs from 
vertebrate sources than there is among the bacterial reductases (13%). DHFR has 
been classified as a doubly wound mixed P-sheet in which the central eight-stranded 
p-sheet is protected on either side by two a-helices. The individual strands of the P- 
sheet are designated A-H in order of their occurrence in the linear protein sequence. 
Each helix is assigned the letter of the p-strand that it precedes in the sequence.
A deep cleft exist on the enzyme surface between a-helices B and C and this 
cavity serves as the binding site for the diaminopyrimidine-type inhibitors and 
presumably the substrate dihydrofolic acid. The nicotinamide portion of the cofactor 
also binds in this cleft, in a position to transfer its hydride equivalent to the adjacent 
substrate. The diphosphate bridge of the cofactor is draped over the edge of the p- 
sheet in a shallow groove between the amino termini of the a-helices C and F, and 
the adenine moiety binds in a niche on the other side of the sheet. 93
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1.6.1 Three-dimensional Structure of M. tuberculosis DHFR and Ligands 
Binding Site
Recently the three-dimensional structure of M. tuberculosis (Mtb) DHFR 
reveals that the central p-sheet of Mtb-DHFR consists of seven parallel strands and a 
single C-terminal antiparallel strand (fig. 11).




Fig. (11) Schematic ribbon diagram of the overall fold of Mtb-DHFR
a-Helices are in red and p-strands in green. NADP is in a ball-and-stick model with 
its molecular surface being transparent. Colour code for atoms: carbon in yellow, 
oxygen in red, nitrogen in blue and dark green for phosphorus.
The p-sheet has a left-handed twist of about 130°. In the holoenzyme, the 
coenzyme NADP is bound in an extended conformation by the C-terminal part of the 
p-sheet, with the nicotinamide ring inserted into a cleft formed by strands p-A and 
P-F.
36
i. im m D V c rro N
NADP interacts extensively with the protein. The pyrophosphate moiety of 
NADP is interacting favourably with helix dipoles by binding near to the amino ends 
of helices a-C and a-E. The pyrophosphate also forms a salt bridge with Arg45. The 
adenine ring contacts the protein through interactions involving two residues Leu65 
and Leul02 on one side, and through stacking interactions with the side chain of 
Arg67 in the other side. In addition, the adenine ring contacts several other residues. 
While the adenosyl ribose loosely interacts with protein its 02-phosphate interacts 
strongly with Mtb-DHFR through five H-bonds. The nicotinamide ribose only 
contacts protein residues in loop LI, while the nicotinamide ring interacts with 
residues from strands p-A, p-E, P-I and loop L I . 8 3  In the ternary complexes, each 
containing NADP plus an inhibitor, the conformation of the cofactor is essentially 
identical with that of binary complex. Also, the interactions of NADP with protein 
residues are very similar.
Enzyme inhibitors such as methotrexate (MTX) and trimethoprim (TMP) 
bind essentially in the same pocket and their nitrogen-containing heterocyclic rings 
position in the same orientation. A common feature of the binding mode is a set of 
H-bonds between the heteroatomic rings and several structurally conserved residues. 
The other moieties of inhibitors bind to quite different protein residues. 8 3
1.6.2 Overall Structural Comparison of Mtb-DHFR and Human DHFR
The overall structural comparison of Mtb-DHFR and human DHFR reveals 
that Mtb-DHFR contains 159 amino acid residues, compared with 187 for the human 
protein with a sequence identity of 26%. A superposition of the enzymes from 
pathogen and host shows that the general fold of Mtb-DHFR is essentially the same 
as that of the human protein, even though the human enzyme is significantly larger. 
Structural differences in the active site of DHFR between Mtb and human enzyme 
are of particular interest for the design of therapeutic compounds that would 
selectively bind to the Mtb protein and would not affect the function of the human 
DHFR. The sequence identity in the active and ligand binding site is significantly 
higher, about 55%, than the sequence identity of 17% for the reminder of the chain 
but some aspects of the ligand binding area of Mtb-DHFR appear to differ in a 
significant and promising way from that in the human enzyme.
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These key differences make them suitable to be exploited for the design of 
antituberculous specific compounds.8 3 ,9 3
1.6.3 Structural Basis for Selectivity
The structure of Mtb-DHFR has been determined alone and in complexes 
with NADP and with the inhibitors such as MTX and TMP. Detailed analysis of the 
interaction of human DHFR and Mtb-DHFR with cofactor NADP and with inhibitors 
shows important differences relevant for drug design.
The key differences in the active site between the Mtb-DHFR and human 
enzyme are: first, the presence of a glycerol (A) molecule that is found in a 
depression near the folate binding site. This glycerol molecule is bonded through 
hydrogen bonds with the side-chains of Trp22 (indole nitrogen is H-bond donor), 
Asp27 (carboxylate is H-bond acceptor) and Gln28 (amide carbonyl is H-bond 
acceptor) which form a pocket in Mtb-DHFR. In contrast, in the human DHFR 
complexes containing folate or MTX, this glycerol A site is well packed with three 
hydrophobic residue side-chains of Leu22, Pro26 and Phe31. Second, two small 
hydrophobic residues in Mtb-DHFR, Pro25 and Ala29, correspond to two large 
positively charged residues, Arg28 and Arg32, in the human enzyme while one 
negatively charged residue, Glu33 in Mtb-DHFR is changed into a positively 
charged Arg36 in the human enzyme. 83
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2. AIMS AND OBJECTIVES
2.1 Aims
DHFR has distinct advantages as a potential drug target. Firstly, the 
biochemistry of the folate pathway and DHFR enzyme are well characterised and the 
crystal structure of Mtb-DHFR has been recently solved. Secondly, this long history 
means that the safety and selectivity of these inhibitors have been intensively studied.
The aim of this research project was to explore the active site of Mtb-DHFR 
looking for features for selectivity and potency and accordingly design and synthesis 
novel selective Mtb-DHFR inhibitors. Selective inhibitors will provide lower doses, 
shorter schemes for treatment, minimal side-effects and consequently reduce the 
number of MDR-TB cases.
2.2 Objectives
The objectives of this research project are as follows:
1- Study the active site of Mtb-DHFR and compare it with the corresponding 
enzyme in the human.
2- Design a new functional group to increase the selectivity o f 2,4- 
diaminopyrimidine nucleus as inhibitors towards Mtb-DHFR.
3- Modify the structure of the newly designed functional group in order to 
explore its structural and stereochemical requirements for selectivity as Mtb- 
DHFR inhibitors.
4- Synthesis the designed group of compounds.




3.1 Potency and Selectivity of DHFR Inhibitors
One of the most important questions in antifolate chemotherapy concerns the 
tremendous selectivity of trimethoprim for bacterial enzymes compared to vertebrate 
enzymes.95,96 Trimethoprim is over 100,000 times as potent an inhibitor against E. 
coli DHFR compared with human DHFR.95 What factors determine the differences 
in substituent effects between the two enzymes? Why is the design o f selective 
bacterial antifolates with minimal mammalian toxicity so cumbersome, complex and 
difficult?97
In an early analysis of the problem, the inhibition of DHFR by 
benzylpyrimidines (fig. 12) constitutes one of the most thoroughly studied QSAR 
(quantitative structure activity relationship). In a SAR study of rat liver DHFR, Hyde 
and Roth realised that the hydrophobic interactions of the substituents were of 
paramount importance while, with E. coli DHFR, only steric factors came into
i 95play.
NH
Fig. (12) Substituted 2,4-diamino-5-benzylpyrimidines
It is not easy to select the best derivatives from the point of view of 
maximizing potency in one system while minimizing it in another, even with the 
QSAR for the two systems. The crux of the matter in the present case is that, in order 
to make more bacterial antifolates, one needs to synthesise unsymmetrical 
benzylpyrimidines with a lipophilic substituent in the 3-position and a polar
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substituent in the 5-position. The more polar the substituent at 4-position is, the 
better the selectivity. However, polar groups also tend to reduce antibacterial as well 
as antiavian potency.97 It is not surprising, then, that obtaining more effective novel 
inhibitors calls for making unusual derivatives.98
3.2 Molecular Graphics-Based Drug Design
QSAR studies have relied heavily on the use of computers from the 
beginning for statistical calculations involving multiparameter equations. 
Researchers soon realised that drug design could be aided significantly if structures 
of receptors and drugs could be displayed on computer terminal and molecular 
processes could be observed
Molecular graphics is the visualisation and manipulation of three-dimensional 
representations of molecules on a graphics display device. The potential to apply this 
technology to protein crystallography was quickly realised and by early 1970s 
electron density data from X-ray diffraction studies could be presented and 
manipulated in stick or space-filling multicolour representations on a computer 
terminal.99 The number of X-ray crystal structures available in the Protein Data Bank 
(PDB) went from about 200 in 1990 to more than 31,000 by 2005.99’100
A three-dimensional computer graphics representation of a protein that can be 
manipulated in three dimensions allows the operator to visualise the interactions of 
small molecules with biologically important macromolecules. Superimposition of 
structures can be performed easily by molecular graphics. The most effective use of 
molecular modeling is when a high-resolution crystal structure o f a receptor with a 
ligand bound is available. Molecular graphics visualisation of the electron density 
map of this complex may reveal empty pockets in the complex that could be filled by 
appropriate modification o f a lead compound"
Numerous molecular graphics systems are available, but the typical system 
consists of a mainframe or supermini computer linked to a high-resolution graphics 
terminal with local intelligence. The mainframe or minicomputer executes all of the 
molecular calculation of bond lengths and bond angles. One of these systems which
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we have used on my research is the Silicon Graphics INDY together with the Midas 
Plus program.101
The molecular Interactive Display and Simulation (MIDAS) System is a 
collection of programs developed by the Computer Graphics Laboratory at the 
University of California, San Francisco (UCSF). The major component of the 
MIDAS system is an interactive graphics display program. Midas Plus , designed 
for the display and manipulation of macromolecules such as proteins and nucleic 
acids. Midas Plus is capable of displaying molecular structures and surfaces from 
information contained in PDB format files.102
3.3 Design of the Target Compounds
The three-dimensional structure of Mtb-DHFR was recently studied and 
became available from the PDB. Three crystal structures of ternary complexes of 
Mtb-DHFR with NADP and different inhibitors as trimethoprim (TMP) and 
methotrexate (MTX), have been determined as well as the binary complex with 
NADP.83
Structural comparison of these complexes with the human DHFR reveals 
clearly two major avenues for arriving at novel selective inhibitors of Mtb-DHFR; 
one involves the exploitation of differences in side-chain; a second avenue involves 
the glycerol A pocket of Mtb-DHFR which is essentially absent in the human 
enzyme. The glycerol A pocket refered to the presence of a glycerol molecule bound 
to a cavity close to the N8 position of MTX (fig. 13) and the aminopyrimidine ring of 
TMP. In contrast, in the human DHFR complexes containing folate or MTX, this 
glycerol A site is well packed with three hydrophobic residue side-chains, Leu22, 
Pro26 and Phe31.103,104
Moreover there are two residues, Leu22 and Phe31, adjacent to the N8 and 
C7 of MTX in the human DHFR, which restrict the accessibility of MTX to solvent, 
with the distance between the side-chains of Leu22 and Phe31 being about 3.8 A. 
These two residues in the human enzyme correspond to residues Leu20 and Gln28 in 
Mtb-DHFR where the shortest distance between side-chain atoms is about 6.5 to 9.4
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A. Consequently, a MTX analogue with an additional group connected to N8 or C7, 
and incorporating features of binding mode of the glycerol molecule to Mtb-DHFR 
active site, may bind selectively to Mtb-DHFR as such a MTX-derivative should be 
sterically and chemically hindered from forming a complex with human DHFR.
It was found that the glycerol molecule in the active site of Mtb-DHFR is 
bound to the protein through three hydrogen-bonds between all the hydroxy groups 
and residues Asp27, Gln28 and Trp22. The glycerol carbon atoms are in hydrophobic 
contact with the side-chain of Leu20. Consequently the conformation of the glycerol 
molecule is fixed on a definite conformation (fig. 13) that could be studied and used 
as a template for designing a new function group that could form hydrogen-bonds 
with the hydroxy groups of the glycerol molecule.83
The conformation and the binding mode of the inhibitors MTX and TMP in 
ternary complexes revealed that both bind essentially in the same pocket and their 
nitrogen-containing heterocyclic rings position in the same orientation. A common 
feature of the binding mode is a set of strong hydrogen-bonds between the 
heteroatomic rings and several structurally conserved residues. The other moieties of 
inhibitors bind to quite different protein residues.
Since the inhibitors MTX and TMP bind in a similar fashion to the active site, 
the glycerol A pocket near N8 of MTX is also in immediate neighbourhood of TMP. 
This suggests that not only MTX but also TMP can be extended by substituents 
which bind in the glycerol A pocket. These extensions to the common 
diaminodiazine motif which contributes the affinity of the inhibitors could increase 
the selectivity of the new inhibitors over human DHFR. Clearly, such diaminodiazine 
variants would have veiy different chemical structures than compounds derived from 
MTX, increasing therefore the likelihood that novel and highly selective inhibitors of 
Mtb-DHFR can be obtained.
Significant differences were also observed near to the glutamate moiety of 
MTX. Two small hydrophobic residues in Mtb-DHFR, Pro25 and Ala29, correspond 
to two large positively charged residues, Arg28 and Arg32 in the human DHFR. 
These differences are also favourable for design of selective inhibitors, as Pro25 and
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Ala29 in Mtb-DHFR allow for favorable interactions with hydrophobic substituents 
of new inhibitors, at the same time, these hydrophobic substituents are likely to 
decrease significantly the affinity of the inhibitors for human DHFR.83
Aiming to develop such selective Mtb-DHFR inhibitors, we studied the X-ray 
crystal structure of the binary complex of MTX and Mtb-DHFR to explore the 
relationship between the MTX and the glycerol pocket at the active site. By the aid 
of Silicon Graphics INDY and using the Midas Plus program we could determine the 
conformation of the glycerol molecule at the active site (fig. 13) and could measure 
the distance between MTX molecule and the glycerol molecule (fig. 14) which in 
turn helped us to determine the appropriate configuration and length of the side chain 
that should fit perfectly into the glycerol pocket.
It is reported that the best known inhibitors of DHFRs include methotrexate, 
trimethoprim and pyrimethamine, which to a different extent discriminate between 
DHFRs from eukaryotic and prokaryotic organisms. Methotrexate is more potent 
inhibitor to the mammalian DHFR, while trimethoprim and pyrimethamine are 
potent inhibitors of bacterial and protozoal DHFR, respectively, but only weak 
inhibitors of the mammalian DHFRs.83 Pyrimethamine had shown some activity 
against M. avium complex.105 Trimethoprim was reported to have poor activity 
against mycobacteria.106
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Fig. (13) Stereoview of the glycerol molecule (red) and the glycerol pocket A in 
the active site of Mtb-DHFR in MTX (blue)-DHFR binary complex (left) and in
space-filling (right)
^  V
Fig. (14) Measurement of the distance between the glycerol molecule and MTX 




Being aware of the crucial contribution of 2,4-diaminopyrimidine 
pharmacophore to the DHFR binding together with our study to the active site, we 
decided to integrate this information into a design of novel compounds to be 
synthesised and tested as selective Mtb-DHFR inhibitors.
Accordingly our target compounds would contain the 2,4-diaminopyrimidine 
nucleus with an unique extension at 6-position that would provide strong binding to 
the glycerol A pocket and a hydrophobic group at 5-position such as a substituted 
phenyl group could bind to the hydrophobic residues on Mtb-DHFR and decrease 
significantly the affinity of these novel inhibitors to the human DHFR. The new side- 
chain at the 6-position was constructed depending on our study to the conformation 
of the glycerol molecule at the active site (fig. 13) and measuring the distance 
between N8 of MTX and the glycerol A pocket which was 2 A  (fig 14) at MTX-Mtb- 
DHFR ternary complex.
Firstly, the new functional group should be 2 A  away from the N8 of MTX 
molecule. As the bond length of the C-C (sp3-sp3) bond is 1.54 A  and by considering 
that the tetrahedral bond angle is 109.5°,107 accordingly the designed functional 
group should have two carbon bond lengths apart from the N8 of MTX or three 
carbon bond lengths apart from the pyrimidine ring.
Secondly, the new function group should contain three substituents such as 
hydroxy group that could form hydrogen-bonds with the glycerol molecule at the 
active site of Mtb-DHFR. Finally the configuration of these three hydroxy groups 
should resemble the fixed conformation of the glycerol molecule in the active site to 
provide perfect binding conditions.
Consequently, the (3R,4iS)-3,4,5-trihydroxypentyl group was the best 
extension at the 6-position of the pyrimidine ring that would satisfy these 
requirements and should provide the desired selectivity for our target compounds. 
The designed target compounds (fig. 15) would contain the 2,4-diamino-5- 
(substituted phenyl)pyrimidine nucleus with the new side-chain, (3R,4S)-3,4,5- 
trihydroxypentyl, at the 6-position to bind to the glycerol pocket in Mtb-DHFR and 
should provide steric hindrance that could prevent these compounds from binding to
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the human DHFR. Furthermore, different substituents at the phenyl group at 5- 
position also were designed to explore their effects on the activity and selectivity as 
DHFR-inhibitors.
OH
r 1 = h , c i , n o 2
R2 = H, Cl, Br, NCETjBn
Fig. (15) Target compounds group (A)
There are five hydrophilic groups already present on this group A target 
compounds (fig. 15) and in order to increase the hydrophobicity of such compounds 
we considered the introduction of lipophilic substituents such as chlorine, bromine 
and NCHsBn group to the phenyl side-chain aiming to increase the probability o f the 
target compounds to pass the lipophilic mycobacterial membrane.
The introduction of an electron-withdrawing group, such as the nitro group, ortho 
to the halogen was essential chemically to increase the activity of the benzene ring 
towards the nucleophilic substitution of the halogen with secondary amine. The 
designed target compounds group A (fig. 15) should accommodate in the active site 
of Mtb-DHFR with the new functional group at 6-position that resembles the 
structure and configuration of the glycerol molecule located in the active site o f Mtb- 
DHFR. That new function group should provide a strong binding of the novel 
inhibitors group A to the glycerol pocket through strong hydrogen-bonds as the 
configurations of three hydroxy groups on the side chain were designed to be 
perfectly fitted in the glycerol pocket.
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To understand the steric requirements of the hydroxy groups of this side-chain at 
6-position, we designed another group of novel compounds group B (fig. 16) which 
would have the same nucleus as (group A) apart from the configuration of the chiral 
centres.
The side-chain for group B target compounds at 6-position would be the (3S,4S)~
3,4,5-trihydroxypentyl group. We anticipate that this side-chain should not fit as well 
into the glycerol A pocket, compared to group A target compounds. Consequently 
group B target compounds should be less potent than group A compounds. On the 
other hand, it should not affect the selectivity of group B compounds as there are still 
two hydroxy group that should bind probably to the glycerol A pocket in Mtb-DHFR 




r 1 = h , c i , n o 2
R2 = H ,Cl,Br,NCH 3Bn 
Fig. (16) Target compounds group (B)
Furthermore, we decided to preserve the same carbon skeleton of the side- 
chain at the 6-position but with only one primary alcohol functional group to explore 
the importance of the deleted hydroxy-groups on potency and selectivity which could 





R ^ H ^ N C ^
R2 = H, Cl, Br, NCH3B11
Fig. (17) Target compounds group (C)
Finally, to establish the predictive value of the design of our target 
compounds, group D (fig. 18) was designed to have the same side chain as group A 
but with a shorter carbon chain at 6-position to assess the importance of the 
measured distance between the main nucleus and the glycerol pocket at the active 





r 1 = h , c i , n o 2
R2 = H, Cl, Br, NCH3B11 
Fig. (18) Target compounds group (D)
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Three model compounds of substituted 2,4-diaminopyrimidines (fig. 19) with 
three different side-chains would also be synthesised to be compared with the 
activity of the target compounds.
The importance of these parameters for potency and selectivity can be 
conveniently determined by microbiological examination of the compound in 
question on Mtb-DHFR and the human enzyme as well.
Toward this end the synthesis of the target compounds was carried out and 
biological examination was performed.
3.4 Strategies for Preparation of 2,4-Diaminopyrimidine Derivatives
Different strategies have been employed for the synthesis of different derivatives 
of 2,4-diaminopyrimidine.
By the principal synthesis, a primary amino group results in position 2 when 
guanidine is used as the one-carbon fragment in synthesis of the 2,4- 
diaminopyrimidine nucleus, while the primaiy amino group in position 4 and/or 6 
arises by using a nitrile or dinitrile as a three-carbon fragment.108 However, 
p-aldehydonitriles such as formylphenylacetonitrile (1), condensed with guanidine to
R1 = CH3, C2Hs, CH2CH2Ph 
R2 = H , Cl
3> ° 2 n 5»
Fig. (19) Model compounds
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give 2-amino-4-benzyl-l,3,5-triazine (3) rather than the expected 2,4-diamino-5- 

















Scheme (7) Reaction of formylphenylacetonitrile with guanidine
The reason for the anomalous reaction of these formyl intermediates may 
possibly be due to their existence mainly as enols (2) which might well have too high 
an acidic strength for normal condensation but, when they were first converted with
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diazomethane to enol ethers (4), they readily condensed with guanidine to give the 
expected pyrimidine (5) (scheme 7).110
Different strategies have been employed for the preparation of 2,4-diamino-5- 
phenylpyrimidine derivatives. For example a-formyl-p-phenylesters, in general, 
would condense with guanidine to give 2-amino-4-hydroxypyrimidine (6) derivatives 
which could be converted to the corresponding 2,4-diaminopyrimidine (9) 
derivatives via 4-chloropyrimidine analogues (7),111,112 although an alternative route 










(8) ( 9 )
Scheme (8) Preparation of 2,4-diaminopyrimidine derivatives from the 2-amino-
4-hydroxypyrimidine analogues
The systematic synthesis of 2,4-diaminopyrimidine derivatives via the
2-amino-4-hydroxy and 2-amino-4-chloropyrimidines proved to be very
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unsatisfactory. Although the 5-phenyl and the meta and para chloro and 
bromophenyl derivatives could be prepared by this route, the yields of the 
aminohydroxypyrimidines were exceptionally poor. Moreover, the condensation of 
a-formyl-p-phenylester and guanidine failed entirely with ortho-substituted phenyl 
derivatives, when the aromatic nucleus was substituted by electron donor groups and 
with a-phenyl-p-ketoesters. The last limitation was considered the most serious.113
A number of possible alternative methods of synthesis involving modification 
of urea derivatives and esters were examined. However, several derivatives of a- 
acetylphenylacetonitriles failed under a variety of conditions to condense with 
different urea derivatives to give 2,4-diaminopyrimidines. it seemed probable that the 
high degree of enolisation and acidity of these p-carbonyl derivatives was 
fundamentally responsible for their failure to condense.110 Rupe has overcome this 
difficulty by condensing guanidine with enol ether (10) to give 2-amino-5- 





( i i )
Scheme (9) Preparation of 2-amino-5-phenylpyrimidine
A modified method has been employed by Tamchompoo and Sirichaiwat,68 
for the preparation of pyrimidine analogues. This improved synthetic route is 
outlined in (scheme 10). Lithiation of phenylacetonitrile derivatives (12) with lithium 
diisopropylamide (LDA) followed by acylation with acid chloride (13) afforded the 
corresponding acylphenylacetonitrile (14). Upon treatment of (14) with 
diazomethane, it provided the corresponding methoxyacrylonitrile (15), which was
53
3. (DISCUSSION















Scheme (10) General procedure for synthesis of 2,4-diaminopyrimidine 
derivatives from phenylacetonitrile and acid chlorides
Recently the Suzuki reaction, which involves the palladium-catalysed cross­
coupling of heteroaryl-halides with arylboronic acids, has been used to prepare 6- 
aryl-2,4-diaminopyrimidines (18) from 6-halo-2,4-diaminopyrimidine (17) building 












Scheme (11) Synthesis of 2,4-diamino-6-arylpyrimidines using Suzuki cross­
coupling reactions
3.5 Strategy for Synthesis of the Target Compounds
The most convenient procedure that provides the mildest conditions that 
could be compatible with the trihydroxyalkyl side-chain at the 6-position of the 
target compounds is the strategy outlined in scheme (12). The key step for the 
synthesis of 2,4-diamino-5-(substituted phenyl)pyrimidine nucleus is the 
condensation of different derivatives of phenylacetonitrile with the appropriate esters 
to form the f3-ketonitriles. The second step was the synthesis of the enol ethers 
through O-methylation of the P-ketonitriles. The final step would be condensation of 















Scheme (12) Strategy for synthesis of 2,4-diamino-5-(substituted 
phenyl)pyrimidine
According to our strategy for the preparation of target groups of compounds, 
different phenylacetonitrile derivatives have been designed to be condensed with 
different esters to give the corresponding p-ketonitriles. Phenylacetonitriles with 4- 
chloro, 4-bromo and 3,4-dichloro substituents were commercially available. 








Fig. (20) Structure of phenylacetonitrile derivatives
The first series of target compounds, group A, contain a 3,4,5- 
trihydroxypentyl group linked to the 6-position o f the pyrimidine ring (fig. 15). Two 
of these hydroxy groups are attached to two chiral carbons with (3R,4S) 
configuration.
Retrosynthetic analysis of the pyrimidine synthesis revealed that this part of 
the structure derived from the corresponding ester (21) carrying three hydroxy 
groups (scheme 13), which was not commercially available. A common requirement 
in synthesis is that a hydroxy group should be masked as a derivative lacking a 
hydroxylic proton. Such a requirement appeared in the reaction of phenylacetonitrile 
with a strong base to generate the corresponding anion, which would react with ester 
to give the {3-ketonitrile derivatives (scheme 12). Being aware of the acidic hydrogen 
of the hydroxy group (the pKa of RCH2OH = 16,117 while pKa of RCH2CN = 25)118 
that could destroy one equivalent of the strong base used in the latter reaction and 
possibly adversely affect the reaction in other ways,117 the retrosynthetic analysis of 
the structure of ester (21), scheme (13), revealed that these hydroxy groups should be 
protected with suitable protecting groups that keep the hydroxy groups protected 
along the synthetic pathway.
The most common route for the protection o f vicinal hydroxy groups is 
formation of an acetal.119 The third hydroxy group should be protected with another 
protecting group such as the formation of the benzyl ether as in ester (22). The acetal 
protecting group is inert to nucleophilic reagents and is unchanged under conditions 
such as hydride reduction, organometallic reactions or aqueous base-catalysed 
reactions. It also protects the hydroxy group against oxidation.120’121 The benzyl ether
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linkage is also providing protection to the primary hydroxy group towards 
nucleophilic reagents, oxidation reactions and aqueous base or acid-catalysed 
reactions.122
Consequently, we could proceed through the different reaction conditions 
involved in scheme (12) and scheme (13) while keeping the hydroxy groups 
unreactive towards all the reagents used along the synthetic pathway. The proposed 
ester (22) could be derived from the corresponding unsaturated ester (23) through 
Wittig reaction of the triphenylphosphoranylidene ester (24) with aldehyde (25). The 
latter could be derived from oxidation of the corresponding alcohol (26).
The second group of the target compounds (group B), contains the same 
functional group at 6-position of the pyrimidine ring apart from the configuration of 
one hydroxy group which had been manipulated to afford the corresponding (3S,4S)~
3,4,5-trihydroxypentyl derivatives. The corresponding ester was not commercially 
available and should be synthesised using the same principle for the preparation of 



















Scheme (13) Retrosynthetic analysis of the 3,4,5-trihydroxyhexanoate ester
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Our strategy for preparation of group C of target compounds was to use the 
commercially available e-caprolactone (27) (fig. 21), rather than the corresponding 
hydroxy ester, which is a novel method for preparation of p-ketonitrile.
The use of the corresponding lactone has the advantage of having 
intramolecular protection of the hydroxy group which in turn could shorten two steps 
along the synthetic pathway, one for protection and second for deprotection of the 
hydroxy group. Thus it should also improve the overall yield of the final product.
Fig. (21) Structure of 8-caprolactone (27) and 2,3-O-isopropylidine-D- 
erythronolactone (28)
Furthermore, we decided to prove the validity of the previous principle on the 
preparation of target compounds group D by using the commercially available 
lactone (28) (fig. 21), with a shorter carbon skeleton and two protected hydroxy 
groups, for preparation of the corresponding p-ketonitrile.
For the synthesis of model compounds, the commercially available ethyl 
acetate, ethyl 3-phenylpropanoate and ethyl propanoate were used as the ester 
counterpart for the synthesis of the corresponding P-ketonitriles.
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3.6 Phenylacetonitrile and Its Derivatives
Phenylacetonitrile and its derivatives were used for condensation with esters 
or lactones to afford the corresponding P-ketonitrile. The novel 4-(N-benzyl-N- 
methylamino)-3-nitrophenylacetonitrile (19) was synthesised through radical 
monobromination of 4-chloro-3-nitrotoluene (29) using N-bromosuccinimide (NBS) 
and dibenzoyl peroxide as a radical initiator to give (30) in a good yield.123
NBS, (P h C 0 2)2
(C2H5)4NCN BnNHMe
(19)
Scheme (14) Synthesis of 4-(N-benzyl-N-methylamino)-3-nitrophenylacetonitriIe
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Compound (30) has two different halogens which are susceptible to 
nucleophilic substitution with a strong nucleophile such as cyanide ion (CN"), with 
two different mechanisms.
The first one is through the bimolecular nucleophilic substitution (Sn2 
mechanism) of the bromide on the aliphatic side-chain where the nucleophile 
approaches the substrate from a position 180° away from the leaving group (Br). The 
reaction is a one-step process with no intermediate. The identity of the leaving group 
influences the rate of Sn2 reaction because it departs with the pair of electrons from 
the covalent bond to the reacting carbon atom. The leaving group comes off more 
easily the more stable it is as a free entity. A correlation with electronegativity may 
be expected. The order of the halide as a good leaving groups is I > Br > Cl > F. This 
order is opposite from that of electronegativity and is dominated by the strength of 
the bond to carbon which ranges from ~ 50 Kcal mol'1 for C-I bond to ~ 100 Kcal 
mol"1 for C-F bond.119 Thus iodide is the best leaving group and fluoride is the 
poorest.124
The second one is through aromatic nucleophilic substitution (SnAt 
mechanism) of the chloride on the benzene ring in two steps where the nucleophile 
forms a bond with the substrate first, giving a tetrahedral intermediate, (the rate- 
determining step) and then the leaving group (chloride) departs. An increase in 
electronegativity of the halogen as a leaving group causes a decrease in the electron 
density at the site of attack resulting in a faster attack by a nucleophile. Thus when 
fluoride is the leaving group, the relative rate was 3300 (compared with 1=1) .  Thus 
fluoride is the best leaving group while iodide is the poorest.125
The principal reason for the order I > Br > Cl > F in Sn2 reaction is the 
carbon-halogen bond strength which increases from I to F. The carbon-halogen bond 
strength is not so important a factor in SnA t because bond breaking is not ordinary 
part of the rate-determining step. Furthermore, the highly electronegative fluorine 
favours the addition step more than other halogens.126 Consequently, by doing the 
nucleophilic substitution reaction under mild conditions, compound (30) was more 
active towards Sn2 mechanism than SnA t reaction as compound (30) reacted with
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tetraethylammonium cyanide at room temperature to afford the nitrile derivative (31) 
but in a relatively low yield.127
The expected substituted phenylacetonitrile (19) was obtained (scheme 14) 
from the aromatic nucleophilic substitution (SnA t) of the chloride in compound (31) 
with N-benzyl-N-methylamine under stronger conditions than the previous Sn2 
reaction by heating under reflux overnight with the nucleophile.128 The SnAt 
substitution reaction is accelerated by the electron-withdrawing effect of the nitro 
group ortho to the chloride because the addition step in the SnA t mechanism is 
greatly facilitated by strongly electron-withdrawing substituent, so that 
nitroaromatics are the best substrate for SnAt reactions.125’129
Another novel phenylacetonitrile derivative to be synthesised was 4-(N- 
benzyl-N-methylamino)phenylacetonitrile (20) (scheme 15). The first step was the 
formation of the amide derivative (34) by the acylation of methyl 4-(N- 
methylamino)benzoate (32) with benzoyl chloride (33) to afford the expected amide 
(34) in an excellent yield.130 The reduction of (34) was established by using two 
equivalents of LiAlTL* as a reducing agent in dry ether to afford the corresponding 
alcohol (35). Substitution of the hydroxy group by the bromide was obtained by the 
reaction of alcohol (35) with 30% hydrobromic acid in acetic acid to afford the 
hydrobromide salt (36).131 Compound (36) was recovered in a very good yield as a 
very hygroscopic orange solid which could not be further purified. The NMR 
spectrum showed that it was sufficiently pure to be used as such for the following 
reaction. The corresponding free base of compound (36) was very unstable and could 
not be isolated by subsequent neutralisation with sodium bicarbonate. The presence 
of the bromide as a good leaving group along with such a strong nucleophile as the 
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LiAlH4
(34) (35)
P h "  \
30% HBr/CH-iCOOH
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Scheme (15) Synthesis of 4-(N-benzyl-N-methylamino)phenylacetomtrile
The final step to target compound (20) was the nucleophilic substitution of 
the bromide with cyanide using tetraethylammonium cyanide as the nucleophile. The 
best reaction condition to get the required product (20) was by the addition of 
triethylamine first to liberate the free base followed immediately by the addition of
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the nucleophile under dry conditions, and leaving the reaction mixture overnight to 
obtain the target compound (20).
Phenylacetonitriles (19) and (20) were prepared as starting phenylacetonitrile 
derivatives for the synthesis of the corresponding 2,4-diaminopyrimidine derivatives 
of the designed target compounds, as a similar 2,4-diaminopyrimidine derivative, 
methylbenzoprim (39), having the same side-chains on the phenyl group showed a 
strong inhibition of DHFR 81,82
In the literature, the preparation of methylbenzoprim (39) and its derivatives 
was derived from pyrimidine (37) (scheme 16). Compound (37) was nitrated in the 
ortho position to the chloride using HNO3/H2SO4 mixture to give compound (38). 
The final step was then the SnAt nucleophilic substitution of the chloride with the 






Scheme (16) Preparation of methylbenzoprim50,81
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Our strategy was to incorporate these side-chains on the starting 
phenylacetonitrile derivatives as in compounds (19) and (20) before their 
condensation with the 3,4,5-trihydroxypentyl ester (22) to avoid the drastic condition 
of the nitration reaction which would destroy the polyhydroxylated side-chain at the
6 -position of the target compounds.
3.7 Esters and Lactones
A variety of esters and lactones were used for condensation with different 
phenylacetonitriles for synthesis of the corresponding P-ketonitriles. For synthesis of 
group A target compounds, ester (48) (scheme 17) was to be synthesised for 
condensation with phenylacetonitrile and its derivatives to form the corresponding p- 
ketonitriles.
Retrosynthetically, ester (48) could be constructed from erythrose, by chain 
elongation at its terminus, enabling the eventual preparation of ester (48) as an 
enantiomerically pure substance. L-Arabinose (40) was the starting compound for 
preparation of erythrose (44) , 1 3 3 ,1 3 4  according to scheme (17). Our strategy aimed to 
generate an aldehydic functional group at one particular side of the dioxolane ring 
followed by chain elongation at that end in order to end with the required 
configuration for ester (48).
Consequently the first step was protection of the vicinal hydroxy groups of L.- 
arabinose (40) by reacting with 2,2-dimethoxypropane (41) to form the 
corresponding ketal (42) followed by periodate cleavage of compound (42) in one 
pot to give the aldehyde (43) . 1 3 5 ,1 3 6  Ketal formation provide the required protection 
for the vicinal hydroxy groups against oxidation reactions, catalytic hydrogenation 
and nucleophilic substitution reactions as well as aqueous basic reactions. Formic 
acid, formed as a second product of the periodate oxidation of compound (42), 
catalyses the intramolecular cyclisation of the aldehyde (43) to the corresponding 
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The reaction of aldehyde (43) with the Wittig reagent, ethyl 
triphenylphosphoranylidineacetate, afforded a mixture of (45) E and (46) Z alkenes, 
which were successfully separated by chromatography. ’ The Z geometry of the 
major product (46) (54% yield) was assigned by NMR 8 h spectroscopy. The signals 
due to the alkenyl protons (-CH=CH-) showed J  — 11.7 Hz. The corresponding 
signals in the E isomer (15) (15% yield) showed J  = 15.6 Hz. In addition, the 5-H 
signal ( 8  5.65) in Z-isomer (16) appeared at considerably lower field compared with 
the corresponding 5-H in the E-isomer (15) ( 8  4.79) due to deshielding by the ester 
carbonyl group. 1 3 9
The reduction of a mixture of alkenes (45) and (46) was achieved by catalytic 
hydrogenation using 5% palladium on charcoal as a catalyst to afford (47) in a 
quantitative yield . 1 3 8  Protection of the hydroxy group of compound (47) through 
formation of benzyl ether was preferably carried out at the last step to avoid the 
cleavage of the ether linkage by the previous catalytic hydrogenation reaction. The 
final step was the protection of the hydroxy group of (47) to form the target ester 
(48) through the formation of the benzyl ether by reacting with benzyl bromide. The 
reaction proceeds by nucleophilic substitution of the bromide with alcohol (47) 
toward the formation of the ether linkage using lithium bis(trimethylsilyl)amide as a 
base to afford the target ester (48). Unfortunately, this reaction is only efficient on 
small scale (10 mmol or less). Working with larger scales resulted in formation of 
traces of the desired product. As a consequence, separate batches on small scales 
were run to prepare the required quantity of ester (48).
For synthesis of the group (B) target compounds, the ester counterpart 
required for coupling with phenylacetonitrile and its derivatives should be (4S,5S)-4- 
benzyloxymethyl-5-(ethoxycarbonylethyl)-2,2-dimethyl-1,3-dioxolane (57). The
synthetic pathway employed for the preparation o f compound (57) is outlined in 
scheme (18).
Our strategy for preparation of (57) was devised to construct the threo series 
2,3-O-isopropylidenethreitol (50) and its derivatives (51-57) while keeping the 
hydroxy groups protected and the stereocentres enantiomerically pure. This approach 
was achieved by the protection of the vicinal hydroxy groups of diethyl RJl-2,3-
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dihydroxybutanedioate (49) through ketal exchange with 2,2-dimethoxypropane (41) 
to afford the symmetrical ester (50) in a good yield.
Compound (50) was reduced to the corresponding C2 symmetrical alcohol 
(51) in a good yield using LiAffiU as reducing agent. 140
The C2 symmetrical alcohol (51) has two equivalent alcoholic side-chains 
(CH2OH) at C-4 and C-5; consequently protection of either of them and oxidation of 
the other will afford the same aldehyde. On the other hand, this strategy for 
preparation of ester (57) could not be used for preparation of its epimer (48) starting 
from the corresponding diethyl ester of meso tartaric acid as in such a case we would 
have a meso alcohol, the epimer of compound (51), with two non-equivalent side- 
chains at C-4 and C-5. Consequently, protection of one hydroxy group will result in 
formation of a pair of enantiomers which should be separated before proceeding to 
the oxidation step to ensure the enantiomeric purity of the target ester (48). Since 
enantiomers have identical physical properties and their separation is a complicated 
process so it was more convenient and practical to use a sugar as a starting material 
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The Ci symmetry of alcohol (51) was then broken down by protection of one 
hydroxy group using a stoichiometric amount of benzyl chloride to give a mixture of 
compounds (52) and (53). Our investigation of the reaction conditions revealed that 
by using an equivalent amount of benzyl chloride and sodium hydride as a base and 
using dry DMF as a solvent, we have successfully prepared compound (53) in a good 
yield (64%), compared to compound (52) (28%), after an effective chromatographic
141142separation. ’
Pyridinium chlorochromate (PCC) is one of the reagents of choice for 
oxidation of primary alcohol to aldehyde1 4 3 ’14 4 and was used for the oxidation of 
alcohol (53) to afford aldehyde (54) in a higher yield than that reported by 
Mukaiyama1 4 5 by using Swem oxidation procedure using oxalyl chloride-activated 
dimethyl sulfoxide (DMSO) as oxidising agent. Furthermore, by using PCC, we 
avoided the use of excess reagent and formation of unpleasant-smelling volatile 
(boiling point 37 °C) by-product, dimethyl sulfide, on using Swem oxidation. 1 4 6 ’147
Wittig reaction of aldehyde (54) with ethyl triphenylphosphoranylidineacetate 
afforded the adducts E (55) and Z (56) geometrical isomers, which were separated by 
column chromatography. 1 4 3  This reaction was achieved with unusual acid catalysis, 
as the presence of the carbonyl group in the phosphorus ylid resulting in decreasing 
its reactivity as a consequence of charge delocalisation which in turn reduces the 
nucleophilicity of the ylid . 123 Accordingly, acid-catalysis of the reaction should 
enhance the electrophilicity of the aldehyde and hence the reactivity of the aldehyde 
and as a result the reaction go to completion with a reasonably good yield.
The final step to the target ester (57) was the reduction of the side-chain 
double bond of a mixture of the unsaturated esters (55) and (56) without the cleavage 
of the benzyl ether linkage and, accordingly, deprotection of the primary hydroxy 
group. For that purpose, a carefully controlled catalytic hydrogenation of a mixture 
of esters (55) and (56) was investigated and the best reaction condition was achieved 
by using a catalytic amount of 5% palladium on charcoal and using ethanol as a 
solvent under an atmosphere of hydrogen for one hour to afford (57) in a good yield. 
Increasing the reaction time and the amount of the catalyst resulted in deprotection of 
the primary hydroxy group and accordingly would decrease the yield of the target
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ester (57). Following the latter catalytic hydrogenation reaction by ]H NMR 
indicated that after two hours the cleavage of the ether linkage started as indicated in 
the JH NMR spectrum by the disappearance of the characteristic peaks of the benzyl 
group protons and, after five hours, the benzyl group was completely removed and 
afforded compound (58).
The protection of alcohols as terr-butyldimethylsilyl (TBDMS) ethers has 
been recognised as one of the most useful methods because of its easy installation 
and general stability to basic, mild acidic reagents and hydrogenolysis but they are 
unstable to strong oxidising agents, 1 4 3 ,1 4 8 ’1 4 9  Consequently, silyl ethers could not be 
used for protection of the hydroxy group of the starting alcohol. The formation of a 
silyl ether is carried out by treatment of alcohol with the silyl chloride in the presence 
of a base. 1 4 9 ,1 5 0
Silylation of alcohol (58) was tried by using either TBDMS chloride or tert- 
butyldiphenylsilyl (TBDPS) chloride with imidazole as a base and 
dimethylformamide (DMF) as solvent. 1 5 1 ,1 5 2  Such methods suffered from drawbacks 
such as the difficulty in removal of amine salts derived from the reaction o f by- 
produced acid and co-bases during the silylation reaction, 15 0 and tedious and time 
consuming work up due to the presence of DMF which must be removed by repeated 
extraction of the mixture with water. 1 53 There was a visualization problem on 
following the reaction progress, in the case of using TBDMS chloride, by TLC as 
both the starting alcohol and the resulted ether are invisible under UV lamp or 
spraying with aqueous sulfuric acid. Consequently, purification by column 
chromatography was useless. Furthermore, silyl ethers are unstable under the PCC 
oxidation reaction condition as it is reported that PCC cleaved the TBDMS ether of 
p-hydroquinone at room temperature within 2  h . 1 4 3
Consequently, it was then more convenient to reduce compound (56) to the 
target ester (57) and save protection and deprotection steps.
The prepared compounds were characterised by NMR spectrum which 
showed the characteristic peaks for each functional group transformation. The mass
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spectrum and the accurate mass for the final ester (57) were also recorded. The 
specific rotations were also determined for the optically active compounds.
There are significant differences between the NMR spectra o f ester (48) 
and its epimer (57). The two methyl groups at C-2 of the dioxolane ring for ester (48) 
gave two singlets at 8  1.33 and 8  1.42 while the corresponding signals for ester (57) 
appeared at 8  1.38 and 8  1.39 as a result o f changing the configuration of C-5. There 
are also significant differences in chemical shifts of the protons of the C-5 side chain 
between the two diastereoisomers. There is also a difference between signals due to 
the 4-H and 5-H on both diastereoisomers as they are present in different magnetic 
environment. In compound (48), the 5-H signal appeared as a multiplet overlapping 
with the quartet of the ethyl group at 8  4.08-4.15, while the 4-H with cis geometry to 
5-H appeared as a double doublet at 8  4.28. The corresponding signals of compound 
(57) appeared as a multiplet for both 4-H and 5-H upfield at 8  3.80-3.87. These 
significant differences in !H NMR indicated that we have successfully synthesised 
two different diastereoisomers during the two different synthetic pathways.
In addition to NMR characterisation, esters (48) and (57) have different 
optical activity values as ester (48) has [a]D2 0  = +24.8° (c 4.4, CHCI3) while ester 
(57) has [ g i] d 20 = -15° (c 4.0, CHCI3) which indicate that they are diastereoisomers 
and not a pair of enantiomers.
A variety of commercially available esters and lactones has also been used 
for preparation of target groups C, D and model compounds. For synthesis of group 
C and group D target compounds, e-caprolactone and 2,3-O-isopropylidene-D- 
erythronolactone, respectively, were used as they have the advantage of having the 
terminal hydroxy group intramolecularly protected compared with the open-chain 
ester analogues. Ethyl acetate, ethyl propanoate and ethyl 3-phenylpropanoate were 
successfully used as the starting ester counterparts for condensation with the 




3.8 Preparation of p-Ketonitrile Derivatives
The first step for the preparation of our target compounds was the acylation 
of the phenylacetonitriles with different esters and lactones to form the 
corresponding p-ketonitriles (scheme 19).
((CH3)3Si)2M i
phenylacetonitrile ester ketonitrile
Scheme (19) Preparation of p-ketonitrile derivatives
The acylation of phenylacetonitrile with ethyl acetate was usually achieved 
by using sodium methoxide as a base1 5 4 ,1 5 5 but, unfortunately, this method failed in 
the case of other esters or lactones. In the literature, Das and Boykin used sodium 
ethoxide as a base for acylation of phenylacetonitrile with ethyl formate; however, in 
the case of acylation with ethyl propanoate, the yield was very low, so alternatively 
they employed aprotic conditions and used sodium hydride (NaH) as the base. 156
Bliss and Griffin also used sodium ethoxide as a base for the condensation of 
phenylacetonitriles with ethyl acetate or ethyl propanoate; however, problems were 
encountered at the condensation of 2 -chlorophenylacetonitrile with ethyl propanoate 
as only ( 1 0 % yield) of the corresponding p-ketonitrile was formed under optimum 
conditions. Furthermore, 2-methoxyphenylacetonitrile did not condense with ethyl 
propanoate, even under forcing conditions. 132
Cook and Corly used the sodium salt of dimethylsulfoxide (Na+ ‘CHiSOCHk) 
as a base for acylation of phenylacetonitrile with esters to prepare the corresponding 
p-ketonitriles. In a previous investigation a method was developed for acylation of 
nitriles with esters with sodium amide (NaNH2) as a base but nitriles may be attacked
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by sodium amide not only at a-hydrogen to form the sodionitrile (59) but also at the 




Scheme (20) Reaction of nitriles with sodium amide
Such nitriles having only one a-hydrogen have been alkylated but special 
conditions (involving addition of sodium amide to a mixture of the nitrile and alkyl 
halide) appear to be required. Apparently some ionisation of a-hydrogen of these 
nitriles first occurs but the reaction gradually reverses in favor of amidine 
formation. 158
According to the Kayaleh and Gupta procedure, p-ketonitriles were produced 
from a Claisen condensation of benzoate esters with alkyl- or phenyl-acetonitriles in 
the presence of an excess of lithium diisopropylamide (LDA) as a base (4-6 
equivalents). However, the yields were poor to modest, due to preferential attack of 
LDA (which is usually considered as non-nucleophilic) on the benzoate ester to give 
the N,N-diisopropylamide. Generally ethyl esters were used because they gave less 
of the N,N-diisopropylamide by-product than methyl esters. In no case was the 
reaction complicated by lithiation of the aryl ring derived from the acetonitrile even 
when methoxy groups were present. 160
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In the present work, many trials were made to achieve this condensation 
reaction by using a large variety of reported bases such as sodium alkoxides, sodium 
hydride and the sodium salt of dimethylsulfoxide under different conditions but they 
were all unsuccessful.
The possible complications with this condensation reaction were considered 
and rationalised. Firstly, the relatively high pK* values of nitriles (phenylacetonitrile 
pK* = 21.9) 16 1 demand the utilisation of a strong base to abstract the a-hydrogen to 
form the corresponding anion. 1 6 2 Secondly, the acylation of nitriles furnishes a 
product (p-ketonitrile) which is considerably more acidic than the starting 
material. 1 6 3 Consequently, a strong, non-nucleophilic and sterically hindered base is 
needed to be able to abstract the proton from the nitriles and could not react with the 
product due to steric hindrance. Furthermore, the reaction condition was adjusted in 
such a procedure that prevents the Claisen condensation of two molecules o f the 
esters together and formation of the p-keto ester, 11 2 rather than the target p- 
ketonitrile. Thus our strategy was to use an equivalent amount of the base to be 
added to the starting nitrile derivatives first to ensure the formation o f the 
corresponding anion intermediate and at the same time ensure the complete 
consumption of the added amount of the base before the addition of the ester or 
lactone at low temperature (-78 °C) under dry conditions in order to minimise the 
possibility of Claisen condensation reaction and secure the formation of the target P- 
ketonitriles. 16 4
Lithium bis(trimethylsilyl)amide (LSA) was successfully used to favour the 
formation of the nitrile-anion to react with the ester or lactone as the electrophiles. 164  
The advantage of using LSA as the base in this reaction is being a strong, non- 
nucleophilic base and being veiy bulky as well which, in turn, inhibits the 
nucleophilic addition of that base to the nitrile as in case of using sodium amide as a 
base which favour the formation of amidines. 15 9
P-Ketonitriles (61-78) (fig. 22) were successfully synthesised and fully 




(61): R1 = H, R2 = H
(62): R1 = H, R2 = Q
(63): R1 = H, R2 = Br
(64): R1 = a ,  R2 = Q
/ — -Ph
(65): R1 = H, R2=H
(66): R1 = H, R2 = a
(67): R1 = H, R2 = Br
The corresponding ketonitriles of group A The corresponding ketonitriles of group B
(68): R1 = H, R2 = H
(69): R1 = H, R2 = Q
(70): R1 = H, R2 = Br
(71):R1 = Q ,R2= a
The corresponding ketonitriles of group C
HO
R1
(72): R1 = H, R2 = H
(73): R1 = H, R2 = C1
(74): R1 = H, R2 = Br
(75): R1 = G , R2 = Cl
The corresponding ketonitriles of group D
R2 = H(76): R1 = CH3,
(77): R1 = CH2CH2Ph, R2 = H
(78): R1 = C2H5, r2 = ci
The corresponding ketonitriles of model compounds
Fig. (22) Structures of the prepared p-ketonitriles
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Assignment of NMR spectral data of P-ketonitriles corresponding to group 
A and B target compounds revealed significant differences between the resonance 
and multiplicity of the protons of the aliphatic side-chain as a consequences of 
changing the configuration of one chiral centre. The 4-H on the dioxolane ring of 
group A compounds (61-64) resonated at the range of 8  3.90 to 8  4.29 while the 
corresponding proton of group B (65-67) resonated further upfield at the range of 8  
3.53 to 8  4.03. Furthermore, the 5-H on the dioxolane ring of group A compounds 
resonated at the range of 8  4.20 to 8  4.22 as a quartet while the corresponding proton 
of group B compounds resonated further upfield at the range of 8  3.53 to 8  4.03 as a 
multiplet on its own or overlapping with the 4-H signals.
On the other hand, in case of group A compounds, the two protons of the 
(CHiOBn) group resonated at the range of 8  3.45 to 8  3.49 while the corresponding 
protons of group B compounds resonated further downfield in the range of 8  3.55 to 
8  3.89. Another feature was concerned with the protons of the CH2 group attached to 
the chiral C-4 of the dioxolane ring. In the case of group A compounds, these protons 
resonated at the range of 8  1 . 6 6  to 8  1 . 8 8  as a multiplet with integration equivalent to 
two protons, while the corresponding protons of group B resonated further downfield 
at the range of 8  1.81 to 8  2.04 as they were appeared as a two sets of a well- 
separated multiplets.
These differences in the values of the chemical shift were because these 
protons are magnetically non-equivalent due to the presence of two chiral centres on 
the dioxolane ring. The inversion of configuration of C-5 in compounds of group B 
(65-67) was responsible for the previously mentioned differences of their ]H NMR 
spectra, compared to their epimers of group A compounds (61-64).
The assignment of the !H NMR spectra of the aliphatic side chain of the p- 
ketonitriles (68-71) corresponding to group C target compounds called for doing the 
COSY spectra (Correlated SpectroscopY), which indicated all the spin-spin coupled 
protons and hence enabled us to allocate the correct arrangement of the protons 
especially of the aliphatic side chain, on the NMR spectra in addition to the reported 
values of the chemical shifts of different groups. Methylene protons that are away
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from the carbonyl and hydroxy groups should resonate upfield ( 8 h  = 1.4) followed by 
the methylene protons attached to the carbonyl group ( 8 h  = 2.9) and further 
downfield there should be the signals from the methylene protons attached to the 
hydroxy groups (5h  = 3.6).165
The ]H NMR spectra of p-ketonitriles (68-71) of group C revealed that the 
5 -H2  resonated relatively upfield at 8 1.21-1.42 as it was away from the deshielding 
effect of the hydroxy and carbonyl groups. According to the COSY spectra the latter 
protons were coupled with the 6 -H2 which resonated at 8  1.44-1.58. On the other 
hand, the former protons was reported also to be coupled with signals of 4 -H2  which 
resonated at 8  1.58-1.65. the latter protons were found to be coupled with 3 -H2  which 
resonated at 8  2.58-2.66 as a triplet for compound (6 8 ), or as two sets of douple 
triplet each integrating for one proton as in compounds (69 and 70), or as a multiplet 
as in compound (71). Finally, 7 -H2 were coupled to the 6 -H2 signals and resonated 
further downfield at 8  3.40-3.60 as a triplet due to the deshielding effect of the 
hydroxy group.
The *H NMR spectra of p-ketonitriles o f group D (72-75) were quite 
interesting. The methylene protons of the (CH2OH) group are in a different magnetic 
environment because they are connected to a chiral atom (C-5) of the dioxolane ring 
and consequently resonated at different values. One o f the latter protons resonated at 
8  3.93-4.41 as a double doublet while the second proton resonated at 8  4.00-4.48 as a 
doublet due to geminal coupling with Jgem = 10.1-11.0 Hz as recognised from the 
COSY spectra and values of the coupling constant.
The *H NMR spectra of several of the prepared p-ketonitriles (61-78) 
revealed the presence of two tautomers, the enol and the keto-forms which is a very 
common form of tautomerism between a carbonyl compounds containing an a- 
hydrogen and its enol-form (scheme 2 1 ).
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Scheme (21) Keto-enol tautomerism of p-ketonitrile
In simple cases, the equilibrium lies well to the left as the keto form is 
thermodynamically more stable than the enol form. 16 6 However, in the case of p- 
ketonitriles (61-78), the enol form is the predominant form. The enol forms are more 
stable than the keto forms as the double bond of the enol form is in conjugation with 
the double bond system of the benzene ring in addition to the triple bond of the 
nitrile group. The enol forms are presumably the forms that are participating in the 
O-methylation reaction in a similar manner to the esterification of carboxylic acid. 167  
The percentages of the enol-form and keto-form were determined from the 
integrations of the corresponding peaks to each form on the NMR spectra as 
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5CHCN






1 0 0 8.96 CDC13
62 1 0 5.52 90 9.33 CDCI3
63 35 5.48 65 9.35 CDCI3
64 0
—
1 0 0 9.61 CDCI3






67 25 5.51 75 9.60 CDCI3
6 8 0
—
1 0 0 11.52 DMSO-d6
69 1 0 0 4.65
— —
CDCI3
70 1 0 0 4.65
— —
CDCI3


























1 0 0 11.70 DMSO-de
78 0
—
1 0 0 11.87 CDCI3
Table (2) Percentage of keto and enol tautomers of the prepared p-ketonitriles
Previous studies on keto-enol tautomerism of the diketo esters revealed that 
substituents with weak electronic demands may not have significant effect on the 
position of the equilibrium. On the other hand, strong electron-withdrawing para 
groups shift the equilibrium towards the keto-form. 1 6 8 ’169 This effect could be noticed 
in case of compounds of group A and B (61-67) as in case of compounds (62, 63 and 
67), the para-chloro group in the phenyl ring slightly increases the percentage of the 
keto forms or has no effect as in compound (6 6 ) while the para-bromo substituent 
has a significant effect on the position of the equilibrium toward the formation of the 
keto form as observed in compounds (63 and 67).
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The same observation was true for group D of P-ketonitriles (72-75). In the 
case of compounds of group C of the prepared p-ketonitriles (68-71), compounds 
(69-71) are present in the keto form. That may be due to the possibility of having 
intramolecular hydrogen-bond as well as intermolecular hydrogen-bond between the 
terminal primary hydroxy group (H-bond-donor) of one molecule and the carbonyl 
group (H-bond-acceptor) of another one in the keto-form make it more stable than 
the enol-form as long as the NMR spectra have been done in non-polar solvents such 
as CDCI3 .
The effect of the polarity of the solvent used on NMR on the keto-enol 
equilibrium is clearly apparent in the NMR spectrum of compound (6 8 ). A dramatic 
change on the equilibrium observed once using a polar solvent as DMSO-ck (H-bond 
acceptor) which favours the formation of the enol form (H-bond donor) and hence 
form hydrogen-bonds with both hydroxy groups rather than intramolecular or 
intermolecular ones. 1 7 0 Consequently, compound (6 8 ) is present as 100% enol form 
although the IR spectrum showed the characteristic peak of the carbonyl group at 
1731 cm'1.
Our early target was to prepare p-ketonitrile derivative (79) (scheme 22,1) by 
condensation of phenylacetonitrile (19) with an ester or lactone in order to increase 
the hydrophobicity of the corresponding 2,4-diaminopyrimidine derivative, as the 
Mtb-DHFR structure-revealed the presence of pockets which are more hydrophobic 
in the mycobacterial enzyme than the human enzyme. That finding suggested that 
improved Mtb-DHFR inhibitor might be created by the addition of neutral and 
hydrophobic groups to these substituents would increase affinity and selectivity, and 
also beneficial in other ways, e.g. by enhancing the capability of compounds to pass 
the mycobacterial membrane. 8 8
Considering compound (79), the presence of an electron-withdrawing (nitro 
group) would be predicted to reduce the basicity of the adjacent amine substituent 
and thus favour association with a hydrophobic domain at the active site of DHFR. 
Furthermore, our approach was to increase the reactivity to nucleophiles imparted 
upon the 4-chloro substituent by the introduction of a nitro group to displace the
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chloro group with amine.50 In the literature, the preparation of methylbenzoprim 
(MBP) and its derivatives (scheme 16) was started by reaction o f 4- 
chlorophenylacetonitrile as the nitrile counterpart with an ester until complete 
synthesis of the corresponding pyrimethamine derivatives and followed by nitration 
ortho to the chloride. The final step was then the nucleophilic substitution o f the 
chloride with the amino side chain.50’81’132 In case of our target group of compounds 
(A-D) which contain one or more of the hydroxy group, final step nitration will be 
impractical as these hydroxy groups will not survive the drastic conditions of 
nitration reactions. Consequently, we decided to prepare the nitrated 
phenylacetonitrile derivative (19) as a starting material but unfortunately, its 
condensation reaction with different esters and lactones failed under different 
conditions, (scheme 22,1).
Another strategy was to synthesise phenylacetonitrile derivative (20) with an 
electron-donating group at the 4-position to activate the ring toward final step 
nitration of the corresponding 2,4-diaminopyrimidine derivative at 3-position under 
mild condition. We have successfully prepared compound (20) but unfortunately its 
condensation with any ester or lactone was unsuccessful, (scheme 22,2).
Finally, the condensation of 3,4-dichlorophenylacetonitrile with ester (57) 
failed to give the expected p-ketonitrile (81) (scheme 22,3), although it was 




















Scheme (22) Unsuccessful trials for preparation of p-ketonitriles (continue)
3.9 Preparation of Enol Ether Derivatives
Direct condensation of p-ketonitriles with guanidine was reported to form 2- 
amino-4-benzyl-l,3,5-triazines and thus led to the development of the enol ether 
sequence where enol ethers formed the desired pyrimidines and not 
benzyltriazines.109,113
The desired enol ethers were obtainable by treatment of P-ketonitriles with 
diazomethane. The products of the reaction of diazomethane with
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a-acylphenylacetonitrile did in fact condense with guanidine to afford the 5-aryl-2,4- 
diaminopyrimidines in excellent yield.113
Having successfully synthesised the P-ketonitriles, preparation of the 
corresponding enol ethers (scheme 23) was then the next aim.
ketonitrile diazomethane enol ether
Scheme (23) Preparation of enol ether derivatives
O-Methylation of the p-ketonitriles (61-78) (fig.22) to afford the corresponding enol 
ethers (82-99) (fig. 23) was achieved successfully by using diazomethane (CH2N2 ), 
which is considered the most effective and common alkylating agent for carboxylic 





(82): R1 = H, R2 = H
(83): R1 = H, R2 = Cl
(84): R1 = H, R2 = Br
(85): R1 = C1,R2 = C1
The corresponding enol ethers of group A
(86): R1 = H, R2 = H
(87): R1 = H, R2 = C1
(88): R1 = H, R2 =Br
The corresponding enol ethers of group B
(89): R1 = H, R2 = H
(90): R1 = H, R2 = C1
(91): R1 = H, R2 = Br
(92): R1 = Cl, R2 = Cl
The corresponding enol ethers of group C
HO
R“
(93): R1 = H, R2= H
(94): R1 = H, R2 = Cl
(95): R1 = H, R2 = Br
(96): R1 = Q ,R 2=CI
The corresponding enol ethers of group D
R2 = H(97): R1 = CH3,
(98): R1 = CH2CH2Ph, R2 = H
(99): R1 = C2Hs, R2 = C1
The corresponding enol ethers of model compounds
Fig. (23) Structures of the prepared enol ethers
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Diazomethane can be generated from different precursors such as N-methyl- 
N-nitrosourea (NMU),172 N-methyl-N'-nitro-N-nitrosoguanidine (MNNG),173 or N- 
methyl-N-nitroso-4-toluenesulfonamide (Diazald),174 (scheme 24).
H,N















Scheme (24) Preparation of diazomethane from different precursors
Diazald was used for generation of diazomethane by using the Aldrich Mini 
Diazald apparatus according to the Ngan and Toofan method.171 Freshly synthesised 
diazomethane was used directly from the reaction apparatus for methylation of the (3- 
ketonitriles to form the corresponding enol ethers (82-99) in very good yields.
The NMR of the synthesised enol ethers revealed in some cases the 
presence of two geometrical isomers which could not be separated by 
chromatography or clearly identified by NMR spectra. However, the overall 




On the other hand, whenever only one isomer was the predominant product, 
the lH  NMR spectra were completely clear and could be then resolved and recorded. 
Generally, the !H NMR spectra of enol ether derivatives (48-65) revealed the 
presence of the characteristic peak of the protons of the methoxy group (CH3O-) as a 
singlet in the range between 8 3.33 and 8 3.95.
3.10 Preparation of 2,4-Diaminopyrimidine Derivatives
The target 2,4-diaminopyrimidine derivatives were prepared by cyclisation o f 
the appropriate enol ethers derivatives (48-65) with guanidine (scheme 18), as it has 
been reported to be the most effective method for the preparation of 5-aryl 
derivatives of 2,4-diaminopyrimidine.108’113’132
NH
h2n n h 2
O R
NH.
enol ether guanidine 2,4-diaminopyrimidine
Scheme (25) Preparation of 2,4-diaminopyrimidine derivatives
The condensation of some enol ethers derivatives failed by using ethanol as a 
solvent but by replacing it by a higher boiling point alcohol such as 2- 
methoxyethanol (boiling point =124 °C), the target pyrimidine derivatives (100-117) 







(100): R1 = H, R2 = H
(101): R1 = H, R2 = C1
(102): R1 = H, R2 = Br
(103):R1 = Q,R2 = a
corresponding 2,4-diaminopyrimidines (group A)
Ph
(104): R1 = H, R2 = H
(105): R1 = H, R2 = C1
(106): R ^ H , R2 = Br




(107): R1 = H, R2 = H
(108): R1 = H, R2 = C1
(109): R1 = H, R2 = Br
(110):R1 = a ,R 2= a
(111): R1 = H, R2 = H
(112): R1 = H, R2 = Cl
(113): R1 =H, R2=Br
(114):R1 = a ,R 2 = Q
corresponding 2,4-diaminopyrimidines (group C) corresponding 2,4-diaminopyrimidines (group D)
R2 = H(115): R1 = CH3,
(116): R1 = CH2CH2Ph, R2 = H
(117): R1 = C2H5, R2 = Q
corresponding 2,4-diaminopyrimidines (model compounds)
Fig. (24) Structures of the prepared 2,4-diaminopyrimidine derivatives
All of the novel products (100-114 and 116) were fully characterised by 
NMR spectroscopy as well as the mass and accurate mass spectra. In case of group 
(C) target compounds (107-110), and model compounds (115-117) (fig. 24), they are
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the final products but, for others, there have been still further deprotection steps to 
liberate the hydroxy groups to afford the final target products.
Interestingly, the *H NMR spectra of group D compounds (111-114) revealed 
that the 2- and 6-protons and the 3- and 5-protons of the benzene ring at the 5- 
position are diastereotopic in the cases of the H-compound, the monochloro- and the 
monobromo-compounds (111-113). The bulky group at the 6-position restricts the 
free rotation of the benzene ring in addition to the two chiral centres at the dioxolane 
ring as shown in (fig. 25), which was made by MM2 calculation energy 
minimisation, using Chem 3D 9.0 program. Consequently, these diastereotopic 
protons appeared at different chemical shifts and split each other. Furthermore, the 
two methyl groups of the dioxolane ring present in different magnetic environments 
and appeared as two well-separated singlets.
Fig. (25) Stereoview of compound (112), carbon in grey, hydrogen in 
white, oxygen in red, nitrogen in blue and chloride in green
In the NMR spectrum of the monochloro-compound (112), these 
diastereotopic protons resonated at 8 7.05 for Ph 3-H, 8 7.27 for Ph 5-H, 8 7.43 for 
Ph 2-H and 8 7.47 for Ph 6-H. These protons split each other as each appeared as a 
doublet of doublets and the two methyl groups of the dioxolane ring appeared as two 
singlets at 8 1.24 and 8 1.63. On the contrary, the corresponding protons of the
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benzene ring of the compounds of group B (104-106) are isochronous. In the 
NMR spectrum of compound (105), the protons of the benzene ring resonated at 5 
7.10-7.35 as a multiplet because of the free rotation of the benzene ring and being 
away from the chiral centres of the dioxolane ring that make these protons 
magnetically equivalent. Furthermore, the two methyl groups of the dioxolane ring 
resonated at 8 1.28 and 8 1.31.
In the case of dichloro compound (114), there are two different conformers, 
as shown in (fig. 26), as a result of the restricted rotation of the benzene ring due to 
the bulky substituent at the 6-position. Thus the protons of the benzene ring of each 
conformer present in different magnetic environment because of the two chiral 
centres of the dioxolane ring at the 6-position.
Fig. (26) Stereoview of the two conformers for compound (114), carbon 
in grey, hydrogen in white, oxygen in red, nitrogen in blue and chloride in green
In the *H NMR spectrum of compound (114), the signals of the protons of the 
benzene ring resonated at different values in 1:1 ratio. These protons for one 
conformer resonated at 8 7.11 for Ph 6-H as a doublet of doublets, 8 7.38 for Ph 2-H 
as a doublet and at 8 7.60 for Ph 5-H as a doublet. The corresponding protons of the 
other conformer resonated at 8 7.21 for Ph 6-H as a doublet of doublets, 8 7.48 for Ph 
2-H as a doublet and at 8 7.62 for Ph 5-H as a doublet. Each of these peaks was
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integrating for 0.5 protons. Furthermore, the two methyl groups of the dioxolane ring 
resonated at 8 1.20 and 8 1.49 as two singlets.
3.11 Deprotection of the Hydroxy Groups
Aiming to prepare the target compounds of groups A, B and D, deprotection 









Scheme (26) Deprotection of group (D) compounds
The hydroxy groups were protected from unwanted reactions until the last 
step because they are nucleophilic, weakly acidic (pK* 15-17), easily oxidised by a 
wide range of reagents and can participate in numerous transformations under mild 
conditions. Over 200 hydroxy protecting groups have been reported to date but, o f 
these, only a comparatively small fraction are in common use,122 such as the 
formation of silyl ethers,175,176 alkyl ethers177 and esters.122
Cyclic isopropylidene acetals (also known as acetonides) have been used 
more frequently than any other protecting group for the protection of 1,2- and 1,3- 
diols. The acetals are easily prepared and they are stable to most reaction conditions 
except protic and Lewis acids. The isopropylidine acetals have been synthesised to 
protect the 1,2-diols in group A, B and D (fig. 24). Aqueous trifluoroacetic acid 
(30%)178 was used successfully for cleavage of the dioxolane ring and deprotection
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(118): R1 = H, R2 = H
(119): R1 =H, R2 = Q
(120): R1 = H, R2 = Br
(121):R1 = a , R 2 = Q
(122): R1 = H, R2 = H
(123): R1 = H, R2 = Q





(125): R1 = H, R2 = H
(126): R1 = H, R2 = C1
(127): R1 = H, R2 = Br
(128): R1 = C1,R2 = C1
Fig. (27) Structures of target compounds (118-128)
For group D target compounds, it was the last step and compounds (125-128) 
(fig. 27), are our final target novel products for group D, which have been completely 
characterised by NMR and mass spectra. The NMR spectra are characterised by the 
disappearance of the two upfield signals corresponding to the two methyl groups of 
the dioxolane ring as a result of the deprotection step.
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The ]H NMR spectra revealed that the (3 -H2 ) protons of the aliphatic side 
chain, because of being attached to the chiral (C-2) atom, resonated at 8 3.40-3.63 as 
two sets of double doublet each integrated for one proton for compounds (125-128) 
or as a multiplet for compound (128). The (2-H) proton resonated further downfield 
at 8 3.68-3.72 as a multiplet while the (1-H) proton resonated furthermore downfield 
at 8 4.35-4.54 as a douplet for compounds (125-128) because of the deshielding 
effect of the neighbouring oxygen and nitrogen.
In the 13C NMR spectra and with the help of 135 DEPT spectra the (C-3) 
carbon was identified as the signal resonating at 8 62.60-63.67 as the corresponding 
peak projecting downwards in the DEPT spectra while the (C-l) and (C-2) carbons 
remain upwards and resonated further downfield at 8 68.98-74.29 for compounds 
(125-128).
The specific rotation [a]D was also determined for compounds (125-128) as 
they rotated the plane of polarised light to the left and are designated (-), for example 
compound (126) has [a]20D = -41° (c 0.4, CH3OH).
For group A and B target compounds the corresponding products (118-124) 
still need another step for cleavage of the benzyl ether protecting group (scheme 27) 









protected groupA and B compounds target groupA and B compounds
Scheme (27) Deprotection of group A and B compounds
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The cleavage of benzyl ether linkage of compounds (118-124) (fig. 27) was 
our last aim for preparation of my target compounds (129-135) (fig. 28).
Benzyl ethers are stable to a wide range of aqueous acidic and basic 
conditions. They are not readily attacked by most metal hydride reducing agents or 
mild oxidising agents.122 Catalytic hydrogenolysis offers the mildest method for 
deprotecting benzyl ethers. The catalyst of choice is palladium on charcoal in THF, 
ethanol or ethyl acetate.122,179
Unfortunately, the latter method for deprotection was unsuccessful and the 
starting material was recovered after 96 hours. Addition of perchloric acid which 













(129) : R1 = H, R2 = H
(130) : R1 = H, R2 = C1
(131) r R ^ H ,  JR2 = Br
(132): R1 = Cl, R2 = Cl
(133): R1 = H, R2 = H
(134): R1 = H, R2 = C1
(135): R1 — H, R2 = Br
Fig. (28) Structures of group A and B target compounds
On the other hand, the addition of a few drops of chloroform to the catalytic 
hydrogenolysis deprotection procedure and using methanol as a solvent,180 
effectively deprotected compounds (118 and 122). However, in the cases of the 
deprotection of the 4-chloro and 4-bromo substituted compounds (119, 120, 123, 
124) (fig. 27), dehalogenation took place in addition to the deprotection reaction as 
indicated by the NMR and mass spectra. The deprotection of compounds (119,120)
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of group A by the latter method afforded the same product, compound (129), and it 
was also true for the corresponding compounds (123, 124) of group B. In the case o f 
the 3,4-dichloro derivative (121) a mixture of chlorinated and dechlorinated 
derivatives was recovered and could not separated by chromatography due to the 
high polarity of the deprotected compounds.
Attempted removal of the benzyl group by dealkylation with HBr/HOAc 
resulted in a dramatic substitution of the hydroxy groups by bromides beside 
acetylation of the primary hydroxy group as well as formation of the hydrobromide 
salt of the pyrimidine ring.181
An alternative method for reductive deprotection was by using sodium metal 
and liquid ammonia182 which successfully cleaved the benzyl ether for compounds 
(118 and 122). Unfortunately, the use of the latter method for deprotection of the 
halogenated compounds (119-124) resulted in dehalogenation of the benzene ring 
and consequently compounds (118-121) and compounds (122-124) afforded the 
dehalogenated products (129) and (133) respectively.
Although numerous methods are available for cleavage of benzyl ethers, 
problems arise in the presence of multiple functionalities. It was found that the use o f 
anhydrous iron (HI) chloride in dichloromethane is highly efficient for the cleavage 
of benzyl ethers at room temperature. The cleavage reactions presumably involve 
initial complexation of the Lewis acid iron (IE) chloride to the ethereal oxygen atom 
and subsequent displacement with chloride to yield the free alcohols and benzyl 
chloride. This reaction does not proceed in protic or lone pair electron-rich solvents 
such as alcohols, diethyl ether and acetone.183
The use of anhydrous iron (IE) chloride was effective and successfully 
debenzylated compounds (118-124) to the corresponding target compounds (129- 
135) without affecting the halogens on the benzene ring. Moreover, it was also a very 
effective method for deprotection of the isopropylidene protecting group of 1,2-diol 
of compounds (100-106 and 111-114) (fig. 24) as well. Following the deprotection o f 
compounds (100-106 and 111-114) using the latter method by TLC and NMR, it was
97
3. (DISCUSSION
found that cleavage of the acetal linkage was achieved after 5 min and the 
debenzylation step was finished within 80 min.
Owing to the problems encountered with the final-step cleavage o f the benzyl 
ether linkage and depending on our experience gained from the successful cyclisation 
of the enol ethers (89-96) (fig. 23) of the corresponding group C and D compounds 
without protecting the primary hydroxy group, We thought that it could be possible 
and worth trying to synthesise the corresponding p-ketonitriles for group A target 
compounds by condensation of the hydroxyl ester (47) with different derivatives of 
phenylacetonitrile to form the corresponding p-ketonitriles.
p-Ketonitrile derivatives (136-139) (scheme 28) were successfully prepared 
by the same method described before, which in turn O-methylated exclusively at the 
enol oxygen with diazomethane to afford the corresponding enol ethers (140-143). 
These were finally cyclised with guanidine to give the corresponding 2,4- 
diaminopyrimidine derivatives (144-147). By using aqueous trifluoroacetic acid 
(30%), we could effectively obtain the corresponding target group A compounds 
(129-132) (fig. 26). The spectroscopic analysis data for target group A compounds 









(136): R1 = H, R2 = H
(137): R1 = H, R2 = Cl
(138): R1 = H, R2 = Br
(139): R1 = Cl, R2 = Cl
The corresponding ketonitriles of group A
OH
(140): R1 = H, R2 = H
(141): R1 = H, R2 = Cl
(142): R1 = H, R2 = Br
(143): R1 = Q,R2= a






(144): R1 = H, R2=H
(145): R1 = H, R2 = C1
(146): R1 = H, R2 = Br
(147): R1 = Cl, R2 = Cl
The corresponding 2,4-diaminopyrimidines of group A




The !H NMR spectra of group A and B compounds (129-135) (fig. 26) have 
significant differences in chemical shifts of the protons of the aliphatic side chain 
carried on the two chiral carbons (C-3 and C-4). The (3-H) proton resonated at 8 
3.14-3.34 as a multiplet for compounds (129-132). The (4-H) proton resonated at 8 
3.37-3.52 as a double triplet for compound (129) or as a multiplet as in compounds 
(130-132). On the other hand, the (3-H) proton of the corresponding diastereoisomers 
of group B (133-135) resonated further downfield at 8 3.31-3.61 as a multiplet 
overlaping with (4-H) proton signals as a result of inversion of the configuration of 
(C-3).
Assignment of 13C NMR spectra of the final novel compounds depended on a 
previous study made on the proton-coupled 13C and *H NMR spectroscopy of 2,4- 
diaminopyrimidines.184 In case of group A (129-132) and group B (133-135), the 
three carbon atoms o f the pyrimidine ring (C-2, C-4 and C-6) adjacent to ring 
nitrogens (some bearing amino group) should experience considerable deshielding 
and resonances of all three appeared in the range 8c 160-166. The (C-5) carbon, 
which is not adjacent to nitrogen, gave a resonance at 8c 105-109.
By comparing 13C NMR and DEPT spectra of compound (129) representing 
group A and compound (133) for group B, it was found that the two chiral carbons 
(C-3 and C-4) of the aliphatic side chain resonated at different values. In case of 
compound (129) one of them resonated at 8c 71.35 while the second carbon 
resonated at 8c 74,11. On the other hand, the corresponding carbon atoms of 
compound (133) resonated at 8c 73.61 and 8c 73.64 because of inversion of 
configuration of (C-3) carbon in group B compounds.
The specific rotations [a] for both group A and B compounds were calculated 
as group A compounds rotated the plane of polarised light to the left and designated 
(-) while their enantiomers in group B rotated the plane of polarised light to the right 
and designated (+). Surprisingly compound (129) has a  = zero0, even by trying 
different concentrations and solvents. It may be a result of rotation of the plane of 
polarised light due to one of the chiral centre was coincidentally equal but in 
opposite direction to the rotation resulted from the second chiral centre. It can not be
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a racemic mixture from the applied synthetic pathway as indicated by the pure NMR 
spectra that indicated the presence of one product along the synthetic pathway.
Finally, the expected chemical structures of the entire final novel compounds 
were confirmed by the correct mass and accurate mass spectra.
3.12 Conclusions
The active sites of Mtb-DHFR and h-DHFR have been studied to explore the 
glycerol A pocket as a new avenue for selectivity of new inhibitors. The glycerol A 
pocket was present only in Mtb-DHFR and was absolutely absent in the human 
enzyme. Accordingly four groups of target compounds (A, B, C and D) were 
designed with different side chains at 6-position of 2,4-diaminopyrimidine nucleus.
The synthetic pathway started by condensation of different derivatives of 
phenylacetonitrile with esters or lactones using bis(trimethylsilyl)lithium amide as a 
base to afford the corresponding P-ketonitriles. Diazomethane was used for O- 
methylation of p-ketonitrile derivatives to afford the expected enol ethers which in 
turn cyclised with guanidine to afford the corresponding 2,4-diaminopyrimidine 
derivatives. The final step was the deprotection of the hydroxy groups for group A, B 
and D. the deprotection of 1,2-diols were easily achieved by acid catalysis of 
aqueous TFA (30%) but the cleavage of benzyl ether linkage was robust due to the 
multifunctional groups present on the prepared products. Many deprotection 
procedures have been applied and the only compatible procedure was the use of 
anhydrous iron (HI) chloride.
Consequently, an alternative approach was to condense the corresponding 
ester (47) without protecting the primary hydroxy group with phenyacetonitrile 
derivatives. Fortunately, ester (47) did condense well with phenylacetonitrile 
derivatives to form the corresponding P-ketonitriles which were O-methylated with 
diazomethane to form the corresponding enol ethers which, in turn, were cyclised 
with guanidine to afford the corresponding 2,4-diaminopyrimidine derivatives. By 
on-step deprotection of the ketal linkage, the latter afforded the target compounds of
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group A. The products obtained from the two different starting esters (47) and (48) 
respectively have identical physical and spectroscopic properties.
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4. EVALUATION OF TARGET COMPOUNDS
4.1 Introduction
Screening of drugs with M. tuberculosis directly is slow and requires 
biosafety Level 3 facilities and procedures.185 The handling of specimens and 
cultures exposes laboratory staff to a serious risk of infection. Safety measures are 
essential, these include containment laboratories, approved safety cabinets and 
centrifuges, protective clothing, hand basins and facilities for the safe disposal of 
contaminated waste. All staff should be vaccinated with BCG vaccine, unless they 
are tuberculin positive, and must have medical supervision as determined by local 
policies.12
The slow growth rate of M. tuberculosis has been a puzzling and frustrating 
phenomenon for clinicians, technologists and public health authorities. In Koch's 
original report in 1882, he noted that microcolonies appear on the medium gradually 
during the third week of incubation. Over 100 years later, remarkably, most of the 
laboratories around the United States and the world still employ cultivation 
techniques that require three to six weeks to achieve growth. In substantial measure, 
this reflects the slow generation time inherent in the tubercle bacillus.186
An alternative strategy for evaluation of Mtb-DHFR inhibitors has been 
developed: initial screening in an engineered strain of the budding yeast 
Saccharomyces cerevisiae that is dependent on the M. tuberculosis DHFR for its 
growth. By using this system, we could screen all the target compounds as Mtb- 
DHFR inhibitors.185 Furthermore, by using another engineered strain o f the yeast that 
is dependent on the human DHFR for its growth, we could test the selectivity of the 
target compounds.
Genetic engineering is the deliberate modification of an organism’s genetic 
information by directly changing its nucleic acid genome and is accomplished by a 
collection of methods known as recombinant DNA technology. First, the DNA 
responsible for a particular phenotype is identified and isolated. Once purified, the
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gene or genes are fused with other pieces of DNA to form recombinant DNA 
molecules. These are propagated (gene cloning) by insertion into an organism that 
need not even to be in the same kingdom as the original gene donor. In gene cloning 
the new gene is inserted into a so-called vector that is inserted into the living cell. 
Vectors are usually plasmids, bacteriophages (viruses that specifically infect 
bacteria) and cosmids (a hybride between a bacteriophage and a plasmid that has 
been specially synthesised for use in gene cloning).187
Plasmids are small, circular molecules that can exist independently of host 
chromosome and are present in many bacteria and they are also present in some 
yeasts and other fungi. They have their own replication origins and are autonomously 
replicating and stably inherited. Plasmids have relatively few genes, generally less 
than 30. Their genetic information is not essential to the host, and bacteria that lack 
them usually function normally. Single-copy plasmids produce only one copy per 
host cell. Multicopy-plasmids may be present at concentrations of 40 or more per 
cell. Characteristically, plasmids can be eliminated from host cells in a process 
known as curing. Curing may occur spontaneously or be induced by treatments that 
inhibit plasmid replication while not affecting host cell reproduction. The inhibited 
plasmids are slowly diluted out of the growing bacterial population. Some commonly 
used curing treatments are UV and ionising radiation, thymine starvation and growth 
above optimal temperatures.187 Plasmids may be cleaved at specific points by 
restriction enzymes, the new gene being inserted into the cut and joined to the 
original DNA by DNA ligase to form so-called recombinant DNA. The new plasmid 
is reinserted into the bacteria where bacterial reproduction resulted in the production 
of more recombinant DNA molecules.188
The slow growth and difficulty of working with mycobacteria led Gerum and 
her group to develop a system that could more quickly and safely screen potential 
inhibitors of the M. tuberculosis DHFR. As a first step, they constructed a yeast 
strain dependent on the M. tuberculosis DHFR for growth. The TH5 strain of yeast 
lacks endogenous expression of DHFR and is maintained by supplementing the 
medium with dTMP and a full complement of amino acids, uracil and adenine. To 
construct isogenic strain whose growth and viability depend on genetic 
complementation by plasmid-borne M. tuberculosis DHFR gene, M  tuberculosis
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DHFR dfrA gene was cloned into different yeast vectors and then transformed into 
the TH5 strain o f yeast and tested for their ability to grow without dTMP and for 
inhibition by DHFR-inhibitors.
The optimal strain for the screening of DHFR inhibitors must express the 
enzyme at a level high enough that the yeast can grow without supplementation but 
low enough that a proportional decrease in growth is achieved when an inhibitor of 
DHFR function is added. The strain that carried dfrA gene on p414CYCl vector 
drove an intermediate level of DHFR and so this plasmid was chosen for use in all 
subsequent experiment and was designated TB-yeast.
S. cerevisiae has several advantages that have been exploited to develop 
similar systems for screening inhibitors of DHFR enzymes from different species 
such as P. falciparum  and Pneumocystis carinii. The simple yeast system offers 
the possibility to screen rapidly for inhibitors of the M. tuberculosis DHFR. The 
heterologous system circumvents the slow growth of M. tuberculosis and health risks 
inherent in working with mycobacteria.185
One might have chosen to screen these drugs in Mycobacterium smegmatis, 
taking advantage of its rapid growth (the growth rate is about equal to S. cerevisiae) 
and ease of genetic manipulation relative to those for M. tuberculosis. However, drug 
screening in M. smegmatis has not always been an accurate predictor of activity190 or 
of the mechanism of action in M. tuberculosis.191
In addition, S. cerevisiae has several advantages. Firstly, plasmids that carry a
centromere (a key component of a chromosome which is required for the
192chromosome to be distributed correctly to the daughter cells during cell division) 
are maintained at one copy per cell in yeast, so the level of expression of an 
introduced gene can be controlled, even on a plasmid. In bacterial systems, control of 
plasmid number is far less precise and integration of genes into the chromosome 
would be required for equivalent studies to be carried out in M. smegmatis. Secondly, 
a series of yeast centromere plasmids that carry promoters that drive different levels 
of expression of linked genes had already been created.193 These plasmids were used
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to identify rapidly yeast clones that express the heterogeneous enzyme at a level 
convenient for drug screening. Lastly, homologous recombination is highly active in 
S. cerevisiae and foreign genes can be integrated into a plasmid simply by 
cotransformation with a gapped plasmid, a significant advantage when a large 
number of different alleles are to be tested.185
To use the complementation system to screen antifolate drugs, it was 
important that the heterologus DHFRs be expressed at an extremely low level so that 
inhibition of the enzyme would be reflected as a proportional decrease in yeast 
growth. Preliminary work had shown that the Pf-yeast strain expressed the 
plasmodium DHFR domain at very low levels and that the growth of that strain was 
strongly inhibited by the potent inhibitor MTX. Unexpectedly, however, even high 
levels of MTX did not inhibit the growth of any other complemented strains. For 
example human-yeast (Hu-yeast) grew normally in MTX concentrations as high as (1 
pM) even though the IC50 of the purified human DHFR is about (1 nM). As MTX 
binds essentially stoichiometrically to human DHFR, the amount of MTX needed to 
inhibit the growth of yeast dependent on heterologous DHFR expression is 
proportional to the cellular DHFR concentration. The insensitivity of many o f the 
complemented yeast strains to MTX resulted from high DHFR levels and it would be 
necessary to reduce DHFR expression to enhance sensitivity of the system which 
resulted in a MTX IC50 of approximately (3 pM ) for the human yeast.189
The IC50 that one measures for the yeast system is a complex function o f the 
level of Mtb-DHFR enzyme, the level of penetration of the yeast by the drug tested 
and the actual level of inhibition of the enzyme within the cell. For that reason, the 
absolute IC50 cannot predict the MIC for M. tuberculosis. However, the relative 
inhibition of yeast growth by related series of the inhibitors is valuable information 
for drug testing. Further work to develop these compounds will require working with 
mycobacterial cultures, purified enzyme and animal models of tuberculosis infection 
but we have reduced the amount of initial work necessary to identify drug candidates 
by working in this yeast system.185
To increase the sensitivity of this yeast system, we included sulfanilamide 
(1.0 mM) in the growth medium for all yeast assays. Sulfa chugs inhibit
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dihydropteroate synthase, an enzyme upstream of DHFR in the folate pathway.194 
The sulfa drugs are always used in combination with DHFR inhibitors because the 
two drugs work in synergy in many pathogens. In this case, they increase the 
effectiveness of the DHRF inhibitors in the heterologous yeast system and facilitate 
the comparative screening. The addition of sulfanilamide to these assays does not 
compromise the results, since we are measuring the relative inhibition of a set of 
closely related compounds. In any case, it is likely that a sulfa drug would be part of 
a combination therapy which included a DHFR inhibitor, for the treatment of 
tuberculosis.185,189
By using the Hu-yeast and the TB-yeast strains, we could perform a 
qualitative spoke assay for determination of the efficacies of the prepared target 
compounds as DHFR inhibitors. The spoke assays were useful for rapid 
classification of test compounds into categories of approximate potency and 
selectivity.185’195
The spoke assay-based screening of the activities of the test compounds against TB- 
yeast, Hu-yeast and the wild-type S. cerevisiae was performed as following:
1- Sulfanilamide was spread onto fresh plates and allowed to absorb into the medium 
overnight. The medium contains 10% yeast extract, 10% peptone and 10% dextrose.
2- By using the narrow side of the flat end of a sterile toothpick, pick up some yeast 
cells from a plate. Starting from the center of a fresh plate, drag the toothpick in a 
straight line outward toward the edge of the plate. Continue with other strains on the 
same plate, creating a wheel spoke pattern. Incubate the plate until the yeast has 
grown well.
3- Replica plate onto a fresh plate.
4- Replica immediately from the second plate onto additional fresh plate.
5- Place the drug in solution (10 pi of a 10 mM solution in DMSO) in the center of 
the plate and let the plate absorb it (about 5 min).
The last plate should contain no drug and serve as a control for transfer of cells. 
Incubate at 30 °C for 3 days.
6- Measure the distance from the center of the plate to the beginning o f growth for 
each spoke (the inhibition zone). The inhibition zones were calculated from the mean 
of three different experiments. The greater the distance the more sensitive the strain
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is to the drug. The inhibition zones that were at least 4.0 mm more than that from the 
control plate with DMSO alone, were scored as inhibited by the compound on the 
plate.185-1”
4.2 Results and Discussion
Trimethoprim was used for comparison purposes as it is reported to be a 
highly selective inhibitor of bacterial DHFR. Model compounds were tested as well 
because pyrimethamine had shown some activity in vitro against the M. avium 
DHFR complex.185,1,5
The synthesised novel target compounds were evaluated for inhibitory 
activity and selectivity against Mtb-DHFR in vitro by the radial spoke assay with 
three different yeast strains, the TB-yeast, the Hu-yeast and the wild-type S. 
cerevisiae. The measured inhibition zones would be compared with that obtained 
from trimethoprim and model compounds. All compound assays with the TB-yeast 
contained sulfanilamide (1.0 mM) in the growth medium to improve sensitivity to the 
DHFR inhibitors. DMSO was used as a negative control to ensure that the solvent 
and sulfanilamide (1.0 mM) were not inhibiting the yeast growth non- 
specifically.185,189 The same method was applied to the Hu-yeast strain and the wild- 
type S. cerevisiae to test the selectivity of the target compounds.
The results of the radial spoke assay performed for the Hu-yeast, the TB- 
yeast strains as well as the wild-type S. cerevisiae are represented in tables (3-6). The 
relative potency and selectivity of the tested compounds against Mtb-DHFR were 
determined by measuring the diameters of the inhibition zones for the tested yeast 
strains and comparing these values with that obtained from a control plate containing 
DMSO only.
For group A compounds (table 3), compound 129 was the most active 
compound against the TB-strain and was inactive against both the Hu-yeast strain 
and the wild-type S. cerevisiae. Compound 130 had lower activity against the TB- 
yeast and was also inactive against the Hu-yeast and the wild-type S. cerevisiae. 
Compounds 131 and 132 were inactive against all types of the tested strains.
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129 H H 11 (0.57) 6(1.0) 6 (0.0)
130 H Cl 9 (0.57) 7 (0.57) 7 (0.57)
131 H Br 7(1.0) 6 (0.57) 8(1.0)
132 Cl Cl 8 (0.57) 8(1.0) 8 (0.57)
DMSO 5 (0.57) 6 (0.57) 5 (1.0)
Table (3) Structures and inhibition zone diameter of group A target compounds 
against the Hu-yeast, the TB-yeast and the wild-type S. cerevisiae. SD, standard
deviation
Interestingly, compound 129 was the best in term of potency and selectivity 
against TB-yeast among the member of this group of inhibitors.
In case of group B of target compounds (table 4), only compound 133 was 
equipotent to compound 130 from group A against the TB-yeast and was inactive 
against the Hu-yeast and the wild type S. cerevisiae as well. Compounds 134 and 135 
























133 H H 9 (0.57) 8 (1.0) 8 (0.0)
134 H Cl 7 (0.57) 7 (0.57) 6 (0.57)
135 H Br 8 (0.0) 5 (0.57) 6 (0.0)
DMSO 5 (0.57) 6 (0.57) 5 (1.0)
Table (4) Structures and inhibition zone diameter of group B target compounds 
against the Hu-yeast, the TB-yeast and the wild-type S. cerevisiae. SD, standard
deviation
As expected, compound 129 that has the configuration of the chiral carbons 
on the side chain at 6-position of the pyrimidine ring that resemble that o f  the 
glycerol molecule in the active site of Mtb-DHFR was essential requirement for 
potency. By changing the configuration of one chiral carbon (C-3) as in compound
(133) resulted in decreasing the potency but retain the selectivity as it is still inactive 
against the Hu-yeast.
For group C of target compounds (table 5), compounds 107 and 109 were 
weak inhibitors to wild-type S. cerevisiae and were inactive against the TB-yeast and 
the Hu-yeast strains. Compound 110 showed an equipotent inhibition to compound
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107 H H 7 (0.0) 7 (0.0) 9 (0.57)
108 H Cl 8 (0.0) 8 (0.57) 8 (0.57)
109 H Br 8 (0.57) 8 (0.57) 9 (0.57)
110 Cl Cl 9 (0.57) 9 (0.0) 9 (057)
DMSO 5 (0.57) 6 (0.57) 5 (1.0)
Table (5) Structures and inhibition zone diameter of group C target compounds 
against the Hu-yeast, the TB-yeast and the wild-type S. cerevisiae. SD, standard
deviation
The absence of the chiral carbons and the hydroxy groups had a dramatic 
negative effect on potency and selectivity of group C compounds, which reflect their 
great contribution on improving potency and selectivity of these classes o f inhibitors.
All members of group D target compounds (table 6) were inactive against all 























125 H H 5 (0.57) 5 (0.0) 5 (0.0)
126 H Cl 5 (0.0) 5 (0.57) 5 (0.57)
127 H Br 5 (0.0) 5 (0.57) 5 (0.57)
128 Cl Cl 8 (0.57) 8 (0.0) 7 (0.57)
DMSO 5 (0.57) 6 (0.57) 5 (1.0)
Table (6) Structures and inhibition zone diameter of group D target compounds 
against the Hu-yeast, the TB-yeast and the wild-type S. cerevisiae. SD, standard
deviation
This result reflected that the length of the carbon skeleton of the side chain at 
the 6-position of the pyrimidine ring was also an important parameter for perfect 
binding to the glycerol pocket in the active site of Mtb-DHFR. Compounds of group 
D were inactive compared to compounds of group A as a result of shortening the 
side-chain at the 6-position although they were still having the chiral carbons and the 
hydroxy groups.
In case of trimethoprim and model compounds (table 7), all were inactive 
against TB-yeast, human-yeast and S. cerevisiae as well.
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101 c h 3 H 7 (0.57) 8 (0.0) 8 (0.57)
102 CH2CH2Ph H 5 (0.0) 5 (0.57) 5 (0.57)
103 CH2CH3 Cl 5 (1.0) 6 (1.0) 5 (0.57)
Trimethoprim 5 (0.57) 6 (0.0) 6 (0.0)
DMSO 5 (0.57) 6 (0.57) 5 (1.0)
Table (7) Structures and inhibition zone diameter of model compounds and 
trimethoprim against the Hu-yeast, the TB-yeast and the wild-type S. cerevisiae,
SD, standard deviation
The results from the radial assays revealed that the new designed functional 
group at the 6-position of the pyrimidine ring not only successfully increased the 
potency against the TB-yeast compared with trimethoprim and model compounds but 
also retained their selectivity by being inactive against the human and the wild-type
S. cerevisiae DHFR.
Inversion of configuration of one chiral carbon in case of group B target 
compounds alters the potency but does not affect the selectivity. On the other hand, 
disappearance of the two secondary hydroxy groups as in case of group C target 
compounds seriously affects both the potency and selectivity as some members of 
this group of compounds showed activity against the wild-type S. cerevisiae DHFR 
and most of them lost their activity against the TB-yeast.
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Shortening of the carbon skeleton of the side chain at the 6-position of the 
pyrimidine ring had a dramatic effect on potency as all members of group D target 
compounds were inactive against all types of tested enzymes.
Regarding the effect of the side-chain at 5-position of the pyrimidine ring, the 
presence of the 4-chloro substituent at the phenyl ring reduced the activity of group 
A and B compounds as TB-DHFR inhibitors. On the other hand the 4-bromo and the 
3,4-dichloro analogues lost their activity as DHFR inhibitors.
4.3 Conclusion
Screening of drugs with M. tuberculosis cultures is slow and requires 
biosafety Level 3 facilities and procedures. We have used an alternative strategy by 
initial screening of the prepared target compounds in two types of engineered strains 
of the budding yeast that are dependent on the M  tuberculosis DHFR and human 
DHFR respectively for their growth.
By using this system, we have screened all the prepared target compounds 
and found that three compounds 129, 130 and 133 showed higher potency and 
selectivity as Mtb-DHFR inhibitors compared to trimethoprim and model 
compounds. Disappearance of the two chiral centers or shortening of the length of 
the carbon skeleton of the side chain at 6-position made these compounds inactive. 
Inversion of the configuration of one chiral carbon has reduced the potency but does 
not affect the selectivity.
Introduction of a halogen to the phenyl side chain at 5-position o f the 
pyrimidine ring reduces the potency and selectivity although it ncreases the 
lipophilicity of the target compounds and consequently should enhance the potency. 
It might have another influence once tested on the M. tuberculosis itself as it might 
enhance the penetration of the highly lipophilic cell wall of the mycobacteria. Thus, 




These results reveal that we have successfully designed and synthesised a 
new functional group that provid selectivity and potency to the 2,4- 
diaminopyrimidine pharmacophore as inhibitors to Mtb-DHFR. Consequently, 
compounds of group A are good potential leads for a further development of potent 
and selective inhibitors against M. tuberculosis DHFR.
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and 13C NMR spectra were recorded on JEOL/Varian GX270 and EX400 
spectrometers. NMR spectra are reported in ppm downfield from tetramethylsilane. 
Samples were dissolved in CDCI3 , unless otherwise stated. Coupling constants are 
reported in (Hz). FAB mass spectra in [3-nitrobenzyl alcohol (3-NBA)] were 
obtained using a VG7070E spectrometer. IR spectra (cm'1) were measured on neat 
compounds (for oil products) or as KBr discs (for solid products) on the Perkin- 
Elmer RXIFT-IR spectrometer. Optical rotations were measured in a 1 dm cell on an 
Optical Activity Ltd polarimeter and concentration (c) is expressed in g/100 ml. 
Chromatography was performed on silica gel (BDH, 40-63 pm). The synthesised 
compounds were purified by chromatography under gravity or a light pressure 
applied to the column. Reactions were monitored by TLC using pre-coated 
aluminum sheet (Merck, silica 60 F254) and were visualized with UV light at 254 nm, 
solutions of 10% sulfuric acid, ninhydrin or iron (IE) chloride. TLC and R/values 
were performed on the same mobile phase as the column unless otherwise stated. All 
reactions were carried out under a static atmosphere of nitrogen and stirred 
magnetically at room temperature unless otherwise stated. Solvents were evaporated 
under reduced pressure using a Btichi rotary evaporator. Chemicals were supplied by 
Aldrich Chemical Company (Poole, Dorset. UK) or Fluka. Reagent-grade solvents 
were utilised as received except for THF which was freshly distilled under nitrogen 
from Na/benzophenone. Melting points were determined by using a Reichert-Jung 
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(19)
N-Benzylmethylamine (1.2 g, 10 mmol) was added to a solution of compound (31) 
(0.40 g, 2 mmol) in dry THF (5 ml) under nitrogen. The reaction mixture was boiled 
under reflux overnight. The cooled brown solution was diluted with diethyl ether and 
filtered. The resulting solution was concentrated and purified by chromatography 
(diethyl ether/pet. ether (40-60 °C)/dichloromethane, 3:4:3) to afford (19) (0.46 g, 
81%) as a pale yellow oil; IR vm  2361 (CN), 1438, 1375 (N02); NMR SH 2.08 (3H, 
s, CH3), 3.69 (2H, s, CH2 CN), 4.42 (2H, s, CH2N), 7.05 (1H, d, J  = 9.0 Hz, 5-H), 
7.32-7.36 (6 H, m, 6 -H + Ph-H5), 7.72 (1H, d, 7 =  2.0 Hz, 2-H); MS m/z 282.1230 (M 
+ H) (Ci6Hi6N30 2  requires 282.1242), 204 (M - C Jh ), 91 (Bn).
4-(N-Benzyl-N-methylamino)phenylacetonitrile (20)
(20)
Triethylamine (1.3 g, 13 mmol) was added to a solution of compound (36) (6.5 g, 18 
mmol) in dry acetonitrile (60 ml) under nitrogen, followed immediately by the 
addition of tetraethylammonium cyanide (3.3 g, 21 mmol). After stirring overnight 
the reaction mixture was evaporated and the remaining residue was extracted with a 
mixture of diethyl ether and pet. ether (40-60 °C) (50%). The ether solution was 
evaporated and the remaining residue was purified by chromatography (diethyl ether/
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pet. ether (40-60 °C)/chloroform, 1:6:1) to afford (20) (2.0 g, 40%); R /=  0.58 as a 
pale yellow oil; NMR 5h 2.95 (3H, s, CH3), 3.94 (2H, s, CH2 CN), 4.46 (2H, s, 
CH2N), 6.65 (2H, d, J=  8 . 6  Hz, 3,5-H2), 7.01 (2H, d, J = 8 . 6  Hz, 2,6-H2), 7.04-7.27 
(5H, m, Ph-Hs); MS m/z 237.1385 (M + H) (Ci6 Hi7N2 requires 237.1391), 210 (M -  
CN), 194 (M -  C2H3N), 91 (Bn).
4-Chloro-3-nitrobenzyl bromide (30)
(30)
4-Chloro-3-nitrotoluene (31.0 g, 0.18 mmol) was added to a suspension o f N- 
bromosuccinimide (31.0 g, 0.18 mmol) in carbon tetrachloride (200 ml) and 
dibenzoyl peroxide (0.65 g, 2.7 mmol) was added. The reaction mixture was heated 
at reflux overnight. The reaction mixture was cooled, filtered and the solvent was 
concentrated. The residue was purified by chromatography (diethyl ether/pet. ether 
(40-60 °C)/dichloromethane, 3:4:3) to give (30) (29.0 g, 65%) as a reddish brown oil; 
NMR 5h4.48 (2H, s, CH2Br), 7.52 (1H, d, J =  8.3 Hz, 5-H), 7.56 (1H, dd, J  = 8.3, 
1.7 Hz, 6 -H), 7.91 (1H, d, J =  1.7 Hz, 2-H); MS m/z 250 (M - H) C8H6 3 7a 7 9 BrN2 0 2 , 




Tetraethylammonium cyanide (0.50 g, 3.2 mmol) was added to compound (30) (0.66 
g, 2.6 mmol) in dry acetonitrile (10 ml) under argon. The resulting deep green
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solution was stirred for 4 h. the solvent was removed under vacuum and the residue 
was purified by chromatography (hexane/diethyl ether, 1:2) to afford (31) (0.15 g, 
29%) as a pale yellow oil; IR Vmax 2253 (CN), 1536, 1356 (NO2 ), 806 (C-Cl) cm'1; 
NMR 8 h 3.85 (2H, s, CH2 CN), 7.54 (1H, dd, J=  8.2, 2.0 Hz, 6 -H), 7.60 (1H, d, J  =
8.2 Hz, 5-H), 7.86 (1H, d, J =  2.0 Hz, 2-H); MS m/z 197 (M - H) CgH^ClNzO2 , 195 
(M - H) C8H63 5C1N2 02, 350/348 (M + 3-NBA).





Benzoyl chloride (7.7 g, 55 mmol) was added to a solution of methyl 4-(N- 
methylamino)benzoate (9.0 g, 55 mmol) and triethylamine ( 8  ml) in dry diethyl ether 
(200 ml). After stirring for 1 h the ether solution was washed with water, dried 
(MgSCU) and then evaporated. The remaining residue was purified by 
recrystallisation from aqueous ethanol to afford (34) (12.13 g, 90%) as a buff solid: 
mp 58-60 °C (lit. 13 0 mp 57-60 °C); NMR 8 h 3.51 (3H, s. CH3N), 3.85 (3H, s, CH3 0 ), 
7.06 (2H, d, J =  8 . 8  Hz, 3,5-H2), 7.13-7.28 (5H, m, Ph 3,4,5-Hj + 2,6-H2), 7.86 (2H, 
d, 7 = 8 .8  Hz, Ph 2,6-H2).
4-(N-Benzyl-N-methylaraino)benzyl alcohol (35) 131
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Compound (34) (23.0 g, 85 mmol) dissolved in dry diethyl ether (100 ml) was added 
slowly to a stirred suspension of LiAlRi (6.5 g, 170 mmol) in dry diethyl ether (200 
ml). The reaction mixture was stirred at 35 °C for 4 h. The reaction mixture was 
cooled and quenched by the addition of ice cold water ( 1 0 0  ml) followed by 
extraction with ethyl acetate (2 x 200 ml). The organic layer was separated, washed 
with water, dried (MgSCU) and then evaporated to dryness. The remaining residue 
was purified by chromatography (diethyl ether/pet. ether (40-60 °C), 1:1) to give (35) 
(10.4 g, 54%): R /=  0.39 as a pale yellow oil; NMR 5h 2.21 (1H, t, J  = 5.1 Hz, OH), 
2.95 (3H, s, CH3), 4.44 (2H, d, J =  5.1 Hz, CH2OH), 4.46 (2H, s, CH2N), 6.65 (2H, 





An excess of hydrobromic acid in acetic acid (30%, 20 ml) was added to compound 
(35) (4.5 g, 20 mmol) under nitrogen. After 6  h the reaction mixture was evaporated 
to afford (36) (6.2 g, 84%) as a hygroscopic orange solid; NMR 5r3.23 (3H, s, CH3),
4.40 (2H, s, CH2Br), 4.71 (2H, s, CH2N), 7.24-7.35 (5H, m, Ph-H5), 7.39 (2H, d ,J=






To L-arabinose (10.0 g, 67 mmol) and 2,2-dimethoxypropane (23.0 g, 0.22 mol) in 
dry DMF (130 ml) was added 4-toluenesulfonic acid (150 mg) and the reaction 
mixture was stirred for 90 min. The mixture was neutralised with solid sodium 
carbonate and evaporated to dryness. The residue was partitioned between water 
(120 ml) and pet. ether (40-60 °C) (60 ml). Sodium periodate (35.5 g, 0.17 mol) was 
added to the aqueous layer and the reaction mixture was stirred for 2 h. Solid sodium 
carbonate was added and the slurry was stirred for 1 h. Extraction with ethyl acetate 
and evaporation gave a residue, which was extracted with dichloromethane. The pale 
yellow oil that remained after evaporation of dichloromethane was purified by 
chromatography (diethyl ether/pet. ether (40-60 °C), 2:1) to give (44) (5.8 g, 54%); 
R /=  0.68; [a]20D = +20° (c 5.3, CHC13) (lit. 1 3 3  [a]25D = +75° (c 1.0, CH3OH)) as a 
colourless oil; NMR 5h 1.31 (3H, s, Me), 1.46 (3H, s, Me), 3.89 (1H, d, J  = 2.5 Hz, 
OH), 4.01 (1H, d, J =  10.5 Hz, 4-H), 4.05 (1H, dd, .7=10.5, 3.5 Hz, 4-H), 4.55 (1H, 
d, J  = 6.0 Hz, 2-H), 4.82 (1H, dd, J  = 6.0, 3.5 Hz, 3-H), 5.39 (1H, d, J  = 2.5 Hz, 1- 
H); MS m/z 159.0650 (M + H) (C7H n 0 4  requires 159.0657), 181 (M + Na), 101 (M 
- C 3H50).
(£’,45',5R)-5-(Ethoxycarbonylethenyl)-4-hydroxymethyl-2,2-dimethyl-l^}- 






o .  . 0
(45)
C2 H5 0 2C j  ^
. 0
(46)
To ethyl triphenylphosphoranylidineacetate (9.3 g, 27 mmol) in dichloromethane 
(100 ml) was added compound (44) (2.9 g, 18 mmol) in dichloromethane (30 ml). 
The mixture was stirred overnight. Excess diethyl ether was added to the residue
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remaining after evaporation of the dichloromethane. The formed white solid was 
filtered off and the ether was dried (MgSC^), and concentrated. Purification by 
chromatography (diethyl ether/pet. ether (40-60 °C), 1:1) afforded first the Z-alkene
(46) (2 . 2  g, 54%); R /= 0.50; [a]20D = -120° (c 3.7, CHC13), (lit. 1 4 2  [a]22D = -111.3° 
(c 1.5, EtOH)) as a colourless oil and then the Zs-isomer (45) (0.6 g, 15%); R /=  0.21; 
[a]20D = -32.8° (c 3.2, CHCI3), ( lit 1 4 2  [a]22D = -6 .6 ° (c 1.7, EtOH)) as a colourless 
oil. The Z-isomer was characterised with NMR 8 h 1.29 (3H, t, J =  7.0 Hz, CH2 C //3),
1.40 (3H, s, Me), 1.53 (3H, s, Me), 2.44 (1H, dd, J =  7.4, 5.5 Hz, OH), 3.45 (1H, m, 
CHtfOH), 3.59 (1H, m, CtfHOH), 4.16 (2H, q, J =  7.4 Hz, Ctf2 CH3), 4.53-4.57 (1H, 
m, 4-H), 5.58 (1H, dt, 7.1, 1.7 Hz, 5-H), 5.91 (1H, dd, 11.7, 1.7 Hz, CHC02),
6.36 (1H, dd ,J =  11.7, 7.1 Hz, C tfC H ). The £-isomer had NMR 8h 129 (3H, t, J  = 
1 2  Hz, CH2C //3), 1.40 (3H, s, Me), 1.52 (3H, s, Me), 2.41 (1H, t, J  = 5.9 Hz, OH), 
3.55 (2H, t, J  = 5.9 Hz, C/72 OH), 4.18 (2H, q, J = 7.2 Hz, CH2CH3), 4.33-4.38 (1H, 
m, 4-H), 4.79 (1H, dt, / =  5.5, 1.6 Hz, 5-H), 6.12 (1H, dd, J=  15.6, 1.6 Hz, CHC02),
6 . 8 8  (1H, dd, J  = 15.6, 5.5 Hz, C tfC H ); MS m/z 231.1240 (M + H) (C nH 190 5 




^  / ~ ~ 0H  
r \
(47)
A mixture of the unsaturated esters (45) and (46) (2.3 g, 10 mmol) was stirred in 
ethanol (100 ml) with Pd/C (5%, 150 mg) under an atmosphere of hydrogen for 3h. 
The catalyst was removed by filtration through Celite®. The solvent was evaporated 
to afford (47) (2.3 g, 99%); [a]20D = +13.4° (c 2.5, EtOH), (lit. 1 4 2 [a]22D = +22.5° (c 
2, EtOH)) as a pale yellow oil; NMR 8 H 1.26 (3H, t, J = 7.0 Hz, CH2Ctf3), 1-33 (3H, 
s, Me), 1.42 (3H, s, Me), 1.82 (2H, m, CH2 CH), 2.40 (1H, br, OH), 2.40 (1H, dt, J  =
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16.4, 7.8 Hz, CHC02), 2.53 (1H, dt, J =  16.4, 7.4 Hz, CHC02), 3.65 (2H, d, /  = 5.1 
Hz, OT2 OH), 4.09-4.20 (4H, m, 4-H + 5-H + Ctf2CH3); MS m/z 233.1396 (M + H) 





Lithium bis(trimethylsilyl)amide (1 M in THF) (10 ml, 10 mmol) was added to (47) 
(2.3 g, 10 mmol) and benzyl bromide (3.4 g, 20 mmol) in dry DMF (5 ml). After 2h, 
the reaction was quenched by addition of water, followed by extraction with diethyl 
ether. The ether layer was washed with water and brine, dried (MgSC>4 ) and 
evaporated. Purification by chromatography (diethyl ether/pet. ether (40-60 °C), 1:4) 
afforded (48) (1.6 g, 48%); R /= 0.32; [a]20D = +24.8° (c 4.4, CHC13) as a pale yellow 
oil; NMR 8 h 1.24 (3H, t, J  = 7.0 Hz, CH2 C/f3), 1.33 (3H, s, Me), 1.42 (3H, s, Me),
I.72-1.86 (2H, m, CH2CH), 2.34-2.40 (1H, m, CHC02), 2.48-2.54 (1H, m, CHC02), 
3.47-3.54 (2H, m, CH2 OBn), 4.08-4.15 (3H, m, 5-H + Ctf2CH3), 4.28 (1H, dd, 7  =
II.9, 6.1 Hz, 4-H), 4.50 (1 1 1 ,(1 ,/=  12.1 Hz, CHPh), 4.57 (1H, d, /  = 12.1 Hz, 
CHPh), 7.24-7.33 (5H, m, Ph-H5); MS m/z 323.1864 (M + H) (C18H2 7 O5 requires 
323.1858), 265 (M -C 3H5O), 91 (Bn).
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Diethyl (R,R)-2,2-dimethyl-l,3-dioxoIane-4,5-dicarboxylate (50)140
C 2H5OOC £ O O C 2H5
(50)
Diethyl (R,i?)-2,3-dihydroxybutanedioate (15 g, 70 mmol), 2,2-dimethoxypropane 
(8.0 g, 80 mmol), and 4-toluenesulfonic acid ( 6 6  mg, 0.34 mmol) in dichloromethane 
( 2 0 0  ml) were boiled under reflux through activated 4 A molecular sieves (33 g) in a 
Soxhlet apparatus for 3 h. Anhydrous sodium carbonate (83 mg, 1 mmol) was then 
added. Filtration, drying (MgSCU) and evaporation gave (50) (16.0 g, 89%) as a pale 
brown oil. [<x]20D = -29° (c 4.2, CHCI3) (lit. 19 6 [a]20D = -49.4° (neat liquid)); NMR 5H 
1.32 (6 H, t, J =  7.2 Hz, 2  x CH2 Ctf3), 1.50 (6 H, s, CMe2), 4.28 (4H, q, / =  7.2 Hz, 2 
x C //2CH3), 4.77 (2H, s, 4,5-H2).
(kS'^)-4,5-Di(hydroxyniethyI)-2,2-dimethyI-l^-dioxolane (51)140
A suspension of LiAlHL* (6.0 g, 150 mmol) in dry THF (60 ml) was heated for 30 
min. A solution of (50) (18 g, 70 mmol) in dry THF (80 ml) was added over 1.5 h.
water (10 ml), NaOH solution (4 M, 10 ml), and water (30 ml) were added cautiously 
in turn. The aluminium salts were removed by filtration. Water and THF were 
removed under reduced pressure to give crude (51). The aluminium salts were then 
extracted with boiling dioxane (3 x 100 ml); removal of dioxane under reduced 
pressure gave further product (7.0 g, 60%) of (51) as a pale yellow oil. [a]18D -  +7.5°
jCH2OHHOH2C
(51)
The mixture was boiled under reflux for a further 5 h. It was then cooled to 0 °C and
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(c 4.4, ethanol) ( li t 1* 7  [a]25D = +3.8° (c 3.7, CHC13»; NMR 5h 1.41 (6 H, s, CMe2),
(5'fS)-4,5-Di(benzyIoxymethyl)-2,2-dimethyI-l,3-dioxolane (52) and (SVS)-4-
i  A*ybenzyloxymethyI-5-hydroxymethyI-2,2-dimethyl-l,3-dioxolane (53)
Sodium hydride (60% dispersion in mineral oil, 1.4 g, 34 mmol) was stirred in dry 
DMF (20 ml) under nitrogen for 30 min. A solution of (51) (5.0 g, 31 mmol) in DMF 
( 2 0  ml) was then added dropwise and the reaction mixture was stirred for a further 30 
min before benzyl chloride (4.0 g, 32 mmol) was added. The reaction mixture was 
stirred for 1.5 h, and was then poured into ice water (250 ml) and extracted with 
diethyl ether (3 x 150 ml). The combined extracts were washed successively with 
water and brine, dried (MgSCU) and concentrated under reduced pressure. The 
resulting oil was purified by chromatography (pet. ether (40-60 °C)/ether, 1:1) to 
afford (52) (2.2 g, 28%); R/ = 0.79 as a yellow oil; NMR 6 H 1.42 (6 H, s, CMe2),
3.54-3.66 (4H, m, 2 x CH2OBn), 4.00-4.04 (2H, m, 4,5-H2), 4.54 (2H, d, J  = 12.3 
Hz, 2  x CHPh), 4.58 (2H,d, J  = 12.3 Hz, 2 x CHPh), 7.3 (10H, m, 2 x Ph-H5) and 
(53) (3.2 g, 64%) R /=  0 . 1 1  as a pale yellow oil. [cc]20D = +8.0° (c 3.2, CHC13) (lit. 1 4 2  
[a]23D = +8.3° (c 2.9, CHC13)); NMR 6 H 1.41 (3H, s, Me), 1.42 (3H, s, Me), 2.33 
(1H, dd, J=  8 .6 , 4.3 Hz, OH), 3.55 (1H, dd, J=  9.8, 4.3 Hz, CHOBn), 3.64-3.70 (2H, 
m, CHOU + CHOBn), 3.75 (1H, d t ,J  = 11.7, 4.3 Hz, CtfOH), 3.94 (1H, dt, 8.3,
4.3 Hz, 5-H), 4.05 (1H, dt, / =  8.3,4.3 Hz, 4-H), 4.58 (2H, s, CH2Ph), 7.29-7.35 (5H,






The alcohol (53) (3.6 g, 14 mmol) in dichloromethane (15 ml) was added slowly to a 
stirred slurry of pyridinium chlorochromate (3.6 g, 35 mmol), sodium acetate (0.30 g,
3.5 mmol) and powdered 4 A molecular sieves (3 g) in dichloromethane (200 ml) 
under nitrogen. After stirring for 3 h the reaction mixture was filtered on silica gel 
with elution by ether. Evaporation of the solvent gave (54) (3.3 g, 93%) as a pale 
yellow oil. [a]20D = +14° (c 3, CHC13) (lit.145 [a]21D = +16.8° (c 1.1, CHC13); NMR
7.25-7.36 (5H, m, Ph-H5), 9.76 (1H, d, J =  1.5 Hz, CHO).
(£’,45',55)-4-Benzyloxymethyl-5-(ethoxycarbonylethenyl)-2,2-dimethyl-l,3- 




5h 1.43 (3H, s, Me), 1.50 (3H, s, Me), 3.67 (2H, d, J =  4.0 Hz, CH2OBn), 4.19-4.29 
(2H, m, 4,5-H2), 4.58 (1H, d, J =  10.5 Hz, CHPh), 4.61 (1H, d, J =  10.5 Hz, CHPh),
O
(55) (56)
The aldehyde (54) (2 g, 8 mmol), ethyl triphenylphosphoranylideneacetate (4.2 g, 16 
mmol) and benzoic acid (50 mg, 0.4 mmol) in toluene (200 ml) were heated at reflux 
under nitrogen for 4 h. The mixture was allowed to cool to room temperature before
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the solvent was evaporated off under reduced pressure to give a white solid. This 
solid was extracted with diethyl ether (3 x 20 ml) and the ether was evaporated to 
give a pale yellow oil which gave, after chromatography (pet. ether (40-60 °C)/ether, 
5:1), first Z-alkene (56) (0.8 g, 31%); R /=  0.31 as an oil and then the is-isomer (55) 
(0.80 g, 31%); R /=  0.18 also as an oil; [a]20D = -21° (c 4.5, CHCI3 ) (lit. 1 4 2  [a]23D = - 
13.4° (c 2.1, CHCI3). The Z-isomer (56) was characterised by NMR 5h 1.25 (3H, t, J  
= 7.1 Hz, CH2C//3), 1.45 (6 H, s, CMe2), 3.68 (2H, d, J  = 3.1 Hz, CH2 OBn), 3.94-
4.00 (1H, m, 4-H), 4.12 (2H, q, J  = 7.1 Hz, CH2CH3), 4.56 (1H, d, J  = 12.1 Hz, 
CHPh), 4.62 (1H, d, J =  12.1 Hz, CHPh), 5.38 (1H, dt, J =  8.3, 1.2 Hz, 5-H), 5.92 
(1H, dd, J =  11.7, 1.2 Hz, CHC02), 6.18 (1H, dd, / =  11.7, 8.3 Hz, Ctf=CH), 7.32- 
7.37 (5H, m, Ph-H5). The £-isomer had NMR 8 h 1.29 (3H, t, /  = 7.0 Hz, CH2 CH3\
1.43 (3H, s, Me), 1.45 (3H, s, Me), 3.62 (2H, d, / =  4.7 Hz, CH2 OBn), 3.95 (1H, dt, J  
= 8 .6 , 4.7 Hz, 4-H), 4.19 (2H, q, J  = 7.0 Hz, Ctf2CH3), 4.42 (1H, ddd, J =  8 .6 , 5.5,
1.4 Hz, 5-H), 4.56 (1H, J =  12.1 Hz, CHPh), 4.61 (1H, d, J =  12.1 Hz, CHPh), 6.09 
(1H, dd, J =  15.6, 1.4 Hz, CHC02), 6 . 8 8  (1H, dd, / =  15.6, 5.5 Hz, CH=CH), 7.27-




 ^ OPh— \
° 'A - (
°x°
(57)
A mixture of the unsaturated esters (55) and (56) (0.62 g, 1.9 mmol) was stirred in 
ethanol (25 ml) with Pd/C (5%, 30 mg) under atmosphere of hydrogen for 1 h. The 
catalyst was removed by filtration through Celite®. The solvent was evaporated off 
and the residue was purified by chromatography (pet. ether (40-60 °C)/ether, 4:1) to 
give (57) (0.4 g, 63%); R /=  0.29 as a pale yellow oil. [oc]20D = -15° (c 4.0, CHC13); 
NMR 8 h 1.23 (3H, t, J =  7.0 Hz, CH2 C //3), 1.38 (3H, s, Me), 1.39 (3H, s, Me), 1.81-
1.87 (1H, m, Ci/CH2), 1.93-1.99 (1H, m, CtfCH2), 2.37-2.54 (2H, m, CH2 C 02),
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3.53-3.60 (2H, m, CH2 OBn), 3.80-3.87 (2H, m, 4,5-H2), 4.12 (2H, q, J  = 7.0 Hz, 
Ctf2 CH3), 4.56 (1H, d ,J =  12.3 Hz, CHPh), 4.59 (1H, d, J  = 12.3 Hz, CHPh), 7.32-
7.34 (5H, m, Ph-H5); MS m/z 323.1856 (M + H) (Ci9H2 6 0 5 requires 323.1858), 265 





H O - ^ \  ^
°X °
(58)
A mixture of the unsaturated esters (55) and (56) (0.66 g, 2.1 mmol) was stirred in 
ethanol (20 ml) with Pd/C (5%, 35 mg) under an atmosphere of hydrogen for 6 h. The 
catalyst was removed by filtration through Celite®. The solvent was evaporated to 
afford (58) (0.45 g, 93%); as a pale yellow oil; NMR 8 h 1.26 (3H, t, J  = 7.0 Hz, 
CH2Ctf3), 1.39 (3H, s, Me), 1.40 (3H, s, Me), 1.79-1.89 ( 1 H, m, CtfCH2), 1.92-2.01 
(1H, m, CtfCH2), 2.39-2.55 (3H, m, CH2C 0 2 + OH), 3.60 (1H, dd, J =  11.5, 4.1 Hz, 
C//OH), 3.70-3.82 (2H, m, CtfOH + 4-H), 3.91 (1H, dt, / =  8.2, 3.8 Hz, 5-H), 4.13 






Lithium bis(trimethylsilyl)amide (1 M in THF) (9.1 ml, 9.1 mmol) was added to a 
stirred solution of phenylacetonitrile (1.1 g, 9.1 mmol) in dry diethyl ether (10 ml) 
under nitrogen at -78 °C. After 10 min, compound (48) (2.9 g, 9.1 mmol) was added 
and the reaction mixture was allowed to warm to room temperature. The mixture was 
stirred for 72 h. An excess of diethyl ether was added, followed by water. The 
aqueous layer was separated, washed with diethyl ether and then added to ethyl 
acetate (100 ml) in a separating funnel. Acidification by dropwise addition of 1 M 
aqueous citric acid to pH = 6 with rapid extraction with ethyl acetate was followed 
by rapid separation of the organic layer. Ethyl acetate was washed with water, dried 
(MgS04) and evaporated. Purification with chromatography (ethyl acetate/hexane, 
2:1) afforded (61) (1.5 g, 21%); R /=  0.34 as a pale yellow oil; IR Vmax 2207 (CN), 
1728 (C=0) cm'1; NMR 8H 1.26 (3H, s, Me), 1.34 (3H, s, Me), 1.66-1.80 (2H, m, 
Ctf2CHO), 2.58-2.68 (1H, m, CtfCH2), 2.70-2.80 (1H, m, CZ7CH2), 3.45 (2H, d, J  =
6.0 Hz, CH2OBn), 3.95-4.02 (1H, m, 4-H), 4.20 (1H, q, J =  6.0 Hz, 5-H), 4.45 (1H, 
d, / =  11.5 Hz, CHPh), 4.52 (1H, d, / =  11.5 Hz, CHPh), 7.21-7.41 (10H,m,2 x Ph- 
H5), 8.96 (1H, s, OH); MS m/z 394.2016 (M + H) (C24H28N 04 requires 394.2018), 








4-Chlorophenylacetonitrile (3.0 g, 20 mmol) and compound (48) (6.4 g, 20 mmol) 
were condensed in the same method as described above. The resulting yellow oil was 
purified by chromatography (ethyl acetate/hexane, 1:1) to afford (62) (2.2 g, 26%); 
R /=  0.58 as a pale yellow oil; NMR 5h 1.40 (3H, s, Me), 1.51 (3H, s, Me), 1.78-1.88 
(2H, m, Ctf2CHO), 1.98-2.08 (2H, m, Ctf2CH2), 3.45 (2H, d, J =  6.0 Hz, CH2OBn), 
4.29 (1H, ddd, J  = 10.1, 6.0, 3.9 Hz, 4-H), 4.39 (1H, q, J=  6.0 Hz, 5-H), 4.45 (1H, d, 
J =  11.5 Hz, CHPh), 4.49 (1H, d, J =  11.5 Hz, CHPh), 5.52 (0.1H, s, CHCN), 7.16 
(0.2H, d, J =  8.6 Hz, Ph 3,5-H2), 7.24 (1.8H, d, J =  8.6 Hz, Ph 3,5-H2), 7.25-7.32 
(5H, m, Ph-Hs), 7.35 (1.8H, d, J =  8.6 Hz, Ph 2,6-H2), 7.84 (0.2H, d, / =  8.6 Hz, Ph 
2,6-H2), 9.33 (0.9H, br, OH); MS m/z 430.1604 (M + H) (C24H2637C1N04 requires 
430.1599), 428.1618 (M + H) (C24H2735C1N04 requires 428.1628), 372/370 (M - 
C2HtNO), 91 (Bn).
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(4R,5S)-5-Benzyloxymethyl-4-(4-(4-bromophenyl)-4-cyano-3-oxobutyl)-2,2-
dimethyl-1,3-dioxolane (63)
4-Bromophenylacetonitrile (3.9 g, 20 mmol) and compound (48) (6.4 g, 20 mmol) 
were condensed in the same method as described above. The resulting yellow oil was 
purified by chromatography (ethyl acetate/hexane, 2:1) to afford (63) (1.7 g, 18%); 
R /=  0.82 as a yellow oil; NMR 8 h 1.27 (3H, s, Me), 1.35 (3H, s, Me), 1.70-1.82 (2H, 
m, C //2 CHO), 2.62-2.78 (2H, m, CH2C=0), 3.45-3.47 (2H, m, CH2OBn), 4.00 (1H, 
ddd, J =  10.1, 6.2, 3.9 Hz, 4-H), 4.22 (1H, q, J =  6.2 Hz, 5-H), 4.45 (1H, d, / =  11.9 
Hz, CHPh), 4.49 (1H, d, / =  11.9 Hz, CHPh), 5.48 (0.35H, s, CHCN), 7.21-7.35 (5H, 
m, Ph-Hs), 7.45 (1.35H, d, / =  8 . 8  Hz, Ph 3,5-H2), 7.55 (1.35H, d, / =  8 . 8  Hz, Ph 2,6- 
H2), 7.59 (0.65H, d, J  = 8 . 6  Hz, Ph 3,5-H2), 7.76 (0.65H, d, J  = 8 . 8  Hz, Ph 2,6-H2),
9.35 (0.65H, s, OH); MS m/z 474.1100 (M + H) (C24H2781BrN04 requires 474.1102), 










3,4-Dichlorophenylacetonitrile (3.7 g, 20 mmol) and compound (48) (6.4 g, 20 
mmol) were condensed in the same method as described above. The resulting yellow 
oil was purified by chromatography (ethyl acetate/hexane, 2:1) to afford (64) (1.5 g, 
16%); R /=  0.68 as a hygroscopic white solid; NMR 8 h 1.41 (3H, s, Me), 1.52 (3H, s, 
Me), 1.73-1.87 (2H, m, Ctf2 CHO), 2.71-2.84 (2H, m, CH2 C=0), 3.47 (1H, dd, J  =
11.7, 6.0 Hz, CHOBn), 3.49 (1H, dd, J =  11.7, 6.0 Hz, CHOBn), 3.90-4.07 (1H, m, 
4-H), 4.22 (1H, q, J =  6.0 Hz, 5-H), 4.47 (1H, d, J =  12.3 Hz, CHPh), 4.56 (1H, d, J  
= 12.3 Hz, CHPh), 7.26-7.37 (5H, m, Ph-H5), 7.45 (1H, d, J =  8 . 6  Hz, Ph 5-H), 7.50 
(1H, dd, J  = 8 .6 , 2.0 Hz, Ph 6 -H), 7.83 (1H, d, J  = 2.0 Hz, Ph 2-H), 9.61 (1H, br, 
OH); MS m/z 466.1178 (M + H) (C24H2637C12N 0 4 requires 466.1179), 464.1193 (M 
+ H) (C24H2637C135C1N04 requires'464.1209), 462.1217 (M + H) (C24H 2 6 3 5C12N 0 4 






Lithium bis(trimethylsilyl)amide (1.0 M in THF) (1.3 ml, 1.3 mmol) was added to a 
stirred solution o f phenylacetonitrile (0.14 g, 1.3 mmol) in dry diethyl ether (5 ml) 
under nitrogen at -78 °C. After 10 min, compound (57) (0.40 g, 1.3 mmol) was added 
and the reaction mixture was allowed to warm to room temperature. The reaction 
mixture was stirred for 72 h. An excess of diethyl ether was added, followed by 
water. The aqueous layer was separated, washed with diethyl ether and then acidified 
by dropwise addition of 1 M aqueous citric acid to pH = 6 . The aqueous layer was 
extracted with diethyl ether (3 x 50ml) and the combined ether extracts was washed 
with water, dried (MgS0 4 ) and evaporated. Purification by chromatography (ethyl 
acetate/hexane, 2:1) afforded (65) (70 mg, 14%); R /=  0.45 as a pale yellow solid: mp 
75-77 °C; IR Vmax 2206 (CN), 1731 (C=0) cm-1; NMR 5h 1.39 (3H, s, Me), 1.41 (3H, 
s, Me), 1.82-1.90 (1H, m, CtfCHO), 1.97-2.03 (1H, m, CtfCHO), 2.48-2.65 (2H, m, 
Ctf2CO), 3.54-3.63 (2H, m, 4,5-H2), 3.87-3.89 (2H, m, CH2OBn), 4.57 (1H, d, J  =
12.5 Hz, CHPh), 4.61 (1H, d, J =  12.5 Hz, CHPh), 5.59 (0.2H, s, CHCN), 7.33-7.64 
(8 H, m, Ph 3,4,5-H3 + Ph-H5), 7.66 (1.6H, d ,J =  8 . 6  Hz, Ph 2,6-H2), 7.91 (0.4H, d, J  
= 8 . 6  Hz, Ph 2,6-H2), 9.19 (0.8H, br, OH); MS m/z 392.1859 (M - H) (C24H26N 0 4  








4-Chlorophenylacetonitrile (0.19 g, 1.3 mmol) and compound (57) (0.4 g, 1.3 mmol) 
were condensed in the same method as described above. The resulting yellow oil was 
purified by chromatography (ethyl acetate/hexane, 1:1) to afford (66) (0.22 g, 41%); 
R/= 0.68 as a yellow oil; IR 2209 (CN), 1731 (C=0) cm'1; NMR 8h 1.39 (3H, s, 
Me), 1.40 (3H, s, Me), 1.81-1.88 (1H, m, C/7CHO), 1.95-2.04 (1H, m, CHCH.0), 
2.46-2.63 (2H, m, CH2CO), 3.53-3.62 (2H, m, 4,5-H2), 3.83-3.87 (2H, m, CH2OBn), 
4.57 (1H, d, J = 12.1 Hz, CHPh), 4.60 (1H, d, J =  12.1 Hz, CHPh), 7.26-7.40 (5H, m, 
Ph-Hs), 7.44 (2H, d, J=  8.6 Hz, Ph 3,5-H2), 8.02 (2H, d, J=  8.6 Hz, Ph 2,6-H2); MS 
m/z 430.1608 (M + H) (C24H2737C1N04 requires 430.1599), 428.1623 (M + H) 






4-Bromophenylacetonitrile (2.9 g, 15 mmol) and compound (57) (4.8 g, 15 mmol) 
were condensed in the same method as described above. The resulting yellow oil was 
purified by chromatography (ethyl acetate/hexane, 2:1) to afford (67) (1.7 g9 24%); 
R /=  0.81 as a pale yellow oil; IR Vmax 2208 (CN), 1718 (C=0) cm'1; NMR 8h 1-33 
(3H, s, CMe), 1.34 (3H, s, CMe), 1.68-1.81 (1H, m, C//CHO), 1.83-1.98 (1H, m, 
CtfCHO), 2.66-2.72 (1H, m, CHCO), 2.74-2.84 (1H, m, CHCO), 3.55-3.65 (2H, m, 
CH2OBn), 3.91-3.95 (1H, m, 5-H), 4.03 (1H, dt, / =  8.0, 3.7 Hz, 4-H), 4.53 (1H, d, J  
= 12.0 Hz, CHPh), 4.61 (1H, d, 12.0 Hz, CHPh),5.50 (0.25H, s, CHCN), 7.22 
(1.5H, d, J = 8.1 Hz, Ph 3,5-H2), 7.26-7.36 (5H, m, Ph-H5), 7.53 (1.5H, d, J =  8.1 Hz, 
Ph 2,6-H2), 7.60 (0.5H, d, J  = 8.7 Hz, Ph 3,5-H2), 7.77 (0.5H, d, J  = 8.7 Hz, Ph 2,6- 
H2), 9.60 (0.75H, br, OH); MS m/z 474.1103 (M + H) (C2 4H2 7 81BrN 0 4  requires 




l-Cyano-7-hydroxy-l-pheny!heptan-2-one (6 8 )
(68)
Phenylacetonitrile (1.2 g, 10.2 mmol) and e-caprolactone (1.2 g, 10 mmol) were 
condensed in the same method described for compound (65). The resulting yellow oil 
was purified by chromatography (ethyl acetate/hexane, 2:1) to afford (68) (0.50 g, 
21%); Rf  = 0.26 as a pale yellow solid: mp 98-99 °C; IR Vmax 3402 (OH), 2205 (CN), 
1718 (C=0) cm'1; NMR ((CD3)2SO) 8H 1.35-1.42 (2H, m, 5-H2), 1.44-1.51 (2H, m, 
6-H2), 1.65 (2H, qn, J =  7.4 Hz, 4-H2), 2.60 (2H, t, J =  7.4 Hz, 3-H), 3.40 (2H, t, J  = 
6.2 Hz, 7-H2), 4.36 (1H, s, OH), 7.20 (1H, t, J =  7.6 Hz, Ph 4-H), 7.30 (2H, t, 7.6 
Hz, Ph 3,5-H2), 7.61 (2H, d, J  = 7.6 Hz, Ph 2,6-H2), 11.52 (1H, br, OH); MS m/z 




4-Chlorophenylacetonitrile (1.5 g, 10 mmol) and e-caprolactone (1.1 g, 10 mmol) 
were condensed in the same method described for compound (65). The resulting 
yellow oil was purified by chromatography (ethyl acetate/hexane, 2:1) to afford (69) 
(0.30 g, 11%); Rf  = 0.16 as a white solid: mp 92-94 °C; NMR 8h 1.21-1.30 (2H, m,
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5-H2), 1.50 (2H, m, 6 -H2), 1.58 (2H, qn, 7.4 Hz, 4-H2), 2.58 (1H, dt, J =  18.2, 7.4 
Hz, 3-H), 2.66 (1H, dt, J =  18.2, 7.4 Hz, 3-H), 3.60 (2H, t, J  = 6 . 8  Hz, 7-H2), 4.65 
(1H, s, CHCN), 7.32 (2H, d, J =  8.4 Hz, Ph 3,5-H2), 7.41 (2H, d, J =  8.4 Hz, Ph 2,6- 
H2); MS m/z 268.0912 (M + H) (Ci4Hi7 3 7ClN0 2  requires 268.0918), 266.0942 (M + 
H) (Ci4Hi7 35ClN0 2 requires 266.0947), 250/248 (M -  OH), 207/205 (M - CsHgO).
l-(4-Bromopheny!)-l-cyaiio-7-hydroxy-l-phenylheptan-2-one (70)
4-Bromophenylacetonitrile (1.3 g, 6 . 6  mmol) and e-caprolactone (0.73 g, 6 . 6  mmol) 
were condensed in the same method described for compound (65). The resulting 
yellow oil was purified by chromatography (ethyl acetate/hexane, 3:1) to afford (70) 
(0.3 g, 15%); Rf  = 0.24 as a pale yellow solid: mp 76-78 °C; NMR 8 h 1.28 (2H, qn, J  
= 7.3 Hz, 5-H2), 1.50 (2H, m, 6 -H2), 1.58 (2H, qn, 7.3 Hz, 4-H2), 2.62 (1H, dt, J  
= 18.0, 7.3 Hz, 3-H), 2.65 (1H, dt, J =  18.0, 7.3 Hz, 3-H), 3.60 (2H, t, J =  6.4 Hz, 7- 
H2), 4.64 (1H, s, CHCN), 7.26 (2H, d, / =  8.2 Hz, Ph 3,5-H2), 7.41 (2H, d, / =  8.2 
Hz, Ph 2,6-H2); MS m/z 312.0430 (M + H) (C14H I7 8 IC1N02 requires 312.0422), 





3,4-Dichlorophenylacetonitrile (1.4 g, 7.6 mmol) and e-caprolactone (0.84 g, 7.6 
mmol) were condensed in the same method described for compound (65). The 
resulting yellow oil was purified by chromatography (ethyl acetate/hexane, 3:1) to 
afford (71) (0.80 g, 35%); R/ = 0.39 as a pale yellow solid: mp 95-97 °C; NMR 8 h
1.26 (2H, qn, J =  7.3 Hz, 5-H2), 1.53 (2H, m, 6 -H2), 1.62 (2H, qn, J =  7.3 Hz, 4-H2), 
2.66 (2H, m, 3-H2), 3.60 (2H, t, / =  6.4 Hz, 7-H2), 4.69 (1H, s, C H C N ), 7.39 (1H, d, 
J =  8.4 Hz, Ph 6 -H), 7.51 (1H, d, J=  8.4 Hz, Ph 5-H), 7.83 (1H, s, Ph 2-H); MS m/z 
304.0520 (M + H) (Ci4H 163 7Cl2N0 2  requires 304.0499), 302.0537 (M + H) 
(Ci4H,6 3 7 C13 5C1N 0 2  requires 302.0528), 300.0559 (M + H) (C14Hi6 35Cl2N0 2  requires 






Phenylacetonitrile (0.50 g, 4.4 mmol) was condensed with 2,3-O-isopropylidene-D- 
erythronolactone (0.70 g, 4.4 mmol) in the same manner as described before. The 
resulting yellow oil was purified by chromatography (ethyl acetate/hexane, 2 :1 ) to 
give 72) (0.30 g, 27%); R /=  0.81 as a pale yellow oil; IR Vmax 3408 (OH), 2246 
(CN), 1694 (CO) cm'1; NMR 5H 1.41 (3H, s, Me), 1.49 (3H, s, Me), 4.41 (1H, dd, J=
11.0, 3.5 Hz, CtfOH), 4.48 (1H, d, J=  11.0 Hz, CtfOH), 4.75 (1H, d, J =  5.5 Hz, 4- 
H), 4.87-4.89 (1H, m, 5-H), 7.47 (2H, t, J =  7.4 Hz, Ph 3,5-H2), 7.61 (1H, t, J =  1A  
Hz, Ph 4-H), 8.10 (2H, d, J  = 8 . 6  Hz, Ph 2,6-H2); MS m/z 276.1225 (M + H)
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4-Chlorophenylacetonitrile (0.80 g, 5 mmol) was condensed with 2,3-0- 
isopropylidene-D-erythronolactone (0.80 g, 5 mmol) in the same manner as 
described before. The resulting yellow oil was purified by chromatography (ethyl 
acetate/hexane, 2:1) to give (73) (0.33 g, 21%); R /=  0.79 as a pale yellow oil; NMR 
Sh 1.30 (3H, s, Me), 1.59 (3H, s, Me), 4.05 (1H, dd, J =  10.1, 3.4 Hz, CHOU), 4.09 
(1H, d, J = 10.1 Hz, CtfOH), 4.73 (1H, d, / =  5.8 Hz, 4-H), 4.92 (1H, dd, J=  5.8, 3.4 
Hz, 5-H), 7.27 (2H, d, J  = 8.4 Hz, Ph 3,5-H2), 7.48 (2H, d, J  = 8.4 Hz, Ph 2,6-H2); 
MS m/z 312.0849 (M + H) (Ci5H 173 7 ClN0 4  requires 312.0816), 310.0855 (M + H) 







4-Bromophenylacetonitrile (3.0 g, 15 mmol) was condensed with 2,3-0- 
isopropylidene-D-erythronolactone (2.4 g, 15 mmol) in the same manner as 
described before. The resulting yellow oil was purified by chromatography (ethyl 
acetate/hexane, 3:1) to give (74) (2 g, 38%); R /=  0.89 as a pale yellow oil; IR Vmax 
3422 (OH), 2208 (CN), 1777 (C=0) cm'1; NMR Sh 1.39 (3H, s, Me), 1.47 (3H, s, 
Me), 4.40 (1H, dd, / =  10.9, 3.7 Hz, CtfOH), 4.45 (1H, d, J =  10.9 Hz, CHOH), 4.74 
(1H, d, J  = 5.5 Hz, 4-H), 4.86-4.88 (1H, m, 5-H), 5.57 (0.35H, s, CHCN), 7.27 
(1.3H, d, / =  8.6 Hz, Ph 3,5-H2), 7.51 (1.3H, d, J =  8.6 Hz, Ph 2,6-H2), 7.59 (0.7H, d, 
J = 8.6 Hz, Ph 3,5-H2), 7.78 (0.7H, d, 8.6 Hz, Ph 2,6-H2); MS m/z 356.0326 (M + 
H) (Ci5Hi781BrN04 requires 356.0320), 354.0327 (M + H) (Ci5Hi779BrN04 requires 
354.0340), 338/336 (M -  OH), 272 (M -  HBr).
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3,4-Dichlorophenylacetonitrile (3.7 g, 20 mmol) was condensed with 2,3-0- 
isopropylidene-D-erythronolactone (3.2 g, 20 mmol) in the same manner as 
described before. The resulting yellow oil was purified by chromatography (ethyl 
acetate/hexane, 1:1) to give (75) (1.5 g, 22%); R /=  0.81 as a pale yellow oil; ER. Vmax 
3404 (OH), 2250 (CN), 1782 (C=0) cm'1; NMR 5h 1.30 (3H, s, Me), 1.38 (3H, s, 
Me), 3.93 (1H, dd, J =  10.3, 3.7 Hz, CM)H), 4.00 (1H, d, J=  10.3 Hz, CtfOH), 4.70 
(1H, d, J = 5.9 Hz, 4-H), 4.91 (1H, dd, J = 5.9, 3.7 Hz, 5-H), 7.33 (1H, dd, J  = 8.2,
2.0 Hz, Ph 6-H), 7.36 (1H, d, 8.2 Hz, Ph 5-H), 7.58 (1H, d, / =  2.0 Hz, Ph 2-H); 
MS m/z 348.0411 (M + H) (Ci5Hi6 3 7Cl2N0 4  requires 348.0397), 346.0901 (M + H) 
(Ci5Hi637Cl35ClN04 requires 346.0906), 344.0448 (M + H) (Ci5Hi6 3 5Cl2N0 4  requires 





Phenylacetonitrile (1 .8 0  g, 15 mmol) and ethyl acetate ( 1 .3 0  g, 15 mmol) were 
condensed by the same method as described before. An excess of diethyl ether was 
then added, followed by water. The aqueous layer was acidified with 1 M  aqueous 
H C1 and the resulting precipitate was filtered and recrystallised from aqueous ethanol 
to afford ( 7 6 )  (0 .7 5  g, 3 1 % ) as a buff solid: mp 8 7 - 8 8  °C  (lit.112 mp 8 7 -8 9  °C );  N M R  
5 h  2 .2 5  (1 H , s, C H 3), 4 .6 6  (1 H , s, C H C N ), 7 .3 8 -7 .4 7  (5 H , m, Ph-H5); M S  m/z 
1 6 0 .0 7 4 0  ( M  +  H ) ( C io H io N O requires 1 6 0 .0 7 6 2 ) ,  1 4 4 ( M - C H 3), 1 1 8  ( M - C 2H 3N) .
l-Cyano-l,4-diphenylbutan-2-one (77)
(77)
Phenylacetonitrile (1.75 g, 15 mmol) and ethyl 3-phenylpropanoate (2.70 g, 15 
mmol) were condensed by the same method as described above to afford (77) (1.20 
g, 34%) as a buff solid: mp 53-54 °C; IR w  2200 (CN) cm'1; NMR ((CD3)2SO) 5H
2.88 (2H, t, J  = 8.0 Hz, CH2), 2.94 (2H, t, J =  8.0 Hz, CH2), 7.20-7.61 (10H, m, 2 x 
Ph-Hs), 11.70 (1H, br, OH); MS m/z 250.1240 (M + H) (Ci7Hi6NO requires 





4-Chlorophenylacetonitrile (3.03 g, 20 mmol) and ethyl propionate (2.04 g, 20 
mmol) were condensed by the same method as described above to afford (78) (1.55 
g, 37%) as a pale yellow solid: mp 50-51 °C (lit.110 mp 50-52 °C); NMR ((CD3)2SO) 
5h 1.24 (3H, t, J = 7.4 Hz, CH3), 2.62 (2H, q, J  = 7.4 Hz, CH2), 7.42 (2H, d, J = 8.8 
Hz, 2,6-H2), 7.66 (2H, d, J=  8.8 Hz, 3,5-H2), 11.87 (1H, br, OH) (enol form).
(4R,5*S)-5-Benzyloxymethyl-4-(4-cyano-3-methoxy-4-phenylbut-3-enyl)-2,2- 







A solution of compound (61) (1.5 g, 3.7 mmol) in THF (5 ml) was treated with a 
solution of diazomethane (-0.3 g, 8 mmol) prepared from N-methyl-N-nitroso-4- 
toluenesulfonamide and KOH (using Minidiazald apparatus) in diethyl ether (20 ml) 
and the mixture was kept overnight at 10 °C. The excess of diazomethane was 
destroyed by dropwise addition of acetic acid (30% in THF), and the solvent was 
evaporated off to afford (82) (1.2 g, 81%) as a pale yellow oil; NMR 8h 1.37 (3H, s, 
Me), 1.46 (3H, s, Me), 1.77-1.88 (2H, m, Ctf2CHO), 2.78-2.86 (1H, m, CtfCH2), 
2.90-2.98 (1H, m, CHCH2), 3.53 (2H, d, 5.9 Hz, CH2OBn), 3.78 (3H, s, OCH3), 
4.18-4.25 (1H, m, 4-H), 4.31-4.34 (1H, m, 5-H), 4.51 (1H, d, J =  12.1 Hz, CHPh), 
4.59 (1H, d, J =  12.1 Hz, CHPh), 7.21-7.59 (10H, m, 2 x Ph-H5); MS m/z 408.2166 
(M + H) (C25H30NO4 requires 408.2174), 350 (M -  C2H3NO), 91 (Bn). A solution of 
sodium methoxide (0.14 g, 2.6 mmol) in 2-methoxyethanol (5 ml) was added to a 
solution of guanidine hydrochloride (0.3 g, 2.6 mmol) in 2-methoxyethanol (5 ml) 
mixed and stirred for 5 min at 30 °C and sodium chloride was removed. The
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alcoholic guanidine solution was boiled under reflux with compound (82) (0.7 g, 1.8 
mmol) overnight. The cooled concentrated solution was purified by chromatography 
(chloroform/methanol, 9.5:0.5) to afford (100) (0.4 g, 46%); R/ =  0.45 as a 
hygroscopic pale yellow solid; IR Vmax 3415 (NH2), 1685 (C=N) cm'1; NMR 8h 1.23 
(3H, s, Me), 1.24 (3H, s, Me), 1.61-1.67 (2H, m, Ctf2CHO), 2.20-2.27 (1H, m, 
CHCR2\  2.48-2.55 (1H, m, C//CH2), 3.4 (2H, d, J  = 6.0 Hz, CH2OBn), 3.95-4.00 
(1H, m, 4-H), 4.15 (1H, q, J =  6.0 Hz, 5-H), 4.44 (1H, d, J =  12.3 Hz, CHPh), 4.53 
(1H, d, 12.3 Hz, CHPh), 4.68 (2H, br, NH2), 5.01 (2H, br, NH2), 7.09-7.39 (10H, 
m, 2 x Ph-H5); MS m/z 435.2423 (M + H) (C2 5H3 iN4 0 3  requires 435.2396), 200 (M 
- C 14H180 3),91 (Bii).
(4R,5S)-5-Benzyloxymethyl-4-(4-(4-chlorophenyl)-4-cyano-3-methoxybut-3- 
enyI)-2,2-dimethyI-l,3-dioxoIane (83) and 2,4-diamino-6-(2-((4R,55)-5- 
benzyloxymethyl-2,2-dimethyl-l,3-dioxoIan-4yl)ethyl)-5-(4- 





A solution of compound (62) (2.2 g, 5.2 mmol) in THF (5 ml) was methylated with 
diazomethane in the same method described above to afford (83) (2.2 g, 97%) as a 
pale yellow oil; NMR 8H 1.36 (3H, s, Me), 1.45 (3H, s, Me), 1.72-1.79 (1H, m, 
CtfCHO), 1.81-1.88 (1H, m, Ci/CHO), 2.76-2.85 (1H, m, Ci/CH2), 2.90-2.97 (1H, 
m, CtfCH2), 3.51 (1H, dd, J =  11.7, 6.0 Hz, CHOBn), 3.53 (1H, dd, J=  11.7, 6.0 Hz, 
CHOBn), 3.80 (3H, s, OCH3), 4.22 (1H, ddd, 9.4, 6.0, 3.1 Hz, 4-H), 4.33 (1H, q, 
J =  6.0 Hz, 5-H), 4.50 (1H, d, J =  12.1 Hz, CHPh), 4.59 (1H, d, / =  12.1 Hz, CHPh), 
7.28 (2H, d, 8.6 Hz, Ph 3,5-H2), 7.30-7.36 (5H, m, Ph-H5), 7.52 (2H, d, J =  8.6 
Hz, Ph 2,6-H2); MS m/z 444.1746 (M + H) (CzsHj^’C i m ,  requires 444.1755),
144
5. ‘EXPEIUMENnM
442.1764 (M + H) (C25H2935CIN04 requires 442.1785), 428/426 (M - CH3), 386/384 
(M -  C2H3NO), 391 (M -  CH3CI), 91 (Bn). A solution of sodium methoxide (0.40 g, 
8  mmol) in 2-methoxyethanol (5 ml) was added to a solution of guanidine 
hydrochloride (0.80 g, 8  mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 5 
min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (83) (2.3 g, 5.2 mmol) for 2 h. The cooled 
concentrated solution was purified by chromatography (chloroform/methanol, 9:1) to 
afford (101) (0.60 g, 25%); R /=  0.63 as a buff solid: mp 55-56 °C; NMR 8 h 1.28 
(6 H, s, CMe2), 1.62-1.71 (2H, m, CH2CHO), 2.25 (1H, ddd, J  = 13.5, 10.1, 5.9 Hz, 
CtfCH2), 2.51 (1H, ddd, J  — 13.5, 10.1, 5.9 Hz, C//CH2), 3.43 (2H, d, 5.9 Hz, 
CH2 OBn), 4.01 (1H, ddd, J =  10.1, 5.9, 4.3 Hz, 4-H), 4.21 (1H, q, J =  5.9 Hz, 5-H), 
4.47 (1H, d, J  = 12.1 Hz, CHPh), 4.56 (1H, d, J  = 12.1 Hz, CHPh), 4.82 (2H, br, 
NH2), 5.23 (2H, br, NH2), 7.14 (1H, d, 7 =  8.2 Hz, Ph 3-H), 7.15 (1H, d, / =  8.2 Hz, 
Ph 5-H), 7.27-7.37 (5H, m, Ph-H5), 7.39 (2H, d, J  = 8.2 Hz, Ph 2,6-H2); MS m/z 
471.1992 (M + H) (C25H3037ClN4O3 requires 471.1976), 469.2005 (M + H) 
(C2 5H3o3 5C1N4 0 4  requires 469.2006), 236/234 (M -  Ci4Hi80 3), 91 (Bn).
(4R,55)-5-BenzyIoxymethyl-4-(4-(4-bromophenyl)-4-cyano-3-methoxybut-3- 
enyl)-2,2-dimethyl-l,3-dioxolane (84) and 2,4-diamino-6-(2-((4R,55}-5- 
benzyloxymethyl-2,2-dimethyl-1^3-dioxolan-4yl)-ethyl)-5-(4- 




A solution of compound (63) (1.5 g, 3 mmol) in THF (5 ml) was methylated with 
diazomethane in the same method described above to afford (84) (1.5 g, 99%) as a 
pale yellow oil; NMR 8H 1.36 (3H, s, Me), 1.45 (3H, s, Me), 1.75-1.88 (2H, m, 
CH2CHO), 2.74-2.86 (1H, m, CHCH2), 2.89-2.97 (1H, m, CHCH2), 3.51 (1H, dd, J  =
11.7, 5.9 Hz, CHOBn), 3.53 (1H, dd, J =  11.7, 5.9 Hz, CHOBn), 3.80 (3H, s, OCH3), 
4.21 (1H, ddd, J  = 9.4, 5.9, 3.1 Hz, 4-H), 4.32 (1H, q ,J  = 5.9 Hz, 5-H), 4.50 (1H, d, 
J =  11.9 Hz, CHPh), 4.59 (1H, d, /  = 11.9 Hz, CHPh), 7.27-7.32 (5H, m, Ph-H5),
7.43 (2H, d, J  = 8.6 Hz, Ph 3,5-H2), 7.47 (2H, d, J  = 9.0 Hz, Ph 2,6-H2); MS m/z 
488.1255 (M + H) (C25H2981BrN04 requires 488.1259), 486.1263 (M + H) 
(C25H2979BrN04 requires 486.1279), 430/428 (M - C2H3NO), 391 (M -  CHjBr), 91 
(Bn). A solution of sodium methoxide (0.25 g, 4.6 mmol) in 2-methoxyethanol (5 
ml) was added to a solution of guanidine hydrochloride (0.44 g, 4.6 mmol) in 2- 
methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and sodium chloride was 
removed. The alcoholic guanidine solution was boiled under reflux with compound 
(84) (1.5 g, 3 mmol) for 4 h. The cooled concentrated solution was purified by 
chromatography (chloroform/methanol, 9.5:0.5) to afford (102) (0.90 g, 57%); R/ = 
0.34 as a buff solid: mp 62-64 °C; IR Vmax 3462 (NH2), 1635 (C=N) cm'1; NMR 5h
1.26 (6H, s, CMe2), 1.58-1.63 (2H, m, CH2CHO), 2.22 (1H, ddd, J=  13.3, 10.1, 5.9 
Hz, CHCH2), 2.49 (1H, ddd, J  = 13.3, 10.1, 5.9 Hz, C//CH2), 3.41 (2H, d, J =  5.9 
Hz, CH2OBn), 4.00 (1H, ddd, J  = 9.8, 5.9, 3.5 Hz, 4-H), 4.20 (1H, q, J =  5.9 Hz, 5- 
H), 4.45 (1H, d ,J =  12.1 Hz, CHPh), 4.54 (1H, d, / =  12.1 Hz, CHPh), 4.65 (2H, br, 
NH2), 5.06 (2H, br, NH2), 7.04 (1H, d, J =  7.8 Hz, Ph 3-H), 7.06 (1H, d, J = 8.2 Hz, 
Ph 5-H), 7.23-7.33 (5H, m, Ph-H5), 7.50 (2H, d, J  = 8.2 Hz, Ph 2,6-H2); MS m/z 
515.1483 (M + H) (C25H3 081BrN4O3 requires 515.1480), 513.1497 (M + H) 
(C25H3o7 9BrN4 0 3  requires 513.1501), 499/497 (M -  CH3), 280/278 (M -  Ci4Hi80 3), 
91 (Bn).
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(41f,5S)-5-Benzyloxymethyl-4-(4-(3,4-dichlorophenyl)-4-cyano-3-methoxybut-3- 







A solution of compound (64) (1.5 g, 3.2 mmol) in THF (5 ml) was methylated with 
diazomethane in the same method described above to afford (85) (1.5 g, 97%) as a 
pale yellow oil; NMR §h 1.36 (3H, s, Me), 1.45 (3H, s, Me), 1.73-1.80 (1H, m, 
CtfCHO), 1.82-1.88 (1H, m, CtfCHO), 2.76-2.85 (1H, m, CtfCH2), 2.90-2.98 (1H, 
m, CtfCH2), 3.51 (1H, dd, 7 =  11.3, 6.0 Hz, CHOBn), 3.53 (1H, dd, J =  11.3, 6.0 Hz, 
CHOBn), 3.84 (3H, s, OCH3), 4.21 (1H, ddd, J=  9.4, 6.0, 3.1 Hz, 4-H), 4.32 (1H, q, 
J = 6.0 Hz, 5-H), 4.49 (1H, d, J = 12.1 Hz, CHPh), 4.58 (1H, d, J =  12.1 Hz, CHPh),
7.26-7.32 (5H, m, Ph-H5), 7.37 (1H, d, J=  8 . 6  Hz, Ph 5-H), 7.42 (1H, dd ,J=  8 .6 ,2.1 
Hz,‘ Ph 6 -H), 7.73 (1H, d, J  = 2.1 Hz, Ph 2-H); MS m/z 480.1319 (M + H) 
(C25H2 8 3 7C12N 0 4  requires 480.1336), 478.1344 (M + H) (C25H2837C1 3 5C1N04  
requires 478.1365), 476.1367 (M + H) (C25H2835C12N 04 requires 476.1395), 
422/420/418 (M - C2H3NO), 391 (M -  CH2CI2 ), 91 (Bn). A solution of sodium 
methoxide (0.12 g, 2.2 mmol) in 2-methoxyethanol (5 ml) was added to a solution of 
guanidine hydrochloride (0.21 g, 2.2 mmol) in 2-methoxyethanol (5 ml) mixed and 
stirred for 5 min at 30 °C and sodium chloride was removed. The alcoholic guanidine 
solution was boiled under reflux with compound (85) (0.7 g, 1.5 mmol) for 4 h. The 
cooled concentrated solution was purified by chromatography (chloroform/methanol, 
19:1) to afford (103) (0.40 g, 47%); R /=  0.24 as a buff solid: mp 67-69 °C; IR vmax 
3411 (NH2), 1637 (C=N) cm'1; NMR 8 h 1.27 (6 H, s, CMe2), 1.54-1.65 (1H, m,
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CHCHO), 1.68-1.78 (1H, m, CtfCHO), 2.18-2.32 (1H, m, CHCH2), 2.42-2.52 (1H, 
m, CtfCH2), 3.44 (2H, d, J =  6.0 Hz, CH2OBn), 3.99 (1H, ddd, J =  9.8, 6.0, 3.5 Hz,
4-H), 4.20 (1H, q, / =  6.0 Hz, 5-H), 4.47 (1H, d, 12.3 Hz, CHPh), 4.56 (1H, d, J  
= 12.3 Hz, CHPh), 4.85 (2H, br, NH2), 5.21 (2H, br, NH2), 7.03 (5H, dd, /  = 8.0, 2.0 
Hz, Ph 6 -H), 7.26-7.32 (5H, m, Ph-H5), 7.35 (1H, d, J =  2.0 Hz, Ph 2-H), 7.46 (1H, 
d, J  = 8.0 Hz, Ph 5-H); MS m/z 507.1563 (M + H) (C2 5H2 9 3 7C12N4 0 3  requires 
507.1557), 505.1586 (M + H) (C2 5H2 9 3 7C13 5C1N4 0 3 requires 505.1587), 503.1617 
(M + H) (C2 5H2 9 3 5C12N4 0 3  requires 503.1616), 272/270/268 (M -  Ci^igCh), 91 
(Bn).
(4<S',55)-5-Benzyloxymethyl-4-(4-cyano-3-methoxy-4-phenylbut-3-enyl)-2,2- 









A solution of compound (65) (1.22 g, 3.1 mmol) in diethyl ether (5 ml) was treated 
with a solution of diazomethane (-0.2 g, 6  mmol) prepared from N-methyl-N- 
nitroso-p-toluenesulfonamide and KOH (using Minidiazald apparatus) in diethyl 
ether (20 ml) and the mixture was kept overnight at 10 °C. The excess of 
diazomethane was destroyed by dropwise addition of acetic acid (30% in THF), and 
the solvent was evaporated off to afford (8 6 ) (1.0 g, 79%) as a pale yellow oil; IR 
v„jax 2208 (CN), 1605 (C=C) cm-1; NMR 6 H 1.45 (3H, s, Me), 1.49 (3H, s, Me), 1.79-
1.87 (1H, m, CtfCHO), 1.94-2.02 (1H, m, CtfCHO), 2.40-2.59 (2H, m, CH2CH2),
3.55-3.60 (2H, m, 4,5-H2), 3.75 (3H, s, OCH3), 3.81-3.85 (2H, m, CH2 OBn), 4.55 
(1H, d, / =  12.7 Hz, CHPh), 4.58 (1H, d, / =  12.7 Hz, CHPh), 7.14-7.45 (10H, m, 2 x 
Ph-H5); MS m/z 408.2184 (M + H) (C25H30NO4  requires 408.2174), 391 (M - CHLj),
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380 (M -  CHN), 91 (Bn). A solution of sodium methoxide (0.20 g, 3.7 mmol) in 2- 
methoxyethanol (5 ml) was added to a solution of guanidine hydrochloride (0.35 g,
3.7 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and 
sodium chloride was removed. The alcoholic guanidine solution was boiled under 
reflux with compound (8 6 ) (1.0 g, 2.5 mmol) for 4 h. The cooled concentrated 
solution was purified by chromatography (chloroform/methanol, 9:1) to afford (104) 
(0.70 g, 67%); R /=  0.5 as a hygroscopic pale yellow solid; IR Vmax 3454 (NH2), 1664 
(O N ) cm'1; NMR 8 H 1.26 (3H, s, Me), 1.29 (3H, s, Me), 1.71-1.91 (2H, m, 
C//2 CHO), 2.33 ( 1 H, ddd, 7  = 13.5, 10.3, 5.8 Hz, CHCU2), 2.45 ( 1 H, ddd, 7 =  13.5,
10.5, 5.7 Hz, CtfCH2), 3.44 (2H, d, 7 =  4.6 Hz, CH2 OBn), 3.67 (1H, dt, 7  = 7.9, 4.6 
Hz, 4-H), 3.75 (1H, q, 7 =  4.6 Hz, 5-H), 4.28 (1H, d, 7  = 12.1 Hz, CHPh), 4.54 (1H, 
d, 7 =  12.1 Hz, CHPh), 4.64 (2H, br, NH2), 5.14 (2H, br, NH2), 7.19-7.43 (10H, m, 2 
x Ph-Hs); MS m/z 435.2398 (M + H) (C25H3 iN4 0 3  requires 435.2396), 327 (M -  
C7H7 O), 91 (Bn).
(4*S',55)-5-Benzyloxymethyl-4-(4-(4-chlorophenyl)-4-cyano-3-methoxybut-3- 







A solution of compound (6 6 ) (0.22 g, 0.5 mmol) in THF (5 ml) was methylated with 
diazomethane by the same method described above to afford (87) (0.20 g, 91%) as a 
pale yellow oil; NMR 5h 1.39 (3H, s, Me), 1.41 (3H, s, Me), 1.62-1.75 (2H, m, 
Ctf2 CHO), 2.86-2.96 (2H, m, Ctf2CH2), 3.52-3.65 (2H, m, 4,5-H2), 3.81 (3H, s,
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OCH3), 3.84-3.93 (2H, m, CH2 OBn), 4.54 (1H, d, J =  11.1 Hz, CHPh), 4.58 (1H, d, J  
= 11.1 Hz, CHPh), 7.24-7.38 (9H, m, Ph-H5 + PI1-H4 ). A solution of sodium 
methoxide (24 mg, 0.5 mmol) in 2-methoxyethanol (5 ml) was added to a solution of 
guanidine hydrochloride (43 mg, 0.5 mmol) in 2-methoxyethanol (5 ml) mixed and 
stirred for 5 min at 30 °C and sodium chloride was removed. The alcoholic guanidine 
solution was boiled under reflux with compound (51) (0.20 g, 0.5 mmol) for 4 h. The 
cooled concentrated solution was purified by chromatography 
(dichloromethane/methanol, 8:2) to afford (105) (0.10 g, 48%); R/ = 0.87 as a 
hygroscopic pale yellow solid; IR Vmax 3475, 3414 (NH2), 1618 (C=N) cm'1; NMR 8 h 
1.28 (3H, s, Me), 1.31 (3H, s, Me), 1.68-1.77 (1H, m, CtfCHO), 1.80-1.86 (1H, m, 
CtfCHO), 2.30 (1H, ddd, J  = 13.5, 10.5, 5.7 Hz, CHCH2), 2.45 (1H, ddd, / =  13.5,
10.5, 5.7 Hz, CtfCH2), 3.41-3.49 (2H, m, CH2 OBn), 3.3.66 (1H, dt, J  = 8.2, 3.5 Hz,
4-H), 3.51 (1H, m, 5-H), 4.50 (1H, d, J =  12.1 Hz, CHPh), 4.54 (1H, d, J =  12.1 Hz, 
CHPh), 4.69 (2H, br, NH2), 5.11 (2H, br, NH2), 7.10-7.35 (9H, m, Ph-H5 + PI1-H4 ); 
MS m/z 471.1979 (M + H) (C25H3 037ClN4O3 requires 471.1976), 469.1999 (M + H) 
(C25H3o3 5C1N4 0 3  requires 469.2006), 363/361 (M -  C7H7O), 91 (Bn).
(4S,55)-5-BenzyIoxyniethyl-4-(4-(4-bromophenyI)-4-cyano-3-methoxybut-3- 









A solution of compound (67) (1.7 g, 3.6 mmol) in diethyl ether (5 ml) was 
methylated with diazomethane in the same method described above to afford (8 8 )
3.81 (3H, s, OCH3), 3.84-3.94 (2H, m, CH2OBn), 4.54 (1H, d, J  = 12.1 Hz, CHPh),
4.59 (1H, d, J  = 12.1 Hz, CHPh), 7.22-7.42 (9H, m, Ph-H5 + PI1-H4); MS m/z 
488.1255 (M + H) (C25H2 9 8 1BrNC>4 requires 488.1259), 486.1258 (M + H) 
(C2 sH2 97 9BrN0 4  requires 486.1279), 391 (M -  CtfeBr), 91 (Bn). A solution of 
sodium methoxide (0.27 g, 5 mmol) in 2-methoxyethanol (5 ml) was added to a 
solution of guanidine hydrochloride (0.50 g, 5 mmol) in 2-methoxyethanol (5 ml) 
mixed and stirred for 5 min at 30 °C and sodium chloride was removed. The 
alcoholic guanidine solution was boiled under reflux with compound (8 8 ) (1.6 g, 3.3 
mmol) for 4 h. The cooled concentrated solution was purified by chromatography 
(chloroform/methanol, 9:1) to afford (106) (0.90 g, 53%); R/= 0.52 as a hygroscopic 
buff solid; NMR 5h 1.31 (3H, s, Me), 1.34 (3H, s, Me), 1.71-1.80 (1H, m, CtfCHO), 
1.83-1.92 (1H, m, CHCRO), 2.33 (1H, ddd, J =  13.7, 10.5, 5.9 Hz, CHCH2), 2.48 
(1H, ddd, J =  13.7,10.5, 5.9 Hz, CHCH2), 3.45-3.53 (2H, m, CH2 OBn), 3.70 (1H, dt, 
J =  7.8, 3.5 Hz, 4-H), 3.75-3.80 (1H, m, 5-H), 4.51 (1H, d, J =  12.1 Hz, CHPh), 4.57 
(1H, d, J =  12.1 Hz, CHPh), 4.76 (2H, br, NH2), 5.18 (2H, br, NH2), 7.09 (2H, d, J=
8 . 6  Hz, Ph 3,5-H2), 7.28-7.38 (5H, m, Ph-H5), 7.54 (2H, d, / =  8 . 6  Hz, Ph 2,6-H2); 
MS m/z 515.1488 (M + H) (C2 5H3o8 lBrN4 0 3  requires 515.1480), 513.1500 (M + H) 
(C2 5H3o79BrN4 0 4  requires 513.1501), 487/485 (M -  C2H5), 407/405 (M - C7H7O), 91 
(Bn).
l-Cyano-7-hydroxy-2-methoxy-l-pheny!hept-l-ene (89) and 2,4-diamino-6-(5- 
hydroxypentyl)-5-phenylpyrimidine (107)
(1.6 g, 93%) as a pale yellow oil; NMR 6 H 1.39 (3H, s, Me), 1.41 (3H, s, Me), 1.78- 




A solution of compound (6 8 ) (0.70 g, 3 mmol) was methylated with diazomethane in 
the same method described before. The resulting yellow oil was purified by 
chromatography (ethyl acetate/hexane, 2:1) to afford (89) (0.60 g, 78%); R/= 0.58 as 
a pale yellow oil; IR v^x 3439 (OH), 2204 (CN); MS m/z 246.1492 (M + H) 
(C15H2 0NO2 requires 246.1494), 228 (M -  CHN), 214 (M -  CH30), 185 (M -  
C2H6 NO). A solution of sodium methoxide (0.10 g, 2 mmol) in 2-methoxyethanol (5 
ml) was added to a solution of guanidine hydrochloride (0 . 2 0  g, 2  mmol) in 2 - 
methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and sodium chloride was 
removed. The alcoholic guanidine solution was boiled under reflux with compound 
(89) (0.50 g, 2 mmol) overnight. The cooled concentrated solution was purified by 
chromatography (dichloromethane/ methanol, 8:2) to afford (107) (0.20 g, 36%); R/ 
= 0.50 as a white solid: mp 214-216 °C; IR 3420, 3331 (NH2), 3177 (OH), 1619
(1H, t, J  = 1 2  Hz, Ph 4-H), 7.44 (2H, t, J  = 7.2 Hz, Ph 2,6-H2); NMR (CD3OD) 6 C 
25.38 (CH2), 28.49 (CH2), 31.81 (CH2), 33.79 (CH2), 61.33 (5-CH2), 108.29 (Pyr 5- 
C), 127.67 (Ph CH), 128.95 (2 x Ph CH), 130.51 (2 x Ph CH), 134.76 (Ph 1-C), 
161.32 (Pyr 2-C), 162.98 (Pyr 4-C), 165.09 (Pyr 6 -C); MS m/z 273.1704 (M + H) 
(C15H20N4 O requires 273.1715), 213 (M -  C3H7 O), 200 (M -  C ^ O ) .
l-(4-Chlorophenyl)-l-cyano-7-hydroxy-2-methoxyhept-l-ene (90) and 2,4- 
diammo-5-(4-chlorophenyl)-6-(5-hydroxypentyl)pyrimidine (108)
A solution of compound (69) (0.20 g, 0.8 mmol) was methylated with diazomethane 
in the same method described before. The resulting yellow oil was purified by 
chromatography (ethyl acetate/hexane, 3:1) to afford (90) (0.13 g, 62%); R/ = 0.29
(C=N) cm'1; NMR SH 1.27 (2H, qn, 7 =  7.2 Hz, 3-H2), 1.45 (2H, m, 4-H2), 1.55 (2H, 
qn, 7  = 7.2 Hz, 2-H2), 2.28 (2H, t, 7 = 7 .2  Hz, 1-H2), 3.56 (2H, t, 7  = 6.4 Hz, 5-H2),




as a pale yellow oil; NMR 8 h 1.52-1.80 (6 H, m, 4,5,6-Hs), 2.77 (2H, 19J=  7.8 Hz, 3- 
H2), 3.68 (2H, t, J  = 6.2 Hz, 7-H2), 3.85 (3H, s, OCH3), 7.29 (2H, d, J  = 8 . 6  Hz, Ph
3,5-H2), 7.54 (2H, d, J  = 8 . 6  Hz, Ph 2,6-H2); MS m/z 282.1077 (M + H) 
(Ci5Hi9 3 7CIN0 2  requires 280.1074), 280.1102 (M + H) (Ci5H 1935ClN0 2  requires 
280.1104), 264/262 (M -  CH3), 221/219 (M -  QjIWSrO). A solution of sodium 
methoxide (27 mg, 0.5 mmol) in 2-methoxyethanol (5 ml) was added to a solution of 
guanidine hydrochloride (47 mg, 0.5 mmol) in 2-methoxyethanol (5 ml) mixed and 
stirred for 5 min at 30 °C and sodium chloride was removed. The alcoholic guanidine 
solution was boiled under reflux with compound (90) (0.14 g, 0.5 mmol) overnight. 
The cooled concentrated solution was purified by chromatography 
(dichloromethane/methanol, 8:2) to afford (108) (90 mg, 59%); R /=  0.37 as a white 
solid: mp 165-166 °C; IR v™* 3407, 3329 (NH2), 3174 (OH), 1631 (C=N) cm'1; 
NMR ((CD3)2 SO) 8 h 1.11 (2H, qn, J =  7 A  Hz, 3-H2), 1.26 (2H, qn, J=  7.4 Hz, 4-H2),
1.42 (2H, qn, J  = 7.4 Hz, 2-H2), 2.07 (2H, t, /  = 7.4 Hz, 1-H2), 3.29 (2H, t, J  = 1A 
Hz, 5-H2), 4.29 (1H, br, OH), 5.64 (2H, br, NH2), 5.94 (2H, br, NH2) 7.18 (2H, d, J=
8.2 Hz, Ph 3,5-H2), 7.47 (2H, d, J =  8.2 Hz, Ph 2,6-H2); NMR ((CD3)2 SO) 6 C 25.88 
(3-CH2), 28.58 (2-CH2), 32.69 (4-CH2), 34.63 (1-CH2), 61.00 (5-CH2), 106.16 (Pyr 
5-C), 129.34 (Ph 3,5-C), 132.25 (Ph 2,6-C), 134.76 (Ph 1-C), 135.47 (Ph 4-C), 
162.44 (Pyr 2-C), 162.47 (Pyr 4-C), 165.87 (Pyr 6 -C); MS m/z 309.1310 (M + H) 
(Ci5H2 0 3 7ClN4 O2  requires 309.1296), 307.1335 (M + H) (Ci5H2 0 3 5ClN4 O2 requires 
307.1325), 236/234 (M - C ^ O ) .
l-(4-Bromophenyl)-l-cyano-7-hydroxy-2-methoxyhept-l-ene (91) and 2,4- 




A solution of compound (70) (0.30 g, 1 mmol) was methylated with diazomethane in 
the same method described before. The resulting yellow oil was purified by
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chromatography (ethyl acetate/hexane, 3:1) to afford (91) (0.10 g, 32%); R /=  0.29 as 
a pale yellow oil; NMR 8 h 1.53-1.75 (6 H, m, 4,5,6-Hg), 2.76 (2H, t, J  = 7.0 Hz, 3- 
H2), 3.69 (2H, t, J  = 7.0 Hz, 7-H2), 3.85 (3H, s, OCH3), 7.44 (2H, d, J =  8 . 8  Hz, Ph
3,5-H2), 7.48 (2H, d, J  = 8 . 8  Hz, Ph 2,6-H2); MS m/z 326.0583 (M + H) 
(Ci5H,9 81BrN0 2  requires 326.0578), 324.0596 (M + H) (Ci5H 1979BrN 0 2 requires 
324.0599), 293 (M - CH2 0), 259 (M - CH3Br). A solution of sodium methoxide (32 
mg, 0.6 mmol) in 2-methoxyethanol (5 ml) was added to a solution of guanidine 
hydrochloride (57 mg, 0.6 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 5 
min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (91) (0.2 g, 0.6 mmol) overnight. The cooled 
concentrated solution was purified by chromatography (dichloromethane/methanol, 
8:2) to afford (109) (90 mg, 43%); R /=  0.52 as a white solid: mp 177-178 °C; IR v^x 
3550 (OH), 3468, 3414 (NH2), 1617 (C=N) cm'1; NMR ((CD3 )2 SO) 6 H 1.11 (2H, qn, 
J =  7.4 Hz, 3-H2), 1.25 (2H, m, 4-H2), 1.42 (2H, qn, J =  7.4 Hz, 2-H2), 2.07 (2H, t, J  
= 7.4 Hz, 1-H2), 3.27 (2H, t, J  = 6.4 Hz, 5-H2), 4.30 (1H, br, OH), 5.74 (2H, br, 
NH2), 6.00 (2H, br, NH2), 7.11 (2H, d, J  = 8.4 Hz, Ph 2,6-H2), 7.57 (2H, d, J =  8.4 
Hz, Ph 3,5-H2); NMR (TFA salt) ((CD3 )2 SO) 5C 25.33 (CH2), 27.72 (CH2), 30.33 
(CH2), 32.21 (CH2), 60.68 (5-C), 108.00 (Pyr 5-C), 115.78 (CF3, q, J  = 289 Hz)
122.75 (Ph 4-C), 130.74 (Ph 1-C), 132.74 (2 x Ph CH), 133.24 (2 x Ph CH), 153.43 
(Pyr 2-C), 155.31 (Pyr 4-C), 158 (CF3 CO, q, J =  38 Hz), 164.30 (Pyr 6 -C); MS m/z 
353.0807 (M + H) (Ci5H2 0 8 1BrN4O requires 353.0800), 351.0816 (M + H) 
(Ci5H2 0 7 9BrN4O requires 351.0820).
l-(3,4-Dichlorophenyl)-l-cyano-7-hydroxy-2-methoxyhept-l-ene (92) and 2,4- 
diamino-5-(3,4-dichlorophenyl)-6-(5-hy droxy pentyl)py rimidine (110)
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A solution of compound (71) (3.0 g, 10 mmol) was methylated with diazomethane in 
the same method described before. The resulting yellow oil was purified by 
chromatography (ethyl acetate/hexane, 3:1) to afford (92) (2.2 g, 68%); R /=  0.42 as a 
pale yellow oil; NMR 8h 1.41-1.50 (4H, m, 5,6-110, 1-62 (2H, qn, J =  7.6 Hz, 4-H2),
2.75 (2H, t, J  = 7.6 Hz, 3-H2), 3.41 (2H, X,J=  6.0 Hz, 7-H2), 3.95 (3H, s, OCH3), 
7.50 (1H, dd, / =  8.6, 2.0 Hz, Ph 6-H), 7.63 (1H, d, J =  8.6 Hz, Ph 5-H), 7.75 (1H, d, 
J = 2.0 Hz, Ph 2-H); MS m/z 318.0686 (M + H) (Ci5Hi837Cl2N 0 2 requires 318.0655), 
316.0689 (M + H) (CisHi837C135C1N02 requires 316.0685), 314.0715 (M + H) 
(Ci5Hi835C12N 02 requires 314.0714), 291/289/287 (M -  CN), 229 (M - CH2C12). A 
solution of sodium methoxide (0.30 g, 6 mmol) in 2-methoxyethanol (10 ml) was 
added to a solution of guanidine hydrochloride (0.60 g, 6 mmol) in 2- 
methoxyethanol (10 ml) mixed and stirred for 5 min at 30 °C and sodium chloride 
was removed. The alcoholic guanidine solution was boiled under reflux with 
compound (92) (2.0 g, 6 mmol) overnight. The cooled concentrated solution was 
purified by chromatography (dichloromethane/methanol, 8:2) to afford (110) (0.90 g, 
43%); R /=  0.84 as a white solid: mp 94-95 °C; IR v™* 3499 (OH), 3419, 3333 
(NH2), 1622 (O N ) cm’1; NMR ((CD3)2SO) 6H 1.12 (2H, qn, / =  7.4 Hz, 3-H2), 1.25 
(2H, m, 4-H2), 1.42 (2H, qn, /  = 7.4 Hz, 2-H2), 2.07 (2H, t, J  = 7.4 Hz, 1-H2), 3.27 
(2H, q , J =  5.6 Hz, 5-H2), 4.28 (1H, t, J =  5.6 Hz, OH), 5.72 (2H, br, NH2), 5.90 (2H, 
br, NH2), 7.11 (1H, dd, J =  8.2, 2.2 Hz, Ph 6-H), 7.36 (1H, d, J  = 2.2 Hz, Ph 2-H), 
7.62 (1H, d, J =  8.2 Hz, Ph 5-H); NMR ((CD3)2SO) 5C 25.87 (CH2), 28.50 (CH2), 
32.70 (CH2), 34.64 (CH2), 61.02 (5-CH2), 105.23 (Pyr 5-C), 130.21 (Ph C), 131.37 
(Ph CH), 131.74 (Ph C), 131.81 (Ph CH), 133.19 (Ph CH), 137.66 (Ph C), 162.36 
(Pyr 2-C), 162.69 (Pyr 4-C), 165.96 (Pyr 6-C); MS m/z 345.0885 (M + H) 
(Ci5H1937Cl2N40  requires 345.0876), 343.0901 (M + H) (Ci5Hi937C135C1N40  requires 
343.0906), 341.0927 (M + H) (Ci5H1935Cl2N40  requires 341.0935), 285/283/281 (M 
- C3H70), 272/270/268 (M -  GjHgO).
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(4R,5R)-4-(2-Cyano-l-methoxy-2-phenylethenyl)-5-hydroxymethyl-2,2- 





A solution of compound (72) (0.25 g, 0.9 mmol) in THF (5 ml) was methylated with 
diazomethane by the same procedure described before to afford (93) (0.22 g, 85%) as 
a pale yellow oil; IR 3492 (OH), 2209 (CN) cm'1; NMR 8 h 1.44 (3H, s, Me), 
1.58 (3H, s, Me), 3.53 (3H, s, OCH3), 4.39 (1H, dd, J  = 11.0, 3.7 Hz, CtfOH), 4.45 
(1H, d ,J =  11.0 Hz, CHOH), 4.57-4.62 (1H, m, 5-H), 5.37 (1H, d, J =  7.4 Hz, 4-H), 
7.30-7.41 (5H, m, Ph-H5); MS m/z 290.1388 (M + H) (Ci6H2oN04  requires 
290.1392), 274 (M -  CH3), 258 (M - CH30). A solution of sodium methoxide (50 
mg, 0.9 mmol) in 2-methoxyethanol (5 ml) was added to a solution o f guanidine 
hydrochloride (80 mg, 0.9 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 5 
min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (93) (0.26 g, 0.9 mmol) overnight. The 
cooled concentrated solution was purified by chromatography 
(dichloromethane/methanol, 8:2) to afford (111) (0.10 g, 48%); R /=  0.39 as a pale 
yellow solid: mp 214-216 °C; IR v ^  3492, 3465, 3422, 3318 (NH2), 3178 (OH), 
1624 (C=N) cm'1; [a]20D = +3.3° (c 4, CHC13); NMR SH 1.21 (3H, s, Me), 1.62 (3H, 
s, Me), 3.48 (1H, dd, J  = 12.7, 2.1 Hz, CtfOH), 3.57 (1H, dd, J  = 12.7, 3.3 Hz, 
CtfOH), 3.97 (1H, m, 5-H), 4.79 (1H, d, J =  6 . 6  Hz, 4-H), 4.90 (2H, br, NH2), 5.16 
(2H, br, NH2), 7.10 (1H, d, J  = 7.4 Hz, Ph 6 -H), 7.31 (1H, d, J  = 7.4 Hz, Ph 2-H), 
7.41 (1H, t, J  = 7.4 Hz, Ph 4-H), 7.47 (2H, t, J  = 7.4 Hz, Ph 3,5-H2); MS m/z
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317.1622 (M + H) (Ci6H2 0N4 O3 requires 317.1613), 259 (M -  C3H5O), 215 (M -  
C4H5 O3 ).
(4R,5/?)-4-(2-(4-ChIorophenyI)-2-cyano-l-methoxyethenyl)-5-hydroxymethyI-





A solution of compound (73) (0.30 g, 0.9 mmol) in THF (5 ml) was methylated with 
diazomethane by the same procedure described before to afford (94) (0.20 g, 69%) as 
a pale yellow oil; MS m/z 326.0989 (M + H) (Ci6 Hi9 3 7ClN0 4  requires 326.0973), 
324.1014 (M + H) (Ci6H,93 5ClN0 4  requires 324.1002), 307/305 (M - H2 0 ), 265/263 
(M -  C3H8 O), 238/236 (M -  C4H9NO). A solution of sodium methoxide (46 mg, 0.86 
mmol) in 2-methoxyethanol (5 ml) was added to a solution of guanidine 
hydrochloride (82 mg, 0.86 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 
5 min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (94) (0.28 g, 0.86 mmol) overnight. The 
cooled concentrated solution was purified by chromatography 
(dichloromethane/methanol, 8:2) to afford (112) (0.15 g, 50%); R /=  0.92 as a buff 
solid: mp 172-174 °C; IR v^x 3497, 3459, 3433, 3396 (NH2), 3217 (OH), 1613 
(O N ) cm’1; NMR SH 1.24 (3H, s, Me), 1.63 (3H, s, Me), 1.66 (1H, br, OH), 3.47 
(1H, dd, J=  12.8, 2.3 Hz, CtfOH), 3.58 (1H, dd, J =  12.8, 3.3 Hz, CtfOH), 3.98 (1H, 
m, 5-H), 4.66 (2H, br, NH2), 4.77 (1H, d, J =  6.2 Hz, 4-H), 4.93 (2H, br, NH2), 7.05 
(1H, dd, 8 .8 , 2.0 Hz, Ph 3-H), 7.27 (1H, dd, J  = 9.4, 2.0 Hz, Ph 5-H), 7.43 (1H, 
dd, J  = 8 .8 , 2.0 Hz, Ph 2-H), 7.47 (1H, dd, J  = 9.4, 2.0 Hz, Ph 6 -H); MS m/z
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353.1218 (M + H) (C i6 H 2 o3 7 C lN 4 0 3  requires 353.1194), 351.1236 (M + H) 
(C,6 H2o3 5 C1N 4 0 3  requires 351.1223), 395/293 (M -  C 3H 5O ), 242 (M -  C 3H 5 O 2 C I).
(4/?,5i?)-4-(2-(4-Bromophenyl)-2-cyano-l-methoxyethenyI)-5-hydroxymethyl-





A solution of compound (74) (1.40 g, 3.9 mmol) in THF (5 ml) was methylated with 
diazomethane by the same procedure described before to afford (95) (1.30 g, 91%) as 
a pale yellow oil; NMR 8 H 1.44 (3H, s, Me), 1.48 (3H, s, Me), 3.57 (3H, s, OCH3),
4.40 (1H, dd, J =  10.9, 3.5 Hz, Ci/OH), 4.46 (1H, d, J =  10.9 Hz, CtfOH), 4.55-4.67 
(1H, m, 5-H), 5.34 (1H, d, J=  7.0 Hz, 4-H), 7.36 (2H, d, 8 . 6  Hz, Ph 3,5-H2), 7.50 
(2H, d, J  = 8 . 6  Hz, Ph 2,6-H2); MS m/z 370.0481 (M + H) (Ci6H198 lBrN0 4 requires 
370.0476), 368.0501 (M + H) (Ci6H19 7 5BrN0 4  requires 368.0497), 336 (M -  CH30), 
310 (M -  C2H3NO). A solution of sodium methoxide (0.30 g, 5.3 mmol) in 2- 
methoxyethanol ( 1 0  ml) was added to a solution of guanidine hydrochloride (0.51 g,
5.3 mmol) in 2-methoxyethanol (10 ml) mixed and stirred for 5 min at 30 °C and 
sodium chloride was removed. The alcoholic guanidine solution was boiled under 
reflux with compound (95) (1.30 g, 3.5 mmol) for 4 h. The cooled concentrated 
solution was purified by chromatography (chloroform/methanol, 8:2) to afford (113) 
(0.41 g, 29%); R /=  0.68 as a pale yellow solid: mp 181-183 °C; NMR ((CD3 )2 0 ) 5h
1.14 (3H, s, Me), 1.48 (3H, s, Me), 3.45 (2H, d, J = 3.5 Hz, Ctf2 OH), 4.03 (1H, dt, J  
= 6.4, 3.5 Hz, 5-H), 4.73 (1H, d, J =  6.4 Hz, 4-H), 5.70 (2H, br, NH2), 5.85 (2H, br, 
NH2), 7.20 (1H, dd, J =  8.1, 2.0 Hz, Ph 3-H), 7.25 (1H, dd, J =  7.7, 2.0 Hz, Ph 5-H),
158
5. <EX<FE%JMEN1M
7.61 (1H, dd, J =  7.7, 2.0 Hz, Ph 6 -H), 7.63 (1H, dd, J =  8.1, 2.0 Hz, Ph 2-H); NMR 
(CD3 )2 0 ) 6 c 25.44 (Me), 26.37 (Me), 62.49 (CH2 OH), 76.46 (CH), 79.81 (CH),
108.35 (CMe2), 108.72 (Pyr 5-C), 121.70 (Ph 4-C), 132.30 (Ph CH), 132.35 (Ph CH),
132.59 (Ph CH), 133.38 (Ph CH), 134.30 (Ph 1-C), 159.21 (Pyr 2-C), 162.29 (Pyr 4- 
C), 163.21 (Pyr 6 -C); MS m/z 397.0694 (M + H) (C16H2 o8 1BrN4 0 3  requires 
397.0698), 395.0712 (M + H) (Ci6H2o7 9BrN4 0 3 requires 395.0718), 339/337 (M -  
C3H5O).
(4R,5R)-4-(2-(3,4-Dichlorophenyl)-2-cyano-l-methoxyethenyl)-5- 






A solution of compound (75) (1.50 g, 4.3 mmol) in THF (5 ml) was methylated with 
diazomethane by the same procedure described before to afford (96) (1.20 g, 78%) as 
a pale yellow oil; IR v„,ax 3534 (OH), 2247 (CN), 1595 (C=C) cm'1; NMR 8h 1.44 
(3H, s, Me), 1.47 (3H, s, Me), 3.72 (3H, s, OCH3), 4.54 (1H, dd, J  = 10.7, 4.1 Hz, 
CHOU), 4.73 (1H, d , J =  10.7 Hz, C//OH), 4.96 (1H, m, 5-H), 5.52 (1H, d , / =  5.9 
Hz, 4-H), 7.15 (1H, d, J  = 8.5 Hz, Ph 5-H), 7.37 (1H, dd, J =  8.5, 1.4 Hz, Ph 6 -H),
7.40 (1H, d, J  = 1.4 Hz, Ph 2-H); MS m/z 360.0378 (M - H) (Ci6H]63 7Cl2N 0 4 
requires 360.0397), 358.0433 (M - H) (Ci6H,637Cl35ClN0 4 requires 358.0426), 
356.0452 (M - H) (Ci6Hi635Cl2N0 4 requires 356.0456), 346/344/342 (M -  CH3), 
330/328/326 (M -  CH30 ). A solution of sodium methoxide (0.15 g, 2.8 mmol) in 2- 
methoxyethanol (5 ml) was added to a solution of guanidine hydrochloride (0.27 g,
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2.8 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and 
sodium chloride was removed. The alcoholic guanidine solution was boiled under 
reflux with compound (96) (1.0 g, 2.8 mmol) overnight. The cooled concentrated 
solution was purified by chromatography (chloroform/methanol, 9:1) to afford (114) 
(0.50 g, 47%); R /=  0.42 as a pale yellow solid: mp 181-183 °C; NMR (CD3CN) 8 h 
1.20 (3H, s, Me), 1.49 (3H, s, Me), 3.40-3.42 (2H, m, Ctf2 OH), 4.00-4.05 (1H, m, 5- 
H), 4.72 (1H, d ,J=  7.0 Hz, 4-H), 5.21 (2H, br, NH2), 5.31 (2H, br, NH2), 7.11 (0.5H, 
dd, / =  8.2, 2.0 Hz, Ph 6 -H), 7.21 (0.5H, dd, J =  8.2, 2.0 Hz, Ph 6 -H), 7.38 (0.5H, d, 
J  = 2.0 Hz, Ph 2-H), 7.48 (0.5H, d, J = 2.0 Hz, Ph 2-H), 7.60 (0.5H, d, J = 8.2 Hz, Ph
5-H), 7.62 (0.5H, d, J  = 8.2 Hz, Ph 5-H); NMR (CD3 )2 CO) 8 C 24.90 (Me), 25.88 
(Me), 61.93 (CH2OH), 76.13 (CH), 79.16 (CH), 107.43 (CMe2), 108.75 (Pyr 5-C),
130.36 (Ph C), 131.07 (Ph CH), 131.18 (Ph C), 131.51 (Ph CH), 132.89 (Ph CH),
135.14 (Ph C), 159.37 (Pyr 2-C), 161.93 (Pyr 4-C), 162.93 (Pyr 6 -C); MS m/z 
389.0778 (M + H) requires 389.0775), 387.0810 (M + H)
(C,6Hi,3 7Cl3 5a N 4 0 3  requires 387.0833), 385.0833 (M + H) (C isH i^ C y siA  
requires 385.0834), 331/329/327 (M -C 3H5O).





Compound (76) (0.30 g, 2 mmol) in THF (5 ml) was methylated with diazomethane 
as described before. The resulting yellow oil was purified by chromatography (ethyl 
acetate/hexane, 2:1) to afford (97) (0.30 g, 87%) as a pale yellow oil; IR Vmax 2204 
(CN), 1606 (C=C) cm'1; NMR 5h2.45 (3H, s, CH3), 3.85 (3H, s, OCH3), 7.26 (1H, t, 
J  = 7.0 Hz, Ph 4-H), 7.30 (2H, t, J  = 7.0 Hz, Ph 3,5-H2), 7.61 (2H, t, J  = 7.0 Hz, Ph
2,6-H2); MS m/z 174.0921 (M + H) (CnHi2NO requires 174.0918), 115 (M -
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C2H4NO). A solution of sodium methoxide (0.10 g, 1.7 mmol) in 2-methoxyethanol 
(5 ml) was added to a solution of guanidine hydrochloride (0.16 g, 1.7 mmol) in 2- 
methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and sodium chloride was 
removed. The alcoholic guanidine solution was boiled under reflux with compound
(97) (0.30 g, 1.7 mmol) overnight. The cooled concentrated solution was purified by 
chromatography (dichloromethane/methanol, 8:2) to afford (115) (0.13 g, 38%); R /=  
0.42 as a pale yellow solid: mp 250-251 °C (lit. 1 3 2 mp 250-251 °C); IRVmax 3395, 
3323 (NH2) cm'1; NMR ((CD3)2 SO) 8 h 1.85 (3H, s, CH3), 5.62 (2H, br, NH2), 6.00
7.43 (2H, t, J  = 7.3 Hz, Ph 3,5-H2); MS m/z 201.1145 (M + H) (CnHi3N4 requires 
201.1140), 123 (M -CeHs), 109 ( M - C 7H7).
l-Cyano-2-methoxy-l,4-diphenylbut-l-ene (98) and 2,4-diamino-5-phenyl-6-(2- 
phenylethyl)pyrimidine (116)
Compound (77) (0.50 g, 2 mmol) in THF (5 ml) was methylated with diazomethane 
as described before to afford (98) (0.50 g, 95%) as a pale yellow oil; IR Vmax 2204 
(CN) cm'1; MS m/z 264.1390 (M + H) (Cl8H 18NO requires 264.1388), 236 (M -  
CHN), 204 (M -  C2HsNO), 91 (Bn). A solution of sodium methoxide (80 mg, 1.5 
mmol) in 2-methoxyethanol (5 ml) was added to a solution of guanidine 
hydrochloride (140 mg, 1.5 mmol) in 2-methoxyethanol (5 ml) mixed and stirred for 
5 min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (98) (0.40 g, 1.5 mmol) overnight. The 
cooled concentrated solution was purified by chromatography 
(dichloromethane/methanol, 8:1) to afford (116) (0.14 g, 32%), R /=  0.42 as a pale




yellow solid mp 116-118 °C; NMR 8h 2.54 (2H, t, J=  8.0 Hz, CH2), 2.83 (2H, t, J  =
8.0 Hz, CH2), 4.62 (2H, br, NH2), 4.99 (2H, br, NH2), 6.94 (2H, d, J =  6.8 Hz, Ph
2,6-H2), 7.05 (2H, d, J  = 6.5 Hz, Ph 2,6-H2), 7.14 (1H, t , J =  6.8 Hz, Ph 4-H), 7.17 
(2H, U  = 6 .8 H z, Ph 3,5-H2), 7.35 (2H, t , J =  6.5 Hz, Ph 4-H), 7.39 (2H, t, J =  6.5 
Hz, Ph 3,5-H2); MS m/z 291.1616 (M + H) (Ci8H19N4 requires 291.1609), 199 (M -  
C7H7).








Compound (78) (1.50 g, 7.2 mmol) in diethyl ether (5 ml) was methylated with 
diazomethane as described before to afford (99) (1.40 g, 88%) as a pale yellow oil; 
NMR 5h 1.32 (3H, t, J =  7.6 Hz, CH2Ctf3), 2.80 (2H, q, / =  7.6 Hz, Ctf2CH3), 3.88 
(3H, s, OCH3), 7.31 (2H, d, J  = 8.6 Hz,Ph 3,5-H2), 7.61 (2H, d, / =  8.6 Hz, Ph 2,6- 
H2). A solution of sodium methoxide (0.56 g, 10 mmol) in 2-methoxyethanol (5 ml) 
was added to a solution of guanidine hydrochloride (1.0 g, 10 mmol) in 2- 
methoxyethanol (5 ml) mixed and stirred for 5 min at 30 °C and sodium chloride was 
removed. The alcoholic guanidine solution was boiled under reflux with compound 
(99) (1.52 g, 6.9 mmol) for 4 h. The cooled concentrated solution was purified by 
chromatography (chloroform/methanol, 9:1) to afford (117) (0.86 g, 50%); R /=  0.42 
as a white solid: mp 233-235 °C (lit.110 mp 233-234 °C); NMR 5H0.97 (3H, t, J =  7.4 
Hz, CH3), 2.09 (2H, q, J  = 7.4 Hz, CH2), 5.64 (2H, br, NH2), 5.92 (2H, br, NH2),
7.22 (2H, d, J  = 8.2 Hz, Ph 3,5-H2), 7.49 (2H, d, J  = 8.2 Hz, Ph 2,6-H2); MS m/z
162
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251.0884 (M + H) (Ci2H,4 3 7C1N4  requires 251.0877), 249.0909 (M + H) 









The protected compound (100) (0.70 g, 1.6 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 70 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (118) (0.60 g, 95%) 
R /=  0.74 (chloroform/methanol, 2:1) as a very hygroscopic pale yellow solid; NMR 
(CD3OD) 8 h 1.62-1.76 (1H, m, 2-H), 1.83-1.93 (1H, m, 2-H), 2.38-2.48 (1H, m, 1- 
H), 2.60 (1H, ddd, J  = 15.3, 10.6, 5.5 Hz, 1-H), 3.43-3.47 (2H, m, 3,4-H2), 3.49-3.56 
(2H, m, 5-H2), 4.52 (1H, d, / =  12.6 Hz, CHPh), 4.56 (1H, d, J =  12.6 Hz, CHPh),
7.27-7.41 (6 H, m, 2 x Ph 2,4,6-H3), 7.47-7.58 (4H, m, 2 x Ph 3,5-H2); MS m/z 
395.2097 (M + H) (C2 2H27N40 3 requires 395.2083), 547 (M + 3-NOBA), 417 (M + 









The protected compound (101) (0.30 g, 0.7 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 30 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (119) (0.26 g, 87%) 
R/= 0.8 (chloroform/methanol, 2:1) as a white solid mp 131-133 °C; NMR (CD3OD) 
5 h  1.59-1.68 (1H, m, 2-H), 1.78-1.87 (1H, m, 2-H), 2.33-2.40 (1H, m, 1-H), 2.47- 
2.54 (1H, m, 1-H), 3.49-3.55 (2H, m, 3,4-H2), 3.57-3.64 (2H, m, 5-H2), 4.52 (1H, d, J  
= 12.5 Hz, CHPh), 4.56 (1H, d, J =  12.5 Hz, CHPh), 7.24 (2H, d, J =  8 . 6  Hz, Ph 3,5- 
H2), 7.33-7.37 (5H, m, Ph-H5), 7.47 (2H, d, J =  8 . 6  Hz, Ph 2,6-H2); NMR (CD3OD) 
6 C 29.02 (CH2), 30.84 (CH2), 71.03 (5-CH2), 71.61 (CH), 72.09 (CH), 72.99 (C-Ph),
107.42 (Pyr 5-C), 121.01 (Bn 1-C), 127.36 (2 * Bn C H \ 127.58 (2 x Ph CH), 128.01 
(2 x Ph CH), 129.32 (Bn 3,5-C), 132.16 (Ph 1-C), 134.14 (Ph 4-C), 138.10 (Bn CH),
161.81 (Pyr 2-C), 162.16 (Pyr 4-C), 163.66 (Pyr 6 -C); MS m/z 431.1657 (M + H) 
(C2 2H2 6 3 7C1N4 0 3  requires 431.1663), 429.1680 (M + H) (C22H26 35C1N4 0 4  requires 












The protected compound (102) (1.10 g, 2.1 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 110 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (120) (0.90 g, 91%) 
R /=  0.66 (chloroform/methanol, 2:1) as a very hygroscopic buff solid; NMR 8 h 1.65- 
1.84 (2H, m, 2-H2), 2.35-2.55 (2H, m, 1-H2), 3.52-3.71 (4H, m, 3,4,5-RO, 4.49 (1H, 
d, J =  12.1 Hz, CHPh), 4.54 (1H, d, J =  12.1 Hz, CHPh), 4.71 (2H, br, NH2), 5.09 
(2H, br, NH2), 7.05 (2H, d, J  = 8.4 Hz, Ph 3,5-H2), 7.24-7.34 (5H, m, Ph-H5), 7.54 
(2H, d, / =  8.4 Hz, Ph 2,6-H2); MS m/z 475.1184 (M + H) requires
475.1167), 473.1179 (M + H) (C2 2H2 6 7 9BrN4 0 4  requires 473.1188), 497/495 (M + 











The protected compound (103) (0.34 g, 0.7 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 35 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (121) (0.24 g, 74%) 
R /=  0.66 (chloroform/methanol, 2:1) as a pale yellow solid mp 123-125 °C; NMR 
(CD3OD) 8 h 1.53-1.67 (1H, m, 2-H), 1.74-1.90 (1H, m, 2-H), 2.31 (1H, ddd, J  =
14.2, 9.0, 5.9 Hz, 1-H), 2.47 (1H, ddd, J =  14.2, 9.0, 5.9 Hz, 1-H), 3.44-3.51 (2H, m,
3,4-H2), 3.54-3.59 (2H, m, 5-H2), 4.47 (1H, d, J = 14.1 Hz, CHPh), 4.52 (1H, d, J  =
14.1 Hz, CHPh), 7.15 (1H, dd, J =  8.2, 1.9 Hz, Ph 6 -H), 7.22-7.33 (5H, m, Ph-H5),
7.41 (1H, d, /  = 1.9 Hz, Ph 2-H), 7.57 (1H, d, J =  8.2 Hz, Ph 5-H); NMR (CD3 OD) 
8 c 23.30 (CH2), 30.97 (CH2), 71.23 and 71.58 (3,4-CH), 72.99 (5-CH2  + C-Ph),
106.22 (Pyr 5-C), 181.16 (Bn 1-C), 127.31 (Ph CH), 127.55 (Ph CH), 127.99 (Ph 
CH), 130.64 (Ph C), 131.15 (Ph C), 131.95 (Ph 1-C), 132.61 (2 * Bn CH), 134.54 (2 
x Bn CH), 138.17 (Bn CH), 162.09 (Pyr 2-C), 162.83 (Pyr 4-C), 163.16 (Pyr 6 -C); 
MS m/z 467.1258 (M + H) (C2 2H2 5 37C 12N4 0 3  requires 467.1244), 465.1272 (M + H) 
(C2 2H2 5 3 7 C13 5 C1N4 0 3 requires 465.1274), 463.1293 (M + H) 











The protected compound (104) (0.30 g, 0.7 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 30 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (122) (0.21 g, 76%); 
R /=  0.52 (chloroform/methanol, 2:1) as a buff solid: mp 101-102 °C; NMR ( C D 3 O D )  
8h 1.70 (1H, q, J = 7.6 Hz, 2-H2), 2.36 (1H, dt, J = 14.2, 7.6 Hz, 1-H), 2.48 (1H, dt, J  
= 14.2, 7.6 Hz, 1-H), 3.42-3.55 (4H, m, 3,4,5-RO, 4.48 (1H, d, J =  11.7 Hz, CHPh), 
4.52 (1H, d, J =  11.7 Hz, CHPh), 7.22-7.49 (10H, m, 2 x Ph-H5); MS m/z 395.2082 










The protected compound (87) (0.35 g, 0.75 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 35 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (123) (0.24 g, 75%); 
R/-= 0.18 as a pale yellow solid: mp 141-143 °C; IR Vmax 3562 (O H ), 3492, 3430, 
3343 (NH2), 1618 (O N ) cm'1; NMR (CDjOD) 5h 1.65-1.73 (2H, m, 2-H2), 2.28 
(1H, ddd, J  = 13.7, 9.4, 6.6 Hz, 1-H), 2.42 (1H, ddd, J  = 13.7, 9.4, 6.6 Hz, 1-H), 
3.42-3.54 (4H, m, 3,4,5-H2), 4.48 (1H, d, 7 =  11.7 Hz, CHPh), 4.52 (1H, d, / =  11.7 
Hz, CHPh), 7.20 (2H, d, J =  8.6 Hz, Ph 3,5-H2), 7.30-7.36 (5H, m, Ph-H5), 7.44 (2H, 
d, J  = 8.6 Hz, Ph 2,6-H2); MS m/z 431.1680 (M + H) (C22H2637C1N40 3 requires 
431.1663), 429.1702 (M + H) (C2 2H2 6 35C1N 4 0 3  requires 429.1693), 249/247 (M -  








The protected compound (105) (0.20 g, 0.4 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 20 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (124) (0.18 g, 95%); 
R/ = 0.82 (chloroform/methanol, 2:1) as a hygroscopic pale yellow solid; IR Vmax 
3582 (OH), 3350 (NH2), 1613 (C=N) cm'1; NMR (CD3OD) 8H 1.71-1.78 (2H, m, 2- 
H2), 2.36 (1H, dt, J  = 14.6, 7.8 Hz, 1-H), 2.46 (1H, dt, / =  14.6, 7.8 Hz, 1-H), 3.43-
3.61 (4H, m, 3,4,5-HLO, 4.51 (1H, d, 11.9 Hz, CHPh), 4.56 (1H, d, 11.9 Hz, 
CHPh), 7.18 (2H, d, 8.6 Hz, Ph 3,5-H2), 7.34-7.36 (5H, m, Ph-H5), 7.63 (2H, d, J  
= 8.6 Hz, Ph 2,6-H2); NMR (CD3OD) 5C 29.26 (CH2), 31.59 (CH2), 70.80 and 72.32
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(3,4-C), 71.11 (5-C), 72.99 (C-Ph), 107.30 (Pyr 5-C), 120.98 (Ph4-C), 122.10 (Bn 1- 
C), 127.39 (2 x Bn CH), 127.58 (2 x Ph CH), 128.04 (2 x Ph CH), 130.83 (Ph 1-C), 
132.31 (2 x Bn CH), 138.05 (Bn CH), 161.45 (Pyr 2-C), 161.80 (Pyr 4-C), 162.50 
(Pyr 6 -C); MS m/z 475.1184 (M + H) ( C i iK ^ B r N ^  requires 475.1167), 473.1186 
(M + H)(C2 2H2 6 7 9BrN4 0 4  requires 473.1188), 323/321 ( M - C 9H n 0 2), 91 (Bn).
2,4-Diamino-6-((15',2R)-l,2,3-trihydroxypropyl)-5-phenyIpyrimidme (125)





The protected compound (111) (0.35 g, 1.1 mmol) was stirred for 2 h in aqueous 
trifluoroacetic acid (30%, 35 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (125) (0.22 g, 73%); 
R /=  0.16 (chloroform/methanol, 2:1); [a]2°D = -0.38° (c 4, CH3OH) as a hygroscopic 
white solid; NMR (CD3CN) &h 3.45 (1H, dd, J =  11.6, 4.9 Hz, 3-H), 3.48 (1H, dd, J  
= 11.6, 3.9 Hz, 3-H), 3.70-3.73 (1H, m, 2-H), 4.46 (1H, d, J =  6.2 Hz, 1-H), 4.73 
(2H, br, OHZNH), 5.82 (1H, br, OH/NH), 6.98 (1H, br, OHZNH), 7.31 (2H, dd, J  = 
7.4, 2.0 Hz, Ph 2,6-H2), 7.45-7.61 (3H, m, Ph 3,4,5-H3); MS m/z 277.1308 (M + H) 




The protected compound (112) (0.15 g, 0.43 mmol) was stirred overnight in aqueous 
trifluoroacetic acid (30%, 15 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (126) (0.12 g, 90%); 
R /=  0.17 (chloroform/methanol, 2:1); [c c ]20d  = -41° ( c  0.4, C H 3 O H ) as a pale yellow 
solid: mp 196-197 °C; IR v^* 3550 (O H ) , 3475, 3413 (N H 2), 1617 ( C = N )  c m 1; 
NMR ( (C D 3 ) 2 C O ) 5h 3.58 (1H, dd, J =  11.3,4.7 Hz, 3-H), 3.63 (1H, dd, J =  11.3,3.5 
Hz, 3-H), 3.89-3.92 (1H, m, 2-H), 4.54 (1H, d, J  = 7.0 Hz, 1-H), 5.54 (5H, br, 
O H /N H ), 6.62 (1H, br, O H /N H ), 7.40 (2H, d, J=  7.4 Hz, Ph 3,5-H2), 7.47 (2H, d, J  = 
1A Hz, Ph 2,6-H2), 7.79 (1H, br, O H /N H );  NMR (C D 3 C N ) 5C 62.60 ( C H 2), 69.31 
(C H ), 72.47 (C H ) , 108.42 (Pyr 5-C), 129.88 (2 x Ph C H ), 132.39 (2 *  Ph C H ), 
133.53 (Ph 1-C), 134.72 (Ph 4-C), 161.21 (Pyr 2-C), 161.53 (Pyr 4-C), 161.87 (Pyr
6-C); MS m/z 313.0877 (M + H) (Ci3Hi637C1N40 3 requires 313.0881), 311.0905 (M 







The protected compound (113) (0.40 g, 1.0 mmol) was stirred for 4 h  in aqueous 
trifluoroacetic acid (30%, 40 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (127) (0.35 g, 95%); 
R/ = 0.18 (chloroform/methanol, 2:1); [a]20D = -15° (c 0.94, CH3OH) as a 
hygroscopic pale yellow solid; IR Vmax 3550 (OH), 3478, 3414 (NH2 ), 1618 (C=N) 
cm'1; NMR (CD3CN) 5h3.51 (1H, dd, /  = 12.3, 4.9 Hz, 3-H), 3.55 (1H, dd, 12.3,
4.5 Hz, 3-H), 3.72-3.76 (1H, m, 2-H), 4.49 (1H, d, J =  6.2 Hz, 1-H), 5.94 (1H, br, 
OH/NH), 7.03 (1H, br, OH/NH), 7.29 (2H, d ,J=  8.0 Hz, Ph 3,5-H2), 7.71 (2H, d, J=
8.0 Hz, Ph 2,6-H2); NMR (CD3 CN) 6 C 62.47 (CH2), 68.98 (CH), 72.30 (CH), 108.83 
(Pyr 5-C), 123.37 (Ph 4-C), 129.70 (Ph 1-C), 132.92 (Ph CH), 132.98 (Ph CH),
133.81 (Ph CH), 156.05 (Pyr 2-C), 162.06 (Pyr 4-C), 164.91 (Pyr 6 -C); MS m/z 
357.0396 (M + H) (Ci3H 168 1BrN4 0 3 requires 357.0385), 355.0412 (M + H) 













The protected compound (114) (0.20 g, 0.5 mmol) was stirred for 4 h in aqueous 
trifluoroacetic acid (30%, 20 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (128) (0.15 g, 87%); 
R /=  0.34 (chloroform/methanol, 2:1); [ cc] 20d  = -3° (c 4.7, CH3OH) as a pale yellow 
solid: mp 120-121 °C; IR v^x 3549 (OH), 3476, 3415 (NH2), 1618 (C=N) cm’1; 
NMR (CD3CN) 5h 3.40-3.46 (2H, m, 3-H2), 3.63-3.68 (1H, m, 2-H), 4.35 (1H, d, J  =
4.7 Hz, 1-H), 5.25 (2H, br, NH2), 5.67 (2H, br, NH2), 7.20 (1H, dd, /  = 8.0, 1.9 Hz, 
Ph 6 -H), 7.46 (1H, d, J  = 1.9 Hz, Ph 2-H), 7.60 (1H, d, J  = 8.0 Hz, Ph 5-H); NMR 
((CD3)2 SO) 6 c 63.67 (CH2), 69.38 (CH), 74.29 (CH), 106.16 (Pyr 5-C), 130.30 (Ph 
C), 131.08 (Ph CH), 131.44 (Ph C), 131.63 (Ph CH), 132.68 (Ph CH), 134.09 (Ph C),
162.01 (Pyr 2-C), 162.81 (Pyr 4-C), 164.00 (Pyr 6 -C); MS m/z 349.0469 (M + H) 
(Ci3Hi5 3 7Cl2N4 0 3  requires 349.0462), 347.0501 (M + H) (Ci3Hi5 3 7Cl3 5ClN4 0 3 
requires 347.0491), 345.0521 (M + H) (Ci3Hi5 3 5Cl2N4 0 3 requires 345.0521), 
371/369/367 (M + Na), 287/285/283 (M -  C2H50 2).
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2,4-Diamino-6-((3R,4£)-3,4,5-trihydroxypentyl)-5-phenylpyrimidme (129)
Ammonia (10 ml) was distilled and allowed to warm to reflux (-33 °C), and sodium 
(84 mg, 3.6 mmol), was added until a deep blue solution was sustained Compound
(118) (150 mg, 0.4 mmol) in THF (5 ml) was added directly to the Na / NH3 solution. 
After being stirred for 20 min at reflux, the reaction was quenched with saturated 
aqueous ammonium chloride ( 2  ml) and then allowed to warm to room temperature. 
After evaporation to dryness, a mixture of chloroform and methanol (2:1,20 ml) was 
added followed by filtration. The residue remaining after evaporation of the organic 
layer was purified by chromatography (chloroform/methanol, 7:3) to afford (129) (90 
mg, 78%) R/ = 0.13 (chloroform/methanol, 2:1) as a white solid: mp 90-91 °C; NMR
(2H, t, J  = 7.5 Hz, Ph 3,5-H2); NMR (D2 0 )  6 C 30.24 (CH2), 31.10 (CH2), 62.25 (5- 
CH2), 71.35 (CH), 74.11 (CH), 109.19 (Pyr 5-C), 128.08 (Ph CH), 129.19 (2 x Ph 
CH), 130.54 (2 x Ph CH), 133.88 (Ph 1-C), 161.15 (Pyr 2-C), 162.92 (Pyr 4-C), 
165.94 (Pyr 6 -C); MS m/z 305.1616 (M + H) (Ci5H2 iN4 0 3 requires 305.1613), 327 
(M + Na), 243 (M - C2H50 2), 213 (M -  C3H7O3 ).
Y " " " O H
OH
(129)
(D20 )  5h 1.29-1.36 (1H, m, 2-H), 1.49-1.55 (1H, m, 2-H), 2.07 (1H, ddd, 7 =  13.0,
10.2, 6.2 Hz, 1-H), 2.21 (1H, ddd, J =  13.0, 10.5, 5.3 Hz, 1-H), 3.17-3.21 (1H, m, 3- 
H), 3.22-3.25 (2H, m, 5-H2), 3.37 (1H, dt, J =  8.5, 6.1 Hz, 4-H), 7.03 (1H, d, J =  7.5 
Hz, Ph 2-H), 7.04 (1H, d, J =  7.5 Hz, Ph 6-H), 7.23 (1H, t, / =  7.5 Hz, Ph 4-H), 7.29
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2,4-Diamino-6-((3i?,45)-3,4,5-trihydroxypentyl)-5-phenylpyrimidine (129)
The protected compound (144) (0.20 g, 0.58 mmol) was stirred for 6  h in aqueous 
trifluoroacetic acid (30%, 20 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (129) (0.15 g, 85%); 
R/ = 0.13 (chloroform/methanol, 2:1) as a white solid: mp 90-91 °C; MS m/z 
305.1620 (M + H) (C15H21N4O3 requires 305.1613), 327 (M + Na), 243 (M -  







Anhydrous iron (HI) chloride ( 6 8  mg, 0.42 mmol) was added to a solution of 
compound (119) (60 mg, 0.14 mmol) in anhydrous dichloromethane (5 ml) under 
nitrogen. After 80 min the reaction was quenched by addition of water (2 ml). The
5.
residue remaining after evaporation of the solvent was purified by chromatography 
(chloroform/methanol, 7:3) to afford (130) (30 mg, 63%); R/ = 0 . 1 1  
(chloroform/methanol, 2:1); [o c ]20d  = -1.0° ( c  1.1, CH3 OH) as a white solid: mp 250- 
251 °C; NMR (D2 0 ) 6 H 1.40-1.49 (1H, m, 2-H), 1.61-1.68 (1H, m, 2-H), 2.22 (1H, 
ddd, / =  13.6, 10.4, 6.0 Hz, 1-H), 2.36 (1H, ddd, J =  13.6, 10.0, 5.2 Hz, 1-H), 3.29-
3.33 (1H, m, 3-H), 3.35-3.38 (2H, m, 5-H2), 3.48-3.53 (1H, m, 4-H), 7.18 (2H, d, J=
8 . 6  Hz, Ph 3,5-H2), 7.44 (2H, d, J  = 8.5 Hz, Ph 2,6-H2); NMR (CD3OD) 5C 30.05 
(CH2), 31.36 (CH2), 62.70 (5-CH2), 71.97 (CH), 74.14 (CH), 107.03 (Pyr 5-C), 
129.18 (2 x Ph CH), 132.23 (2 x Ph CH), 133.13 (Ph C), 133.71 (Ph C), 161.73 (Pyr
2-C), 162.08 (Pyr 4-C), 163.06 (Pyr 6 -C); MS m/z 341.1185 (M + H) 
(Ci5H2o3 7C1N4 0 3  requires 341.1194), 339.1217 (M + H) ( C is H ^ C m A  requires 







The protected compound (145) (50 mg, 0.13 mmol) was stirred for 6  h in aqueous 
trifluoroacetic acid (30%, 5 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (130) (40 mg, 91%); 
R/ = 0.11 (chloroform/methanol, 2:1) as a white solid: mp 250-251 °C; MS m/z 
341.1200 (M  + H) (Ci5H2o37ClN403 requires 341.1194), 339.1225 (M + H) 
(Ci5H2o35ClN4C>3 requires 339.1223), 308/306 (M - C R tO ), 249/247 (M -  C3H7O3), 







Y '" '" oh
OH
(131)
The protected compound (120) (40 mg, 0.09 mmol) was subjected to reaction with 
anhydrous iron (IE) chloride (44 mg, 0.27 mmol) as described for compound (131) to 
afford (24) (22 mg, 85%); R/ = 0.18 (chloroform/methanol, 2:1); [ oc] 20d  = -4.2° (c 
0.24, CH3OH) as a white solid: mp 198-200 °C; NMR (D2 0 ) 8 H 1.40-1.54 (1H, m, 2- 
H), 1.75-1.87 (1H, m, 2-H), 2.13-2.24 (1H, m, 1-H), 2.28-2.38 (1H, m, 1-H), 3.24- 
3.34 (1H, m, 3-H), 3.32-3.36 (2H, m, 5-H2), 3.44-3.52 (1H, m, 4-H), 7.08 (2H, d, /  =
8.0 Hz, Ph 3,5-H2), 7.55 (2H, d, J  = 8.0 Hz, Ph 2,6-H2); MS m/z 385.0683 (M + H) 
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The protected compound (146) (40 mg, 0.09 mmol) was stirred for 6  h in aqueous 
trifluoroacetic acid (30%, 4 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (131) (30 mg, 87%); 
R /=  0.18 (chloroform/methanol, 2:1) as a pale yellow solid: mp 198-200 °C; MS m/z 
385.0702 (M + H) (C isH ^'B rN -A  requires 385.0698), 383.0714 (M + H) 
(Cj5H2o?9BrN4 0 3  requires 383.0718); NMR spectra are as described before.
2,4-Diammo-5-(3,4-dichlorophenyl)-6-((3l?,4S)-3,4,5- 
trihydroxypentyl)pyrimidine (132)
The protected compound (121) (60 mg, 0.14 mmol) was subjected to reaction with 
anhydrous iron (El) chloride (65 mg, 0.42 mmol) as described for deprotection of 
compound (130) to afford (132) (40 mg, 77%) R /=  0.13 (chloroform/methanol, 2:1); 
[a]20D = -1.4° (c 2.2, CH3OH) as a white solid: mp 180-181 °C; NMR ((CD3)2 SO) Sr
J  = 8.2 Hz, Ph 5-H); NMR ((CD3)2 SO) 6 C 31.26 (CH2), 32.09 (CH2), 63.94 (5-CH2), 
71.95 (CH), 75.19 (CH), 105.22 (Pyr 5-C), 131.38 (Ph CH), 131.81 (Ph CH), 133.16 
(Ph CH), 133.74 (Ph C), 133.97 (Ph C), 137.51 (Ph C), 162.42 (Pyr 2,4-C), 166.19 
(Pyr 6 -C); MS m/z 377.0812 (M + H) (Ci5H 193 7C12N4 0 3 requires 377.0775),
Cl
Y " " " o h
6 h
(132)
1.38-1.48 (1H, m, 2-H), 1.57-1.68 (1H, m, 2-H), 2.08 (1H, ddd, J =  13.6, 10.4, 5.5 
Hz, 1-H), 2.34 (1H, ddd, / =  13.6, 10.4, 5.5 Hz, 1-H), 3.14-3.20 (1H, m, 3-H), 3.28- 
3.31 (2H, m, 5-H2), 3.46-3.49 (1H, m, 4-H), 5.79 (2H, br, NH2), 5.97 (1H, br, NH2),
7.16 (1H, dd, J =  8.2,1.8 Hz, Ph 6 -H), 7.42 (1H, d, J=  1.8 Hz, Ph 2-H), 7.66 (1H, d,
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375.0814 (M + H) (Ci5H,9 3 7C 1 3 5C1N40 3 requires 375.0804), 373.0836 (M + H) 




The protected compound (147) (30 mg, 0.07 mmol) was stirred for 6  h  in aqueous 
trifluoroacetic acid (30%, 3 ml). The solvent was evaporated and the residue was 
purified by chromatography (chloroform/methanol, 7:3) to give (132) (20 mg, 77%); 
R / = 0.13 (chloroform/methanol, 2:1) as a white solid: mp 180-181 °C; MS m/z 
377.0794 (M + H) (Ci5Hi9 3 7C12N4 0 3 requires 377.0775), 375.0820 (M + H) 
(CisHi937Cl 3 5C1N40 3 requires 375.0804), 373.0838 (M + H) (Ci5H i9 35C12N40 3 
requires 373.0834), 315/313/311 ( M - C 2H50 2), 212 (M - C3H<C12 0 3); NMR spectra 











The protected compound (122) (0.20 g, 0.5 mmol) was stirred in methanol (20 ml) 
with Pd/C (5%, 154 mg) and 5 drops of chloroform under atmosphere of hydrogen 
for 2 h. the catalyst was removed by filtration through Celite®. The solvent was 
evaporated off and the residue was purified by chromatography 
(chloroform/methanol, 7:3) to afford (133) (150 mg, 93%); R /=  0.05 as a white solid 
mp >350 °C; [a]20D = +10.9° (c 0.5, H20); NMR (D2 0 )  8 h 1.50-1.64 (2H, m, 2-H2), 
2.28 (1H, ddd, J =  13.9, 10.1, 6.3 Hz, 1-H), 2.40 (1H, ddd, J  = 13.9, 10.1, 6.3 Hz, 1- 
H), 3.31-3.45 (4H, m, 3,4,5-H*), 7.25 (2H, d, J = 7.0 Hz, Ph 3,5-H2), 7.42 (1H, t, /  =
7.0 Hz, Ph 4-H), 7.47 (2H, t, J  = 7.0 Hz, Ph 2,6-H2); NMR (D2 0 ) 6 C 29.75 (CH2), 
31.57 (CH2), 62.63 (5-CH2), 73.61 and 73.64 (3,4-C), 109.24 (Pyr 5-C), 128.37 (Ph 
CH), 129.37 (2 x Ph CH), 130.56 (2 x Ph CH), 133.41 (Ph 1-C), 160.29 (Pyr 2-C), 











Anhydrous iron (ID) chloride (65 mg, 0.4 mmol) was added to a solution o f 
compound (123) (60 mg, 0.14 mmol) in anhydrous dichloromethane (5 ml) under 
nitrogen. After 80 min the reaction was quenched by addition of water (2 ml). The 
residue remaining after evaporation of the solvent was purified by chromatography 
(chloroform/methanol, 7:3) to afford (134) (40 mg, 77%); R/ = 0.13 
(chloroform/methanol, 2:1); [<x ] 20d  = +6.0° (c 0.67, H2 O) as a white solid mp >350 
°C; NMR (CD3OD) 5h 1.73-1.77 (2H, m, 2-H2), 2.41 (1H, dt, J=  14.4, 6.7 Hz, 1-H), 
2.54 (1H, dt, J =  14.4, 6.7 Hz, 1-H), 3.44-3.61 (4H, m, 3,4,5-RO, 7.31 (2H, d, J =  8.4 
Hz, Ph 3,5-H2), 7.53 (2H, d, / =  8.4 Hz, Ph 2,6-H2); NMR (CD3OD) 8 C 27.08 (CH2), 
31.39 (CH2), 62.91 (5-CH2), 70.52 and 73.58 (3,4-C), 108.29 (Pyr 5-C), 129.60 (2 x 
Ph CH), 132.04 (2 x Ph CH), 137.45 (Ph 1-C), 137.50 (Ph 4-C), 156.86 (Pyr 2-C), 
157.38 (Pyr 4-C), 157.80 (Pyr 6 -C); MS m/z 341.1180 (M + H) (Ci5H2 0 3 7ClN4 O3  












The protected compound (124) (80 mg, 0.17 mmol) was subjected to reaction with 
anhydrous iron (IE) chloride (83 mg, 0.5 mmol) as described for deprotection of 
compound (134) to afford (135) (50 mg, 77%); R/  = 0.08; [cc]20d  = +12.5° (c 0.24, 
CH3 OH) as a white solid: mp >350 °C; IR 3649 (OH), 3468, 3418 (NH2), 1618 
(O N ) cm-1; NMR (D2 0 ) 6 H 1.60-1.72 (2H, m, 2-H2), 2.30-2.54 (2H, m, 1-H2), 3.42-
3.56 (4H, m, 3,4,5-H*), 7.25 (2H, d, J  = 8.7 Hz, Ph 3,5-H2), 7.72 (2H, d, J  = 8.7 Hz, 
Ph 2,6-H2); MS m/z 385.0707 (M + H) (Ci5H2o81BrN4 0 3 requires 385.0698), 







Lithium bis(trimethylsilyl)amide (1.0 M in THF) (30 ml, 30 mmol) was added to 
phenylacetonitrile (1.75 g, 15 mmol) in dry diethyl ether (15 ml) under nitrogen at - 
78 °C. After 10 min, compound (47) was added and the reaction mixture was 
allowed to warm to room temperature. The mixture was stirred for 72 h. An excess of 
diethyl ether was added, followed by water. The aqueous layer was separated, 
washed with diethyl ether and then added to ethyl acetate (100 ml) in a separating 
funnel. Acidification by dropwise addition of 1 M aqueous citric acid to pH = 6 with 
rapid extraction with ethyl acetate was followed by rapid separation o f the organic 
layer. Ethyl acetate was washed with water, dried (MgS04) and evaporated. 
Purification with chromatography (ethyl acetate/hexane, 3:1) afforded (136) (0.45 g, 
10%); R /=  0.37 as a hygroscopic pale yellow solid; NMR 8h 1.30 (3H, s, Me), 1.40 
(3H, s, Me), 1.74-1.81 (2H, m, C //2CHO), 2.66-2.76 (1H, m, CHCH2), 2.78-2.88 
(1H, m, CflCH2), 3.62 (2H, d, J =  5.5 Hz, CH2OH), 4.03-4.08 (1H, m, 4-H), 4.12-
4.17 (1H, m, 5-H), 4.79 (1H, s, CHCN), 7.36-7.50 (5H, m, Ph-H5); MS m/z 303.1464 





4-Chlorophenylacetonitrile (2.3 g, 15 mmol) and compound (47) (3.5 g, 15 mmol) 
were condensed in the same method as described above. The resulting residue was 
purified by chromatography (ethyl acetate/hexane, 3:1) to afford (137) (0.35 g, 7%);
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Rf=  0.26 as a pale yellow solid: mp 133-135 °C; NMR 6 h 1.42 (3H, s, Me), 1.52 
(3H, s, Me), 2.35-2.52 (2H, m, Ctf2 CHO), 2.66-2.84 (2H, m, C//2 CH2), 3.63 (1H, dd, 
J=  12.7, 4.9 Hz, CtfOH), 3.73 (1H, dd, J =  12.7, 4.9 Hz, Ci/OH), 4.21-4.28 (2H, m,
4,5-H2), 5.53 (0.2H, s, CHN), 7.44 (2H, d, / =  9.0 Hz, Ph 3,5-H2), 7.63 (0.4H, d, J  =
8 . 6  Hz, Ph 2,6-H2), 8.01 (1.6H, d, J  = 9.0 Hz, Ph 2,6-H2); MS m/z 340 (M + H) 
C i7H2o37C1N 04, 338 (M + H) C i7H2035C1N O 4, 322/320 (M -  OH), 308/306 (M - 




4-Bromophenylacetonitrile (2.9 g, 15 mmol) and compound (47) (3.5 g, 15 mmol) 
were condensed in the same method as described above. The resulting residue was 
purified by chromatography (ethyl acetate/hexane, 3:1) to afford (138) (0.32 g, 6 %); 
R /=  0.21 as a pale yellow solid: mp 128-130 °C; NMR 8 h 1.41 (3H, s, Me), 1.51 
(3H, s, Me), 2.39-2.48 (2H, m, Ctf2CHO), 2.69-2.79 (2H, m, Ctf2CH2), 3.62 (1H, dd, 
J =  11.6, 5.3 Hz, C770H), 3.73 (1H, dd, J = 11.6, 5.3 Hz, CifOH), 4.19-4.27 (2H, m,
4,5-H2), 7.30 (2H, d, J = 8.5 Hz, Ph 2,6-H2), 7.47 (2H, d,J =  8.5 Hz, Ph 3,5-H2); MS 
m/z 382.0480 (M + H) (Ci7H2 0 81BrNO4 requires 382.0476), 380.0475 (M + H) 
(CI7H2 0 7 9BrNO4  requires 380.0497), 368/366 (M - CH3), 342/340 (M - C2H3N), 







3,4-Dichlorophenylacetonitrile (2.8 g, 15 mmol) and compound (47) (3.5 g, 15 
mmol) were condensed in the same method as described above. The resulting residue 
was purified by chromatography (ethyl acetate/hexane, 3:1) to afford (139) (0.40 g, 
7%); R /=  0.37 as a pale yellow solid: mp 117-118 °C; IR v™* 3424 (OH), 2209 
(CN), 1718 (C=0) cm'1; NMR 8 h 1.42 (3H, s, Me), 1.52 (3H, s, Me), 2.38-2.47 (2H, 
m, Ctf2CHO), 2.72-2.84 (2H, m, CH2CR2), 3.64 (1H, dd, J  = 11.5, 5.5 Hz, C//OH), 
3.75 (1H, dd, 7 =  11.5, 5.5 Hz, CtfOH), 4.18-4.29 (2H, m, 4,5-H2), 7.27 (1H, dd, 7  =
8.5,2.2 Hz, Ph 6 -H), 7.43 (1H, d, J=  8.5 Hz, Ph 5-H), 7.54 (1H, d, J=  2.2 Hz, Ph 2-
H). MS m/z 375 (M + H) Ci7Hi9 3 7 C12N 04, 373 (M + H) Ci7Hi9 3 7 C13 5C1N04, 371 (M 
+ H) Ci7H]?3SC12N 0 4, 358/356/354 (M -  CHi), 334/332/330 (M - C2H2N), 
316/314/312 (M -  C2H3NO).
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(4R,55)-4-(4-Cyano-3-methoxy-4-phenyIbut-3-enyl)-5-hydroxymethyl-2,2- 







A solution of compound (136) (0.34 g, 1.1 mmol) in THF (5 ml) was treated with a 
solution of diazomethane (-0.08 g, 2.2 mmol) prepared from N-methyl-N-nitroso-p- 
toluenesulfonamide and KOH (using Minidiazald apparatus) in diethyl ether (5 ml) 
and the mixture was kept overnight at 10 °C. The excess of diazomethane was 
destroyed by dropwise addition of acetic acid (30% in THF), and the solvent was 
evaporated off to afford (140) (.0.33 g, 95%) as a pale yellow oil; NMR 5h 1.40 (3H, 
s, Me), 1.51 (3H, s, Me), 1.87-2.01 (2H, m, Ctf2 CHO), 2.84-3.02 (2H, m, C //2CH2), 
3.69 (2H, d, J  = 5.9 Hz, CH2OH), 3.86 (3H, s, OCH3), 4.22-4.27 (2H, m, 4,5-H2), 
7.24-7.42 (5H, m, Ph-H5); MS m/z 318.1707 (M + H) (Ci8H2 4N 0 4  requires 
318.1705), 302 (M -  CH3), 277 (M - C2H2N), 258 (M -  C2H5NO). A solution of 
sodium methoxide (0.17 g, 3.2 mmol) in 2-methoxyethanol (2 ml) was added to a 
solution of guanidine hydrochloride (0.30 g, 3.2 mmol) in 2-methoxyethanol (2 ml) 
mixed and stirred for 5 min at 30 °C and sodium chloride was removed. The 
alcoholic guanidine solution was boiled under reflux with compound (30) (0.5 g, 1.6 
mmol) for 4 h. The cooled concentrated solution was purified by chromatography 
(chloroform/methanol, 9:1) to afford (144) (0.23 g, 42%); R /=  0.29 as a  buff solid: 
mp 72-75 °C; NMR (D2 0 )  8 H 1.27 (3H, s, Me), 1.31 (3H, s, Me), 1.75-1.88 (2H, m, 
Ctf2 CHO), 2.32 (1H, ddd, J  = 15.9, 9.7, 6.0 Hz, CtfCH2), 2.49 (1H, ddd, J =  15.9, 
8.7, 7.4 Hz, CHCRi), 3.53 (1H, dd, J=  11.6, 5.9 Hz, CHOR), 3.65 (1H, dd, J=  11.6,
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5.9 Hz, Ci/OH), 4.05 (1H, q, J =  12.2, 5.9 Hz, 4-H), 4.12 (1H, q, J =  5.9 Hz, 5-H), 
4.63 (2H, br, NH2), 4.95 (2H, br, NH2), 7.21(1H, d, J=  7.9 Hz, Ph 2-H), 7.22 (1H, d, 
J =  7.9 Hz, Ph 6 -H), 7.36 (1H, t, J  = 7.9 Hz, Ph 4-H), 7.41(2H, t, J =  7.9 Hz, Ph 3,5- 
H2); NMR (D2 0 )  6 c 23.01 (Me), 25.58 (Me), 25.70 (CH2), 28.17 (CH2), 58.60 (C- 
OH), 74.07 and 75.63 (4,5-C), 105.27 (Pyr 5-C), 106.26 (CMe2), 125.50 (Ph CH), 
126.82 (2 x Ph CH), 126.85 (2 x Ph CH), 127.94 (Ph 1-C), 158.71 (Pyr 2-C), 159.82 
(Pyr 4-C), 162.92 (Pyr 6 -C); MS m/z 345.1935 (M + H) (C19H2 4N4 0 3 requires 
345.1926), 329 (M - CH3), 200 (M -  C7H120 3).
(4R,5S)-4-(4-(4-ChIorophenyl)-4-cyano-3-methoxybut-3-enyI)-5-hydroxymethyl-








A solution of compound (137) (0.32 g, 1 mmol) in THF (5 ml) was methylated with 
diazomethane by the same procedure described above to afford (141) (0.3 g, 90%) as 
a pale yellow oil. A solution of sodium methoxide (0.12 g, 2.2 mmol) in 2- 
methoxyethanol ( 2  ml) was added to a solution of guanidine hydrochloride (0 . 2 1  g,
2.2 mmol) in 2-methoxyethanol ( 2  ml) mixed and stirred for 5 min at 30 °C and 
sodium chloride was removed. The alcoholic guanidine solution was boiled under 
reflux with compound (141) (0.3 g, 0.8 mmol) for 10 h. The cooled concentrated 
solution was purified by chromatography (chloroform/methanol, 9:1) to afford (145) 
(50 mg, 12%); R /=  0.24 as a white solid: mp 94-95 °C; NMR 6 H 1.27 (3H, s, Me), 
1.30 (3H, s, Me) 1.68-1.77 (1H, m, CtfCHO), 1.79-1.88 (1H, m, CtfCHO), 2.29 (1H,
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ddd,J =  13.4,10.8, 5.1 Hz, Ci/CH2), 2.46 (1H, ddd, J = 13.4,10.4, 5.9 Hz, CtfCH2),
3.56 (1H, dd, J=  11.7, 6.1 Hz, CtfOH), 3.66 (1H, dd, J =  11.7, 6.1 Hz, Ci/OH), 4.02 
(1H, dt, J=  8.1, 5.8 Hz, 4-H), 4.13 (1H, q, J=  5.8 Hz, 5-H), 5.04 (2H, br, NH2), 5.76 
(2H, br, NH2), 7.16 (2H, d 7.0 Hz, Ph 3,5-H2), 7.42 (2H, d, J = 7.0 Hz, Ph 2,6- 
H2); NMR 6 c 25.57 (Me), 28.04 (Me), 28.42 (CH2), 30.46 (CH2), 60.90 (CH2OH), 
76.77 and 77.09 (4,5-CH), 107.39 (CMe2), 107.94 (Pyr 5-C), 129.71 (2 x ph CH), 
132.64 (Ph 1-C), 134.29 (Ph 4-C), 160.82 (Pyr 2-C), 162.48 (Pyr 4-C), 164.40 (Pyr 
6 -C); MS m/z 381.1506 (M + H) (Ci8H2 4 3 7 ClN4 0 3  requires 381.1507), 379.1525 (M 
+ H) (Ci8H2 4 3 5C1N4 0 4  requires 379.1536), 236/234 (M - C7Hi20 3), 186 (M -  
CsH^ClOj).
(4R,5S)-4-(4-(4-Bromophenyl)-4-cyano-3-methoxybut-3-enyl)-5-hydroxymethyl-








A solution of compound (138) (0.32 g, 0.84 mmol) in THF (5 ml) was methylated 
with diazomethane by the same procedure described above to afford (142) (0.30 g, 
90%) as a pale yellow oil; IR v™* 3435 (OH), 2243 (CN), 1592 (C=C) c m 1; NMR 
5h 1.42 (3H, s, Me), 1.52 (3H, s, Me), 2.38-2.49 (2H, m, CH2CHO), 2.74-2.80 (2H, 
m, CH2CH2), 3.33 (3H, s, OCH3), 3.64 ( 1 H, dd, J=  11.1, 5.0 Hz, CtfOH), 3.74 ( 1 H, 
dd, J=  11.1, 5.0 Hz, CHOH), 4.21-4.27 (2H, m, 4,5-H2), 7.29 (2H, d, J=  8.5 Hz, Ph
3,5-H2), 7.50 (2H, d, /  = 8.5 Hz, Ph 2,6-H2). A solution of sodium methoxide (0.10
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g, 2 mmol) in 2-methoxyethanol (2 ml) was added to a solution of guanidine 
hydrochloride (0.18 g, 2 mmol) in 2-methoxyethanol (2 ml) mixed and stirred for 5 
min at 30 °C and sodium chloride was removed. The alcoholic guanidine solution 
was boiled under reflux with compound (142) (0.37 g, 1 mmol) for 10 h. The cooled 
concentrated solution was purified by chromatography (chloroform/methanol, 9:1) to 
afford (146) (80 mg, 20%); R /=  0.11 as a white solid: mp 124-125 °C; NMR 8h 1.27 
(6H, s, CMe2), 1.61-1.79 (2H, m, Ci/2CHO), 2.26 (1H, ddd, J =  13.0, 10.6, 5.8 Hz, 
CtfCH2), 2.46 (1H, ddd, J  = 13.0, 10.6, 5.8 Hz, CtfCH2), 3.50 (1H, dd, .7= 11.1, 5.9 
Hz, CtfOH), 3.54 (1H, dd, J=  11.1, 5.9 Hz, CtfOH), 4.01 (1H, ddd, J =  9.9, 5.9, 3.9 
Hz, 4-H), 4.08 (1H, q, J  = 5.9 Hz, 5-H), 7.21 (2H, d, J  = 7.7 Hz, Ph 3,5-H2), 7.66 
(2H, d, / =  7.7 Hz, Ph 2,6-H2); NMR (CD3OD) 5C 24.43 (Me), 27.11 (Me), 28.49 
(CH2), 30.66 (CH2), 60.32 (C-OH), 76.63 and 77.89 (4,5-C), 107.20 (CMe2), 107.82 
(Pyr 5-C), 121.84 (Ph 4-C), 132.21 (2 x Ph CH), 132.57 (2 x Ph CH), 133.50 ( Ph 1- 
C), 160.82 (Pyr 2-C), 162.98 (Pyr 4-C), 163.71 (Pyr 6-C); MS m/z 425.1007 (M + H) 
(Ci8H2481BrN40 3 requires 425.1011), 423.1019 (M + H) (Ci8H2 479BrN4C>4 requires 
423.1013), 280/278 (M - C7H 12O3), 186 (M -  CgHuBrOj).
(4R,5kS')-4-(4-(3,4-DichIorophenyI)-4-cyano-3-methoxybut-3-enyl)-5- 









A solution of compound (139) (0.35 g, 0.94 mmol) in THF (5 ml) was methylated 
with diazomethane by the same procedure described above to afford (143) (0.33 g, 
91%) as a pale yellow oil; IR 3467 (OH), 2210 (CN), 1597 (C=C) cm'1; NMR 
8 h 1.40 (3H, s, Me), 1.50 (3H, s, Me), 2.30-2.40 (2H, m, Ctf2 CHO), 2.72-2.80 (2H, 
m, Ctf2 CH2), 3.37 (3H, s, OCH3), 3.58-3.74 (2H, m, Ctf2 OH), 4.18-4.26 (2H, m, 4,5- 
H2), 7.51 (1H, d, J =  8.3 Hz, Ph 5-H), 7.84 (1H, dd, J  = 8.3, 2.0 Hz, Ph 6 -H), 8.10 
(1H, d, J  = 2.0 Hz, Ph 2-H). A solution of sodium methoxide (84 mg, 1.5 mmol) in 
2-methoxyethanol (2 ml) was added to a solution of guanidine hydrochloride (143 
mg, 1.5 mmol) in 2-methoxyethanol (2 ml) mixed and stirred for 5 min at 30°C and 
sodium chloride was removed. The alcoholic guanidine solution was boiled under 
reflux with compound (143) (0.3 g, 0.78 mmol) for 6  h. The cooled concentrated 
solution was purified by chromatography (chloroform/methanol, 9:1) to afford (147) 
(30 mg, 9%); R /=  0.30 as a white solid: mp 114-115 °C; NMR 8 h 1.29 (3H, s, Me),
1.33 (3H, s, Me), 1.74-1.81 (1H, m, CtfCHO), 1.84-1.92 (1H, m, CtfCHO), 2.26- 
2.42 (1H, m, CHCK2\  2.44-2.52 (1H, m, Ci7CH2), 3.58 (1H, dd, J =  11.4, 5.9 Hz, 
CtfOH), 3.67 (1H, dd, J =  11.4, 5.9 Hz, C7/OH), 4.02-4.07 (1H, m, 4-H), 4.15 (1H, 
q, J — 5.6 Hz, 5-H), 4.95 (2H, br, NH2), 5.53 (2H, br, NH2), 7.08 (1H, dd, 8.4,1.7 
Hz, Ph 6 -H), 7.38 (1H, d, J  = 1.7 Hz, Ph 2-H), 7.52 (1H, d, J  = 8.4 Hz, Ph 5-H); 
NMR 8 c 25.53 (Me), 28.04 (Me), 28.12 (CH2), 30.35 (CH2), 61.05 (C-OH), 65.83 
and 70.51 (4,5-C), 106.62 (CMe2), 108.04 (Pyr 5-C), 130.15 (2 x Ph CH), 131.41 (Ph 
CH), 131.45 (Ph C), 133.51 (Ph C), 134.40 (Ph C), 160.93 (Pyr 2-C), 162.22 (Pyr 4- 
C), 168.33 (Pyr 6 -C); MS m/z 417.1091 (M + H) (C ^ ^ C y S U C b  requires 
417.1088), 415.1103 (M + H) (C 18H2 3 37C13 5CrN40 3 requires 415.1117), 413.1129 




5.2 Evaluation of Target Compounds 
Method
The gene modified yeast strains were kindly provided by Dr. Carol Hopkins Sibley, 
Department of Genome Sciences, University of Washington.
Radial Spoke Assay
The TB-yeast, the human-yeast and the wild-type Saccharomyces cerevisiae were 
grown in media contain 1 0 % yeast extract, 1 0 % peptone and 1 0 % dextrose. 
Sulfanilamide (ImM, 100 pi) was spread onto fresh plates and allowed to absorb into 
the medium overnight. A template streaked with the appropriate yeast that had grown 
for 3 days was sequentially replica plated onto these plates, and tested compound (10 
pi, 10 mM in DMSO) was placed in the center of the plate. Assay plates were 
incubated for 3 days at 30 °C to allow growth of the yeast before the inhibition zone 
was measured. The inhibition zones that were at least 4.0 mm more than that from 
the control plate with DMSO alone were scored as inhibited by the drug on the plate. 
The inhibition zones were calculated from the mean of three different experiments 
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